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Abstract 
A polyclonal increase in free light chains (FLCs) has been observed in a number of chronic 
inflammatory and autoimmune conditions and may be considered a biomarker of adaptive 
immune activation. The aim of this study was to examine whether FLCs could be a useful 
clinical biomarker in alpha-1 antitrypsin deficiency (A1ATD) and chronic obstructive 
pulmonary disease (COPD). 
Combined (κ & λ) FLCs (cFLCs) were measured in patients with A1ATD and usual COPD in the 
stable state and assessed for association with clinical phenotype, disease severity, bacterial 
colonisation and mortality. The relationship of FLCs to total immunoglobulin levels was also 
examined in the COPD cohort. In addition, FLCs were measured in a small cohort of patients 
with bronchiectasis to further examine the relationship to bacterial colonisation.  
Circulating cFLCs were static in the stable state in both A1ATD and usual COPD. Levels were 
significantly higher in patients with chronic bronchitis and airway bacterial colonisation in 
A1ATD. After adjusting for renal function and age the relationship between cFLCs and lung 
function was weak, however cFLC levels greater than normal significantly associated with 
mortality in both COPD cohorts. In conclusion, cFLCs may be a promising biomarker for risk 
stratification in A1ATD and COPD. 
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CHAPTER 1: Introduction 
1.1 Chronic Obstructive Pulmonary Disease1 
Chronic obstructive pulmonary disease (COPD) is a major global public health problem with a 
significant associated economic burden on both developing and higher income countries. In 
2004, COPD was the fourth leading cause of death worldwide (2) and due to projected 
increases in tobacco use, it has been predicted by the World Health Organisation (WHO) that 
it will become the third leading cause by 2030 (3). The Global Initiative for COPD (GOLD) has 
defined it as “a common preventable and treatable disease which is characterised by 
persistent airflow limitation that is usually progressive and associated with enhanced chronic 
inflammatory response in the airways and the lung to noxious particles or gases” (4).  
The pathophysiology of COPD is complex resulting from a variety of gene-environment 
interactions and there is there is considerable phenotypic heterogeneity expressed amongst 
disease sufferers (5). Within the last decade, studies have shown the prevalence of COPD to 
be much higher than previously realised (6, 7) and the proportion of patients with COPD that 
remain undiagnosed has been reported to be as high as 66- 73% (8, 9). The prevalence of 
COPD increases with age. A large international population based study found the prevalence 
of at least moderately severe COPD was usually less than 5% in people aged 40-49 but in 
those over 70 it ranged from 19 - 47% in men and 6 - 33% in women (6).  
1 Excerpts of this chapter have been previously published (1. Brebner JA, Turner AM. Early 
chronic obstructive pulmonary diease: Beyond spirometry. World Journal of Respirology. 2013;3(3):57 
- 66.)
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For the purpose of this thesis I will refer to non-alpha-1-antitrypsin deficiency (A1ATD) 
related COPD as ‘usual’ COPD.  
1.1.1 Clinical features of COPD 
In the early stages of COPD, patients can be relatively asymptomatic. As the disease 
progresses key symptoms emerge including chronic cough, dyspnoea and sputum 
production (4). Some patients produce sputum daily and the generally accepted Medical 
Research Council (MRC) definition of chronic bronchitis is “a cough with sputum production 
for at least 3 months of 2 consecutive years” (10). Breathlessness is usually progressive and 
exacerbated by exertion. Patients may also complain of wheezing, chest tightness, weight 
loss and fatigue (4). Weight loss in particular is usually a symptom of more advanced disease 
and a low body mass index (BMI) has been shown to be a predictor of mortality (11). There 
can often be discordance between symptomatic burden and severity of airflow limitation 
(12). A study specifically designed to explore whether symptoms predict the presence of 
COPD found that 92% of the smokers with airflow obstruction reported symptoms such as 
cough, dyspnoea, sputum production and wheeze. However, the same symptoms were also 
reported in 76% of smokers with normal spirometry (13). 
Patients with COPD may suffer from intermittent ‘exacerbations’ of their lung disease. An 
exacerbation has been defined as: “A sustained worsening of the patient’s condition from the 
stable state and beyond normal day-to-day variations that is acute in onset and may warrant 
additional treatment in a patient with underlying COPD” (14). 
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Frequent exacerbations have been shown to impact significantly on quality of life and are 
associated with a more rapid clinical decline in lung function and increased risk of mortality 
(15-17). More recently the contribution of exacerbations and comorbidities to the disease 
burden in COPD has been highlighted. Formal tools for assessing symptoms and health 
status such as the COPD assessment test (CAT) have now moved from being primarily used 
as an end-point in clinical trials to part of the routine assessment of patients with COPD (4). 
1.1.2 Diagnosis and Treatment 
1.1.2.1 Diagnosis 
Spirometry is the primary tool for the diagnosis of COPD. The GOLD and joint American 
Thoracic Society (ATS) and European Respiratory Society (ERS) guidelines advise physicians 
to consider spirometry in patients presenting with symptoms suggestive of COPD with a 
history of exposure to a risk factor such as smoking or occupational dust. In the context of 
such symptoms, the presence of a post-bronchodilator FEV1/FVC ratio <0.7 demonstrates 
incompletely reversible airflow limitation and hence a diagnosis of COPD (FEV1: Forced 
expiratory volume in 1 second, FVC: Forced vital capacity) (4, 18). The FEV1 as a percentage 
of its predicted value for the patient’s sex, age and height is used to sub-classify patients 
with respect to the severity of their airflow obstruction (mild FEV1 ≥80%, moderate ≥50% 
FEV1<80%, severe ≥30% FEV1<50%, very severe ≤30%)(19). Advances in technology, including 
the advent of simple to use hand held spirometers makes it a convenient test which can be 
easily performed in the outpatient clinical setting. 
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Although this fixed cut-off is easy to remember it does not take in to consideration the fact 
that the FEV1/FVC ratio reduces with age (20) resulting in the potential over-diagnosis of 
COPD in the elderly population (21) and under-diagnosis in the young (22).  Other 
approaches to interpreting spirometric values have therefore been advocated, in particular 
the use of statistically derived ‘lower limit of normal (LLN)’ reference values (23). In 
comparison to the fixed ratio method this has been shown to reduce the number of people 
potentially misclassified as having significant airflow obstruction (24-26).  
In addition to spirometry other lung function tests can provide further information in the 
diagnosis and phenotyping of patients with COPD. Reductions in the transfer factor of the 
lung for carbon monoxide (TLCO) are deemed more reflective of alveolar destruction which 
is an important feature of COPD. Indeed, it has been recognised that smokers with an 
isolated reduction in TLCO are more likely to go on to develop airflow obstruction compared 
to smokers with a normal TLCO (27).  
High resolution computed tomography (HRCT) scans are also pivotal in the more detailed 
assessment of patients with COPD (28).  In particular they can provide important 
phenotyping information by examining the extent, type and distribution of emphysema. 
Emphysema can be centrilobular, panlobular or paraseptal (Figure 1.1) and is seen as areas 
of low attenuation within the lung fields of CT images. More advanced scanning techniques 
whereby the degree of emphysema present is quantified (by declaring lung tissue below a 
certain threshold density as emphysematous) have evolved (28). There is significant 
heterogeneity exhibited amongst patients with respect to the extent and distribution of their 
emphysema. How this relates to the phenotypic presentation and prognosis is an area of 
increasing interest (29).  
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Figure 1.1: CT scan findings demonstrating different subtypes of emphysema (images 
reprinted with permission2) 
The subtypes of emphysema relate to the lobular anatomy of the lung. Image A shows 
centrilobular emphysema with central areas of low attenuation. In panlobular emphysema 
(image B) there is more generalised low attenuation. Image C shows paraseptal emphysema 
with arrows highlighting the subpleural well defined cystic areas of low attenuation.  
2 Reprinted from 30. Takahashi M, Fukuoka J, Nitta N, Takazakura R, Nagatani Y, Murakami Y, et 
al. Imaging of pulmonary emphysema: a pictorial review. Int J Chron Obstruct Pulmon Dis. 
2008;3(2):193-204. With permission from Dove Medical Press Ltd. 
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Indeed, one potential pitfall of diagnosing COPD using spirometry alone is the recognition 
that emphysema and airflow obstruction do not necessarily go hand in hand. In a study of 80 
current smokers who underwent HRCT scanning and lung function tests, 20 were found to 
have radiological emphysema but only 5 had evidence of airflow obstruction (defined by the 
authors as a low FEV1 and/or a low MEF50 (maximum expiratory flow after 50% expired 
forced vital capacity) using LLN cut-off) (31). A more recent study followed up current and 
heavy smokers who had participated in a lung cancer screening trial. 1391 individuals had no 
evidence of airflow obstruction at baseline (FEV1/FVC >0.7) but 21.9% progressed to 
developing obstruction over a mean period of 3 years. More severe baseline radiological 
emphysema (quantified by a lower Perc15 value) was found to be a risk factor for developing 
airflow obstruction at follow up (32). The radiation and cost involved in performing HRCT 
scanning are likely to limit its utility in the early investigation of patients in clinical practice 
and many of the patients in these studies were asymptomatic. However, it does serve to 
highlight the point that radiological evidence of smoking related lung damage and lung 
function parameters can be discordant.  
1.1.2.2 Treatment 
Smoking cessation is essential in the management of COPD. Successful smoking cessation 
has been shown to halve the rate of FEV1 decline in patients with mild to moderate COPD, 
returning it to a level comparable with never smokers (33). The main available drug 
treatments are short and long acting inhaled bronchodilators and inhaled steroids. Inhaled 
treatments have been shown to improve symptoms and reduce exacerbations however 
there is lack of disease modifying pharmacological options shown to prevent lung function 
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decline (4). All patients in the UK should be offered pneumococcal and annual influenza 
vaccinations (34). However the international GOLD guidelines states ‘Decisions about 
vaccination in COPD patients depend on local policies, availability and affordability’ (4).  
 Exacerbations considered to be bacterial (guided by clinical symptoms such as sputum 
purulence) should be treated with antibiotics (4, 34) which have been shown to improve 
symptom resolution and prolong the time to next exacerbation (35).  Short-courses of oral 
steroids are also advised and have been shown to improve lung function as measured by 
FEV1 and reduce hospital length of stay (36).  As disease advances, the potential benefits of 
exercise encouraged by formal pulmonary rehabilitation courses are well recognised (37). 
Long term oxygen therapy (>15 hours per day) improves survival in patients with severe 
hypoxia at rest (38, 39). Patients with bullous disease or upper lobe predominant 
emphysema may be appropriate for surgical bullectomy or lung volume reduction surgery 
(40). However patient selection is important as there is a higher risk of death in patients with 
very poor lung function (FEV1 <20% predicted or gas transfer of <20% predicted) (41). 
Appropriate patients who remain symptomatic with a poor quality of life despite maximal 
medical treatment should be considered for lung transplantation (34). National transplant 
centres have specific referral criteria and many patients may not be suitable candidates due 
to age, comorbidity, BMI, smoking status, osteoporosis or co-existent infection with HIV or 
hepatitis. The importance of good palliative care for patients with end-stage disease has 
also been highlighted in international guidelines (4). Figure 1.2 demonstrates the relative 
value of some of the treatments and interventions outlined above in the management of 
COPD. 
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Figure 1.2: COPD ‘Value’ Pyramid 
This ‘Value’ Pyramid was designed by the London Respiratory Team and demonstrates the 
relative value of different treatments and interventions in the management of COPD (42). 
dƌŝƉůĞƚŚĞƌĂƉǇƌĞĨĞƌƐƚŽƚŚĞƵƐĞŽĨĂƐƚĞƌŽŝĚͬ>ŝŶŚĂůĞƌĂŶĚĂůŽŶŐĂĐƚŝŶŐŵƵƐĐĂƌŝŶŝĐ
antagonist inhaler (LAMA such as Tiotropium). QALY: Quality Adjusted Life Year, LABA: Long 
acting beta agonist.  
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1.1.3 Pathogenesis of COPD 
The pathophysiology of COPD has not been entirely elucidated but is known to involve 
complex genetic and environmental interactions. The immune response within the lung to 
inhaled smoke and noxious particles is known to involve cells of both the innate and 
adaptive immune systems (43). However, many questions remain regarding the precise 
nature of this immune response, in particular, what drives the on-going airway inflammation 
following smoking cessation. The apparent self-perpetuating inflammation in COPD may 
represent a breakdown in ‘self-tolerance’ raising the possibility that there is an autoimmune 
component to the pathogenesis of this disease (44, 45).  
The role of the innate immune response in COPD, primarily the infiltration of neutrophils and 
macrophages is well defined (46). However, it is the less clearly defined adaptive immune 
response outlined in Figure 1.3 that is of particular interest for this thesis. The induction of 
adaptive immune activation starts with the ingestion of antigen by immature dendritic cells. 
Dendritic cells perpetuate the innate immune response through the secretion of cytokines 
and play a key role in presenting antigen to T lymphocytes thereby promoting their 
proliferation and differentiation into antigen specific effector cells. Activated helper T cells 
can then promote B cell activation and the production of antibody-secreting mature B cells 
(47).  
The adaptive immune response in COPD is evidenced by the presence of T cells, B cells and 
‘lymphoid follicles’ within the lungs of patients with COPD (48-52).  These lymphoid follicles 
are comprised of B cells and follicular dendritic cells, surrounded by CD4+ T cells (52). They 
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contain germinal centres which is where B cell proliferation and differentiation into mature 
antibody-secreting plasma cells and memory B cells occurs (53). The number of CD8+ T cells 
and B cells present in both the central and peripheral airways of patients with COPD have 
been shown to correlate with airflow obstruction as measured by FEV1 % predicted (48-51). 
Although these correlations do not prove causality it certainly suggests a role of T and B cell 
responses in the perpetuation of inflammation in patients with COPD. It has been 
hypothesised that mature B cells within the lymphoid follicles may produce auto-antibodies 
that promote pulmonary inflammation and the subsequent destruction of lung tissue 
causing emphysema. Lee et al reported an increase in circulating anti-elastin antibodies in 
patients with emphysema compared to controls. Furthermore, they isolated anti-elastin 
antibody secreting B cells from the peripheral lung of patients with emphysema (54). 
Polverino et al found B-cell-activating factor (BAFF – a member of the tumour necrosis factor 
family) expression was increased in the peripheral lungs of patients with COPD. BAFF 
improves B-cell survival and promotes B cell maturation, and its over-expression has been 
reported in a number of autoimmune diseases (55-57). 
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Figure 1.3: The adaptive immune response in COPD 
This figure shows a simplified overview of the adaptive immune response within the lung of a patient with COPD (43, 45). The antigenic trigger 
is not known but it is thought that smoke constituents and infective agents may play a role ○1 . Another theory is that the damage caused to the 
lung through inflammation and oxidative stress may produce so called ‘self’ antigens causing a breakdown in self-tolerance ○2 . Dendritic cells 
ingest antigen ○3  before presenting it to T cells ○4  which proliferate and differentiate into antigen specific effector T cells. CD8+ cytotoxic T 
cells cause apoptosis and cell death of targeted cells by releasing proteolytic enzymes such as perforin and granzymes ○5 . CD4+ helper T cells 
play a role in promoting B cell proliferation and antibody isotype switching ○6 . Within lymphoid follicles B cells mature into antibody-secreting 
plasma cells and memory B cells ○7 . There is some evidence to suggest that mature plasma cells secrete auto-antibodies ○8  thereby promoting 
further pulmonary inflammation and tissue damage (54, 58). 
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At present, the antigenic stimulus to the adaptive immune response in COPD is unknown. 
Viral and bacterial infections have been implicated and the bacterial colonisation of the 
lower airways of patients with COPD is one potential explanation for the chronic 
inflammatory response (59). Another hypothesis is that tissue destruction and oxidative 
stress brought about by the initial environmental insult results in the modification of self-
proteins, producing antigens that are recognised as foreign thereby triggering the adaptive 
immune response (46, 60).  
1.2 Alpha-1 antitrypsin deficiency (A1ATD)3 
Alpha-1 antitrypsin deficiency (A1ATD) is an under-recognised hereditary disorder first 
described by Laurell and Eriksson in 1963, after they linked the absence of an α1 globulin 
band on serum protein electrophoresis to the presence of premature emphysema (62). 
Alpha-1 antitrypsin is a 52 kDa, single chain glycoprotein, with a 394 amino acid sequence 
(63). It is synthesised predominantly in the liver and functions as a serine proteinase 
inhibitor or ‘serpin’, providing essential protection to lung tissue against the actions of 
proteolytic enzymes such as neutrophil elastase (NE) and proteinase 3 (PR3).  
1.2.1 Clinical features of A1ATD 
Deficiency of circulating A1AT is associated with multiple conditions including emphysema, 
hepatic cirrhosis (64), panniculitis (65), bronchiectasis (66) and vasculitis (67).   
3 Excerpts of this chapter have been previously published (61. Brebner JA, Stockley RA. Recent 
advances in alpha-1-antitrypsin deficiency-related lung disease. Expert review of respiratory medicine. 
2013;7(3):213-29; quiz 30.) 
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1.2.1.1 Clinical manifestation of A1ATD in the lung 
1.2.1.1.1 Emphysema 
The premature onset of emphysema was the first identified clinical manifestation of A1ATD 
described in 1963. The classical distribution has a lower zone predominance (68) however all 
zones can be affected. In one study of 102 A1AT deficient patients, 65 (64%) had 
predominantly basal changes and 37 (36%) had a greater degree of apical emphysema (69). 
It was also noted in this study that basal emphysema had a closer association with FEV1 
impairment than apical emphysema, confirming previous observations in usual COPD (70).  
1.2.1.1.2 Bronchiectasis 
Initial reports of the incidence of bronchiectasis in A1AT deficient individuals were as high as 
43% although based on small study populations (66, 71).  In a larger study of 74 severely 
deficient subjects, Parr et al reported the incidence of “clinically relevant” bronchiectasis to 
be 27% which is similar to the reported incidence in usual COPD (72). Using a different 
approach, Cuvelier et al looked at the frequency of deficiency alleles in 202 patients with 
known bronchiectasis compared to a control group and concluded that there was no 
association. They did however, note a higher Z allele frequency in bronchiectasis associated 
with emphysema (73).  Whether or not A1ATD is an independent risk factor for 
bronchiectasis or that bronchiectasis simply occurs in association with emphysema remains 
unresolved and requires a sufficiently powered case control study with usual COPD (74).  
1.2.1.1.3 Small airways disease and bronchodilator reversibility 
A1ATD can be associated with varying degrees of airflow obstruction even varying within 
individual patients. A study of 1052 subjects with A1ATD from the National Heart, Lung and 
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Blood Institute (NHLBI) Registry found that 82% reported symptoms of wheeze without a 
cold and 70% described ‘attacks of wheezing’ associated with breathlessness. The onset of 
these attacks was around 31 years of age, therefore the initial diagnosis of asthma given in 
young A1AT deficient individuals is unsurprising. The study found that 49% of patients 
demonstrated significant reversibility at some stage of their follow up, and the average 
increase in the FEV1 was 382ml (+/-180). Reversibility (defined as an FEV1 increase of ≥ 12% 
and at least 200ml post bronchodilator) was even seen in 12.5 % of patients with a normal 
FEV1 suggesting bronchial hyper-responsiveness may be an early feature of the disease 
process (75). Analysis of data from the UK and US A1AT registries has shown that 
bronchodilator reversibility is associated with a more rapid decline in FEV1 (76, 77). The 
difficulty in distinguishing asthma and COPD in A1AT deficient patients is particularly 
challenging, and recognising overlap between the two conditions is important to ensure 
appropriate therapeutic strategies are used to prevent an accelerated decline in lung 
function (78). 
1.2.1.1.4 Clinical phenotypes 
Emphysema and airflow obstruction often coexist, however as seen in usual COPD, subsets 
of patients with either marked emphysema and preserved spirometry or severe airflow 
obstruction with relatively little parenchymal destruction are identifiable. The lung disease 
associated with A1ATD exhibits considerable heterogeneity and the recognition of distinct 
clinical phenotypes is important as this may lead to more individualised therapy. This 
pathological disparity was first postulated by Parr et al partly reflecting the distribution of 
the emphysema with apical disease having little effect on FEV1 (69). Holme et al confirms 
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this in a prospective study of individuals identified with physiological discordance (normal 
FEV1 and low diffusing capacity and vice versa) (79).  
An observational study of 745 patients with severe A1ATD compared subjects with 
emphysema, chronic bronchitis and ‘asthma overlap’(80). This study found chronic 
bronchitis patients were younger, with a lower number of pack years and had better 
preserved lung function. A greater proportion of ‘asthma overlap’ patients were women 
(55.2%) compared to the emphysema group (34.8%). This highlights the importance of 
patient characterisation in the study of A1ATD.  
1.2.2 Diagnosis and treatment of A1ATD 
1.2.2.1 Diagnosis 
The first step in the diagnosis of A1ATD is the assessment of serum A1AT level which can be 
performed by most clinical laboratories.  If found to be low, more detailed testing of the 
A1AT phenotype and genotype are then performed to confirm which deficient alleles have 
been inherited (81). The A1AT protein is encoded for by the SERPINA1 gene which is 
composed of seven exons on the long arm of chromosome 14 (14q31-32.3) (63). Inheritance 
occurs in an autosomal co-dominant manner. The traditional Pi (proteinase inhibitor) 
nomenclature uses alphabetical abbreviations to denote the speed of migration of the 
different allelic variants on gel electrophoresis (82). The M allele is the ‘normal’ variant and 
the commonest deficiency variants are S and Z which migrate more slowly. The Pi phenotype 
refers to the type of circulating A1AT identified by serum electrophoresis whereas 
genotyping relies on the use of specific probes to identify abnormal allelic sequences. The 
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majority of individuals are homozygotes for the normal M allele. The majority of individuals 
with ‘severe pathophysiological deficiency’, classified by a serum A1AT level below the 
putative protective threshold (11μM), have the PiZZ genotype (83). Rarely individuals can 
also inherit ‘null’ alleles which do not produce any detectable A1AT protein by routine 
quantitative methods and hence cannot be phenotyped. The commonest deficient 
phenotype is PiZ, which includes both PiZZ and PiZnull genotypes (61). There is however a 
large number of other rare genetic variants with over 100 alleles having been identified. 
Some are similarly deficiency alleles such as Mmalton and Mprocida and some are dysfunctional 
variants such as the F variant which results in A1AT with a reduced capacity to bind to NE 
(84).  
In 2003, a joint statement from the American Thoracic and European Respiratory Societies 
recommended genetic screening for all symptomatic adults with COPD or adult onset 
asthma with incompletely reversible airflow obstruction (83). However, the majority of 
severely A1AT deficient patients predicted epidemiologically remain undiagnosed. The 
concept of population based screening has been entertained, but at present only targeted 
testing of high risk groups is recommended (85, 86).  
1.2.2.2 Treatment 
The current mainstay of treatment of A1AT related COPD is similar to that of usual COPD 
(85). This involves the use of inhaled bronchodilators and steroids, pulmonary rehabilitation, 
long term oxygen therapy, antibiotics and steroids during exacerbations in addition to 
smoking cessation advice and preventative influenza and pneumonia vaccinations. Patients 
with end-stage disease are referred if appropriate for transplantation.  
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The evidence for unilateral and bilateral lung volume reduction surgery (LVRS) is limited to a 
number of case series.   Compared to the outcomes in non-A1ATD related emphysema, the 
magnitude of improvement seen post LVRS, appears to be less and is not sustained for the 
same length of time (87-89).  A case series assessing endobronchial valve (EBV) placement as 
an alternative to surgical LVRS demonstrated a median FEV1 improvement of 0.575L to 
0.905L (p= 0.028) with an associated improvement in BODE index (90). Studies with larger 
numbers and longitudinal data will be needed before any firm conclusions can be drawn of 
long term benefit, but this approach may play a role in bridging younger patients to 
transplant.  
1.2.2.2.1 Augmentation 
Intravenous administration of A1AT derived from pooled human plasma is only available in 
some countries as doubts remain over its efficacy and cost effectiveness. Augmentation 
therapy can certainly increase and sustain serum levels above the accepted protective 
threshold (11μM, 80mg/dl or  ̴57mg/dl by nephelometry) at a dose of 60mg/kg plasma 
derived A1AT once weekly and increase the anti-NE capacity in the epithelial lining fluid of 
the lungs (91). Evidence regarding the clinical efficacy of augmentation therapy is less clearly 
defined.  The majority of evidence is based upon observational cohort studies and three 
randomised controlled trials (results summarised in Table 1.1) (92-94).   
The reasons that only a small number of randomised controlled trials have been carried out 
are likely to reflect a number of challenges including the relative rarity of the disease, ethical 
justification for IV placebo arms, high cost, and need for a long duration of follow up (95, 
96).
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Table 1.1: Summary of randomised controlled trials comparing A1AT augmentation to placebo in patients with severe A1ATD. 
Study 1 and 2 demonstrated a trend towards a beneficial effect of augmentation therapy on the annual decline in 15th percentile lung density 
(PD15). A post-hoc integrated analysis which combined the result of 1 and 2 and adjusted for lung volume found a significant difference in lung 
density change in the augmentation group compared to placebo. This finding was replicated in a larger randomised controlled trial (RCT) (Study 
4) looking at annual lung density change at total lung capacity (TLC). FRC: Functional Residual Capacity, Yr: Year, SEM: standard error of the
mean, Rx: treatment).
Study Study design Methods Follow up Primary outcomes 
1. Dirksen et al
1999 (92)
RCT 56 PiZZ patients 
4 weekly infusions of A1AT or placebo. 
Monitored with spirometry and annual 
CT densitometry (PD15).  
3 yrs Annual loss of lung density (mean ± SEM) in placebo 
group was 2.6 ± 0.41g/L/yr compared to 1.5 ± 
0.41g/L/yr in A1AT Rx group (p = 0.07) 
2. Dirksen at al
2009 (93)
RCT 77 PiZZ/PiZnull patients  
Weekly infusions of A1AT or placebo 
2 – 2.5 yrs A trend towards a beneficial effect of augmentation on 
decline in lung density was seen (p = 0.049-0.084). No 
difference in exacerbation frequency but a reduction in 
exacerbation severity was observed 
3. Stockley et al
2010 (95)
Post hoc 
analysis of 1 
and 2. 
119 patients included in combined 
analysis of PD15 densitometry data. 
Results adjusted for lung volume. 
Mean 2.5 yrs Least squares mean change in lung density (PD15) from 
baseline to last CT scan in placebo group was -6.379g/L 
compared to -4.082g/L in A1AT Rx group (p=0.006) 
4. Chapman et
al 2015 (94)
RCT 180 patients (serum A1AT <11µM). 
Weekly infusions of A1AT or placebo 
2 yrs Annual loss of lung density at TLC (mean ± SEM) in 
placebo group was -2.19 ± 0.23g/L/yr compared to -
1.45 ± 0.25g/L/yr in A1AT Rx group (p=0.03). No 
difference seen at FRC. 
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The variability of lung function and damage even in smokers with A1ATD indicates that 
management should be individualised. Smoking cessation slows or stops progression and 
other lung function can decline even when the FEV1 remains stable. Thus, assuming 
augmentation therapy is effective it will remain critical to assess progression accurately 
through a variety of methods and only instigate therapy when clear evidence of decline 
above age related changes, is confirmed. Biomarkers that could identify potential so-called 
‘rapid-decliners’ are therefore an attractive prospect and could be particularly beneficial in 
the field of A1ATD in establishing which patients may benefit from augmentation therapy. 
1.2.3 Pathogenesis of A1ATD 
‘Serpins’ such as A1AT are structurally composed of three β sheets (A-C) and eight or nine 
alpha helices (A-I) with an exposed mobile reactive loop containing residues that act as 
pseudosubstrates for the targeted proteinase (97, 98). In the case of A1AT, a methionine 
residue at position 358 in the polypeptide chain is critical for the interaction with neutrophil 
elastase (NE). The process of proteinase binding brings about a conformational change 
within the A1AT protein, whereby the enzyme cleaves the reactive centre loop, which moves 
to the opposite pole of the protein taking the tethered proteinase with it, before being 
inserted into β sheet A. The structural deformation of the proteinase that occurs as a result 
is key to the inhibitory function of the serpin (99). Serpins have a metastable native state 
that becomes more stable during proteinase inhibition. This makes them prone to aberrant 
structural formation and protein misfolding as a result of genetic mutations (100).  
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1.2.3.1 Polymerisation  
The Z mutation occurs due to the substitution of lysine for glutamic acid at position 342 in 
the polypeptide chain. The resulting structural change promotes the interaction of the 
reactive centre loop of one molecule and the gap in the β sheet A of another causing 
molecular linkage or so-called ‘loop sheet polymerisation’ (101). 
Intracellular accumulation of Z-variant A1AT polymers within the endoplasmic reticulum (ER) 
of hepatocytes can lead to neonatal hepatitis, hepatic cirrhosis and hepatocellular carcinoma 
(102). The resulting lack of circulating A1AT predisposes individuals to proteolytic attack of 
their lung tissue resulting predominantly in emphysema. However, this explanation of the 
pathogenesis of lung disease in A1ATD is over-simplified as we now recognise that the 
manifestation relies on a complex combination of these mechanisms and other 
environmental and genetic factors. 
1.2.3.2 Mechanisms of lung disease in A1ATD 
Figure 1.4 summarises the different mechanisms by which lung tissue is damaged in A1ATD. 
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Figure 1.4: Pathogenic mechanisms responsible for the development of emphysema in 
A1ATD. 
1. Polymerisation in the liver results in serum and lung deficiency, causing unopposed
neutrophil elastase activity as a result of the recruited neutrophils, which in turn can
activate other classes of enzymes in addition to other uninhibited serine proteinases. The
net result is proteolytic degradation of the lung tissue leading to emphysema. In
addition, neutrophil elastase-derived peptide and chemokines can amplify the
neutrophilic load and accelerate parenchymal damage through further release of
proteinases.
2. Polymerisation within the lung leads to local ER stress and establishment of a post-
inflammatory cascade including increased neutrophil recruitment. Lung polymers are
also chemoattractants, recruiting and localising neutrophils further.
3. The loss of the anti-inflammatory properties of A1AT promotes an adaptive immune
response within the lung through the production of antigens as a result of inflammation
and oxidative stress. An increase in T cell and B cells and lymphoid follicles are seen,
however, exactly how they contribute to further parenchymal destruction is not fully
understood.
A1AT: Alpha-1-antitrypsin, MMP: Matrix metalloproteinase, Pr3: Proteinase 3, LTB4: 
Leukotriene B4, ER: Endoplasmic reticulum.
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1.2.3.2.1 Proteinase: antiproteinase theory 
Our knowledge of the pathophysiology of emphysema in A1ATD started with the 
‘proteinase: antiproteinase’ theory. Following the observations made by Laurell and Eriksson 
it was subsequently demonstrated that neutrophil elastase could reproduce changes in 
animal models suggestive of emphysema (103). The development of this animal model and 
the recognition of A1AT as an NE inhibitor formed the basis of the proteinase:antiproteinase 
hypothesis whereby imbalance  in favour of NE (104) leads to excessive tissue destruction 
and hence emphysema.  
There is extensive literature on the role of NE in the pathogenesis of emphysema in A1ATD, 
but other proteinases may also be relevant. Proteinase 3 (PR3) is a serine proteinase found 
in the azurophil granules of neutrophils which also causes emphysema in animal models 
(105). PR3 activity has been shown to be greater than NE in sputum of A1AT deficient 
individuals especially during exacerbations suggesting a potential role (106). Matrix 
metalloproteinases (particularly MMP-12) and cysteine proteinases such as Cathepsin B have 
also been implicated as having a direct role in proteolytic alveolar destruction (107, 108). 
Interestingly, NE has been shown to upregulate MMP-2 and Cathepsin B expression in vitro 
(109) as well as inactivating their relevant inhibitors resulting in further enzyme/inhibitor
imbalance and  a ‘proteinase cascade’ (110). 
1.2.3.2.2  Chemotactic mediators 
High neutrophil counts have been observed in broncheoalveolar lavage (BAL) specimens 
from A1AT deficient patients (111). Neutrophils are key effector cells in airway inflammation 
and have the potential to accelerate parenchymal damage through release of their 
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proteinases. Multiple factors affecting neutrophil recruitment and activation have been 
suggested. Leukotriene B4 (LTB4) is a potent neutrophil chemotactic mediator found in 
increased concentration in the sputum of A1AT deficient patients (112). Furthermore studies 
of sputum chemotactic activity identified both LTB4 and interleukin 8 (IL8) as significant 
contributors to chemotaxis (113) although only the former correlated with the total 
migratory potential. In vitro experiments demonstrated that LTB4 is released following the 
binding of alveolar macrophages to NE, supporting the concept that a proteinase imbalance 
could promote neutrophilic inflammation through the excess production of this chemokine 
(114).  A reduction in sputum LTB4 concentrations in A1AT deficient individuals occurs in 
response to augmentation therapy (115) confirming this as a likely mechanism.   
In a murine emphysema model, elastin degradation products found in BAL fluid have been 
shown to be chemotactic for monocytes. Using a monoclonal antibody (mAb) to inhibit these 
elastin fragments, eliminated the chemotaxis in vitro. Administration of the same mAb at the 
time of cigarette exposure was also shown to reduce the accumulation of macrophages in 
the lung and abrogated the development of emphysema in vivo (116). Since elastin 
degradation is likely to be a key process in the development of emphysema in A1ATD, it is 
possible that elastin fragments also play a role in amplifying neutrophilic inflammation but 
direct evidence is lacking. 
1.2.3.2.3 A1AT polymerisation and the lung 
Z A1AT polymers have been identified in the BAL fluid from A1AT deficient patients (117). 
This extra-hepatic polymerisation may serve to exacerbate the deficiency further in these 
individuals, given the lack of functional anti-proteinase activity of polymerised A1AT. The Z 
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polymers have also been shown to activate neutrophils, manipulate neutrophil shape, 
promote adhesion and stimulate myeloperoxidase (MPO) release in vitro (118). Mahadeva et 
al subsequently demonstrated that polymers of A1AT co-localise with neutrophils in the 
interstitium of PiZ individuals which may also add to the connective tissue degradation. 
Furthermore, Mahadeva and colleagues also showed that instilling polymers into the lungs 
of mice resulted in a significant neutrophil influx (119) which may reflect a direct or indirect 
chemoattractant process.  
Although the majority of A1AT is produced in the liver, it is also synthesised by other cells 
including bronchial and alveolar epithelial cells (120) supported by the presence of Z A1AT 
polymers in the BAL fluid of a patient 9 years post liver transplant (121). The potential pro-
inflammatory properties of polymerised, locally produced, Z A1AT in the lung may partly 
explain the progression of emphysema despite augmentation therapy in some individuals or 
the delay in efficacy seen in clinical trials (92, 93). 
The importance of recognising these so called ‘gain of function’ effects within the lung 
including the concept of ‘ER stress’ (brought about by the accumulation of misfolded Z A1AT 
protein in the ER) and the activation of associated inflammatory signalling pathways has 
been emphasised in recent years (122). ER stress can have multiple effects including NFκB 
activation, promotion of ER associated degradation and apoptosis (123).   
1.2.3.2.4 Role of the adaptive immune system 
In addition to the unopposed action of proteases and gain of function effect of 
polymerisation, the adaptive immune system is now thought to play an important role in the 
pathogenesis of lung damage in A1ATD. There is growing evidence of the anti-inflammatory 
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role of A1AT in addition to its protease inhibitory function (124). It has been hypothesised 
that the absence of A1AT can therefore promote an adaptive immune response within the 
lung through the production of antigenic material as a result of inflammation and oxidative 
stress (125). Baraldo et al examined explanted lungs from patients with severe A1ATD and 
found an increase in CD4+ and CD8+ T cells, B cells and lymphoid follicles compared to 
controls.  Interestingly the B lymphocytes identified within the lymphoid follicles were 
monoclonal suggestive of an immune response to a specific antigen. Moreover, the number 
of CD4+ T cells and B cells correlated with the degree of airflow obstruction within these 
patients (125). Similar findings have been found in usual COPD as previously discussed 
suggesting this is a common pathogenic mechanism to both usual and A1ATD related COPD. 
1.3 Biomarkers: why are they needed in COPD and A1ATD?4 
A ‘biomarker’ is defined as “a characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes, or pharmacologic responses 
to a therapeutic intervention”(127). One of the main drives behind establishing validated 
biomarkers is their utility as surrogate end points in clinical trials. Decline in FEV1 has 
historically been used as the primary outcome measure for pharmacological studies in COPD, 
however its’ limitations in this role are well recognised. FEV1 is a non-specific marker of 
COPD, can have significant day to day variation, doesn’t identify phenotypic subgroups and 
does not usually respond to short-term therapeutic strategies (128). As a significant amount 
4 Excerpts of this section have been previously published (61. Ibid., 126. Hampson JA, Turner 
AM, Stockley RA. Polyclonal free light chains: promising new biomarkers in inflammatory disease. 
Current Biomarker Findings. 2014;4:139-49.) 
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of damage must be done to airways before FEV1 is altered, biomarkers that correlate with 
FEV1 have been described as being “reflective rather than predictive” (128). The use of 
quantitative CT scanning has been supported as an alternative end-point to FEV1 particularly 
in the field of A1ATD (95). However, the potential drawbacks include radiation exposure to 
the patient from sequential scanning and the limited number of centres with adequate 
expertise to ensure consistency of acquisition of densitometry data. Biomarkers that can be 
measured using a simple blood test are therefore an attractive prospect.  
The ECLIPSE study was a large prospective observational study, which aimed to identify 
novel surrogate markers superior to FEV1 that would predict disease progression in COPD 
and help phenotype patients (129).  Severe A1ATD was one of the exclusion criteria for 
enrolment in this study. Table 1.2 summarises the blood biomarkers that were investigated 
in the ECLIPSE trial and the associations found (130). Despite a large number of subsequent 
publications only fibrinogen has since been accepted by the U.S Food and Drug 
Administration as a prognostic biomarker for COPD clinical trials (131). One of the main 
issues highlighted as a potential reason for this is lack of adequate validation (130). Ideally a 
biomarker should be central to the pathophysiology of the disease process, relate to disease 
activity and severity, be stable and fluctuate only with disease flares, predict disease 
progression and be sensitive to treatments known to be effective (128).  
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Studies Biomarker Associations 
(132-134) WCC COPD presence, exacerbation risk, mortality and is stable at follow up 
(132, 133, 135) CRP COPD presence, disease severity (FEV1), mortality  
(132, 133) IL6 COPD presence, mortality 
(133, 135) IL8 Disease severity (FEV1), mortality 
(133, 136, 137) Fibrinogen* COPD presence, disease severity (FEV1), exacerbation frequency, symptoms (MRC 
dyspnoea scale), exercise capacity (6MWT), BODE index and mortality 
(133, 138) Surfactant protein D COPD presence, exacerbation risk, mortality and is responsive to steroid treatment 
(135, 139, 140) CC-16 COPD presence, FEV1 decline, depression 
(11, 141) CCL-18 COPD presence and mortality 
(142) Vitamin D Disease severity (FEV1 and emphysema severity), exercise capacity (6MWT) and 
bronchodilator response 
Biomarker panels 
(132) Inflammome: WBC, CRP, IL6, IL8, 
fibrinogen, TNFα 
Exacerbation risk, mortality 
Table 1.2: Summarising the blood biomarkers investigated in the ECLIPSE trial 
WCC: white cell count, CRP: C reactive protein, IL6: interleukin 6, IL8: interleukin 8, CC-16: clara cell secretory protein 16, CCL-18: CC-
chemokine-ligand-18, FEV1: forced expiratory volume in 1 second, 6MWT: 6 minute walk test, BODE index: Body mass index, airflow 
Obstruction, Dyspnoea and Exercise, MRC: Medical Research Council. (Adapted from (130)).
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The term ‘heterogeneity’ is used time and again with respect to the clinical presentation, CT 
findings, response to treatments and prognosis in patients with COPD. It follows that the 
underlying pathogenesis of the lung disease in individuals may differ as a result of different 
gene-environment interactions. Identifying specific subgroups of patients that may have 
either a preferential or disadvantageous prognosis or response to specific 
immunomodulatory treatments is therefore key in the future approach of managing COPD. 
The use of a biomarker or indeed a panel of biomarkers to help delineate key subgroups is 
therefore an attractive prospect. To date the potential of free light chains as a novel 
biomarker in patients with COPD has not been explored.  
1.4 Free Light Chains5 
1.4.1 Background 
An essential component of adaptive immunity is the production of antibodies by mature B 
lymphocytes. Antibodies are immunoglobulins which are composed of two identical 
polypeptide heavy chains and two identical light chains linked by non-covalent forces and 
disulphide bonds (144) (Figure 1.5). There are two light chain isotypes: kappa (κ) and lambda 
(λ) and each immunoglobulin molecule contain only one of these isotypes. In the process of 
5 Excerpts of this section have been previously published (126. Hampson JA, Turner AM, Stockley 
RA. Polyclonal free light chains: promising new biomarkers in inflammatory disease. Current 
Biomarker Findings. 2014;4:139-49, 143. Brebner JA, Stockley RA. Polyclonal free light chains: 
a biomarker of inflammatory disease or treatment target? F1000 Med Rep. 2013;5:4.) 
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antibody production there is an excess of free light chains (FLCs) produced daily which are 
secreted into the circulation before undergoing renal clearance (145).  
1.4.1.1 Monoclonal versus polyclonal FLCs 
FLCs produced by multiple B cell clones are termed ‘polyclonal’, whereas Bence Jones 
Proteins (BJPs) are ‘monoclonal’ FLCs produced by a malignant proliferation of a single clone 
of B cells. Much of the understanding of the structure and immunological properties of light 
chains originally came from the study of BJPs as they could be readily isolated from both 
serum and urine specimens for analysis (146). 
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Figure 1.5: Intact immunoglobulin and free light chain structure 
Immunoglobulins and free light chains are produced by mature B lymphocytes. Each 
immunoglobulin is composed of two heavy chains and two light chains linked by disulphide 
bonds. Light chains are polypeptides containing both a variable and a constant region. The 
serum  free light chain (FLC) assay targets epitopes which are concealed between the light 
and heavy chains within the immunoglobulin molecule but exposed in circulating FLCs (147). 
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1.4.1.2 FLC structure variability 
Light chains are polypeptides containing both a variable and a constant region. The amino 
acid sequence of the variable region of light chains is unique to each FLC and the number of 
amino acid residues in this region can differ (144). The complementary determining residues 
within the variable region of the light chains contribute to the diversity and heterogeneity of 
FLCs. This is likely to, at least in part, be responsible for their differing capacity to aggregate 
and their varying pathogenic potential (148). 
“Free” light chains (i.e. those not bound to heavy chain within an immunoglobulin molecule) 
can exist in monomeric, dimeric or higher oligomeric and polymeric forms (144, 148-151). 
Classically, kappa FLCs are described as generally monomeric in form but can exist as a non-
covalently linked dimer. On the contrary lambda FLCs are usually dimeric in form with 
covalent bonds between them (144) (Figure 1.5).  
1.4.1.3 FLC synthesis 
Excess FLCs secreted into the circulation are not produced by immunoglobulin breakdown 
(152), but are synthesised de novo by B cells which are matured beyond the pre-B cell phase 
(153). Immunoglobulins are produced by polyribosomes within the endoplasmic reticulum 
which is where the synthesis of both heavy chains and light chains occurs (154). 
Interestingly, there is a conformational difference between the polypeptides of light chains 
that are newly synthesised compared to those secreted. The former ‘precursor’ light chain 
has up to 20 additional amino-terminal residues (155, 156). These extra residues are cleaved 
prior to secretion of the FLC. Initially thought to be an unimportant by-product, the 
immunological properties of these secreted light chains are now an area of much interest.  
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1.4.1.4 Production of polyclonal FLCs in inflammation 
As FLCs are produced in excess as a by-product of antibody production by B cells, measuring 
FLCs has been proposed to be a biomarker of ‘B cell activity’ (145). Interest in polyclonal FLCs 
as a biomarker started with the observation of increased concentrations in a variety of 
biological fluids including blood, synovial fluid, cerebrospinal fluid (CSF) and BAL in patients 
suffering from different inflammatory and autoimmune conditions. Raised polyclonal FLCs 
have been reported in systemic lupus erythematosus (SLE) (157, 158) rheumatoid arthritis, 
Sjögren’s syndrome (159), multiple sclerosis (160), atopic dermatitis (161), food allergy 
(162), inflammatory bowel disease (163), sarcoidosis (164) and a number of respiratory 
conditions including asthma (165), rhinitis (166), idiopathic pulmonary fibrosis, 
hypersensitivity pneumonitis (167), and COPD (168). 
In a review by Wahren-Herlenius et al they describe how “B cell differentiation and 
activation thresholds are disturbed, leading to skewing of the B cell pool and immunoglobulin 
production” in systemic autoimmune disease (169). SLE is an example of an autoimmune 
disease characterised by production of multiple autoantibodies and 
hypergammaglobulinaemia (169). It seems plausible that the excess FLCs produced during 
this humoral B cell response explains the increase polyclonal FLCs seen in the disease state. 
However, an increase in circulating FLCs has also been observed in inflammatory conditions 
which are not typically associated with autoantibody production, such as asthma and 
idiopathic pulmonary fibrosis (165, 167). This is presumed to be due to polyclonal B cell 
activation. An increase in FLCs in response to certain viral infections has also been observed 
(170, 171), such that it is conceivable acute on chronic changes could occur in patients with 
chronic inflammation and coexistent viral infection.  
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1.4.2 Free light chain measurement 
The eponymous ‘Bence Jones protein’ was first described in 1847 (172). Historically serum 
and urine protein electrophoresis and immunofixation electrophoresis have been employed 
to quantify monoclonal FLC overproduction and diagnose a number of haematological 
conditions including monoclonal gammopathy of undetermined significance, multiple 
myeloma, primary systemic amyloidosis and light-chain deposition disease. More recently an 
automated nephelometric immunoassay was developed that could quantify both kappa and 
lambda FLC with high sensitivity and specificity in the serum (147). The assay works by 
utilising antibodies that bind to epitopes on the FLCs which are concealed by the interface 
between the heavy chain and the light chain in an intact immunoglobulin molecule. (Figure 
1.5).  
The use of this serum FLC assay has been incorporated into many guidelines negating the 
need for urine electrophoresis in the screening of many haematological disorders (173). The 
quantity of circulating FLCs depends on the balance between synthesis by B cells and 
clearance within the kidney. A number of factors can affect the production of FLCs some of 
which I have already discussed (e.g. polyclonal B cell activation in autoimmune and 
inflammatory conditions). However, in these situations the kappa lambda ratio should 
remain within the normal range. In patients with monoclonal gammopathies, a monoclonal 
FLC overproduction will alter the balance between kappa and lambda FLC production 
resulting in an abnormal ratio (173). Immune suppression by either a disease process or as a 
result of drug therapy can cause a reduction in FLC production. Serum FLCs have a half-life of 
2-6 hours and are both excreted and catabolised by the kidney thus impairment in renal
function will result higher circulating FLC concentrations (174, 175) although the κ/λ ratio 
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should remain unaltered. Katzmann et al  (176) established the normal ranges for serum κ 
and λ FLCs using the automated immunoassay (κ 3.3 – 19.4 mg/L, λ 5.7 – 26.3 mg/L, κ/λ ratio 
0.26 – 1.65).  
1.4.3 Biological functions and evidence of direct pathogenic role in 
other inflammatory diseases 
In recent years our advancing knowledge of the diverse immunological functions of FLCs has 
also generated new interest in their potential pathogenic role in chronic inflammatory 
disease. Studies of the interaction between FLCs and polymorphonuclear leukocytes were 
prompted by the need to understand why patients with renal failure were at increased risk 
of bacterial infections. Due to reduced renal clearance, FLCs are increased in the serum of 
patients with renal failure and their ability to act as a ‘uremic toxin’ was therefore 
investigated (177). Cohen et al demonstrated that polyclonal FLCs isolated from the plasma 
of patients undergoing haemodialysis inhibited the apoptosis of neutrophils in vitro (178). 
Neutrophils are key effector cells in the innate immune response and apoptosis is essential 
for the resolution of inflammation, thus by inhibiting apoptosis FLCs could potentially be 
responsible for perpetuating chronic neutrophilic inflammation.  FLCs have also been shown 
to influence other neutrophil functions. FLCs themselves are not chemotactic but when 
added to neutrophils they inhibit the chemotaxis towards FMLP (a strong neutrophil 
chemoattractant) (177). In addition, Cohen et al showed that FLCs can reduce neutrophil 
activation in response to FMLP as measured by a reduction in deoxyglucose uptake (177). 
Paradoxically Braber et al found that FLCs can bind to neutrophils in vitro and stimulate IL8 
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production, identifying another mechanism by which FLCs could influence inflammation 
(168). 
Redegeld et al demonstrated that FLCs can elicit hapten-specific hypersensitivity reactions in 
sensitised mice (179). FLCs can bind to mast cells promoting activation and degranulation. 
This effect can be inhibited by using the FLC antagonist ‘F991’. Tamm-Horsfall protein is a 
glycoprotein which is synthesised within the kidney and can bind to both κ and λ FLCs. 
Utilising knowledge of the FLC binding site within this glycoprotein, F991 a 9-mer peptide 
sequence of the Tamm-Horsfall protein was developed to inhibit FLCs interactions with mast 
cells (179, 180). 
Hutchinson et al demonstrated that FLCs bind to a variety of cell membranes (181). They 
confirmed this by incubating biotinylated FLCs with different cells and using streptavidin 
allophycocyanin to detect bound protein. This indicated binding to a number of different cell 
lines as well as peripheral blood mononuclear cell subtypes. In particular, there was a high 
binding affinity for monocytes leading to speculation regarding the role of FLCs in antigen 
presentation and immune response initiation. Subsequently Thio et al demonstrated the 
ability of FLCs to bind directly to antigen and supporting the potential to initiate antigen 
specific cellular responses (182). 
1.4.4 Polyclonal FLCs and mortality 
Polyclonal FLC overproduction has been shown to be associated with an increased risk of 
mortality. Dispenzieri et al followed up over 15000 individuals aged 50 or over who had 
undergone FLC analysis and recorded their mortality and cause of death. All of the patients 
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included in the study had a normal κ/λ ratio thereby excluding any underlying monoclonal 
gammopathies. Correcting for age, sex and renal function they found a combined FLC level 
of greater than 47.2 mg/L was associated with a 2.07 hazard ratio (HR) for death (183). 
These results were echoed in a subsequent study where combined FLC results above a 
higher cut off point of 65mg/L were associated with a high risk of death within 100 days (HR 
7.1, p = 0.015) (184). Forty-one % of the deaths during this period of the study were due to 
cardiovascular causes. A polyclonal increase of FLCs has subsequently been shown to be a 
risk factor for cardiovascular events in patients with type 2 diabetes (185) and an 
independent risk factor for mortality in patients hospitalised with decompensated heart 
failure (186). 
Three large studies have looked at the role of polyclonal FLC concentrations in predicting 
mortality in patients with varying severity of chronic kidney disease (CKD). In all, combined (κ 
& λ) FLC levels were found to be an independent predictor of mortality (187-189). These 
studies highlight the potential utility of polyclonal FLCs in risk-stratification in both the 
general population and disease cohorts.  
1.5 FLCs and the pathogenesis of COPD 
In addition to the potential utility of polyclonal FLCs as a biomarker of adaptive immune 
activation in COPD, there is evidence that suggests FLCs could play a pathogenic role. 
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1.5.1 FLCs and neutrophil interaction 
As previously discussed FLCs are biologically active molecules and on a mechanistic level 
there is evidence they have biological properties that could potentially lead to lung tissue 
damage through their effects on neutrophil function (177, 178). Neutrophils are key effector 
cells in the pathophysiology of COPD. The effects impaired neutrophil function can have on 
promoting inflammation in COPD is currently a topic of much interest, and methods aiming 
to restore normal neutrophil function are becoming an attractive prospect for novel 
therapeutic strategies (190).  
Braber et al published a paper linking FLCs and neutrophils in the pathogenesis of COPD 
(168).  The study demonstrated increased FLC levels in the serum of three murine models of 
emphysema and six patients with COPD compared to controls. In addition, they 
demonstrated that FLCs can bind to human neutrophils and activate them to produce IL8 in 
vitro. F991 (a FLC antagonist) was also shown to inhibit this binding capability and reduce the 
neutrophilia within the BAL fluid in a smoke exposed mouse model. 
1.5.2 Light chain deposition disease 
There are a growing number of case reports detailing cases of nodular and cystic lung 
disease associated with FLC overproduction in light chain deposition disease (LCDD) (191-
198). This is a rare haematological condition which is characterised by the deposition of non-
amyloid kappa or lambda light chains within the body due to overproduction by a single 
clone of plasma B cells (199, 200). In 2006, Colombat et al were the first to describe three 
cases of LCDD presenting with a progressive cystic lung disease, ultimately leading to 
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respiratory failure necessitating lung transplantation (193).  In this case report, the 
microscopic pathological features seen in the lung were described as “patchy deposits of an 
amorphous eosinophilic material in alveolar walls, small airways and vessels. 
Emphysematous like changes were present at the edge or at distance of the deposits”.  
Immunofluorescence staining of this eosinophilic material taken from tissue specimens was 
positive for κ light chains.  The HRCT findings of one of the patients in this case report 
showed a confluent cystic abnormality with a basal predominance (Image D, Figure 1.6) 
which bears a resemblance to the basal panlobular emphysema seen in alpha-1 antitrypsin 
deficiency (Figure 1.7).
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Figure 1.6: High resolution computed tomography (HRCT) scans of two patients with light 
chain deposition disease demonstrating progressive cystic abnormality (image reprinted 
with permission6) 
HRCT images show interval CT scans for two patients (patient 1 – A, B, patient 2 – C, D). 
Image D shows the large thin walled cysts which have become confluent with a basal 
predominance. 
Figure 1.7: High resolution computed tomography scan showing basal panlobular 
emphysema in a patient with alpha-1-antitrypsin deficiency  
6 Reprinted with permission of the American Thoracic Society. Copyright © 2017 American Thoracic 
Society. 193. Colombat M, Stern M, Groussard O, Droz D, Brauner M, Valeyre D, et al. Pulmonary 
cystic disorder related to light chain deposition disease. American journal of respiratory and critical 
care medicine. 2006;173(7):777-80. The American Journal of Respiratory and Critical Care Medicine 
is an official journal of the American Thoracic Society.
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1.6 Aims 
We know that the adaptive immune system is involved in the pathogenesis of both usual and 
A1ATD related COPD but the exact role T cells and B cells play in the contribution to 
inflammation within the lung is not fully understood. Measuring the circulating FLCs in 
patients with COPD may provide an insight to the degree of activation of the adaptive 
immune system within those individuals. The primary aim of this study was to investigate 
the utility of polyclonal FLCs as a clinical biomarker in patients with severe alpha-1 
antitrypsin deficiency (A1ATD) and usual COPD. In order to achieve this, polyclonal FLCs 
were measured in two large patient cohorts to establish whether they: 
• Were static during stable disease
• Related to disease severity
• Distinguished clinical relevant subgroups or phenotypes
• Rose during periods of increased disease activity (i.e. during clinical exacerbations)
• Were associated with longitudinal outcomes such as mortality
These feature were chosen because they represent properties of a good biomarker (128). In 
addition, we examined whether levels were similar in usual COPD to A1ATD. This was 
undertaken, in part, to ascertain whether pulmonary immune activation is similar in the two 
groups, as has been shown by Baraldo et al (125) and in part to ensure replication of our 
results, which is appropriate for any biomarker study (127).  
Ideally to satisfy all the criteria of a useful clinical biomarker we would also explore whether 
polyclonal FLCs are sensitive to effective intervention strategies (128). However, at present 
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there is a lack of pharmacological interventions that have been proven to explicitly impact 
on disease progression (201). This serves to highlight the importance of improving our 
understanding of the complex pathogenic mechanisms involved in the development of COPD 
as this has the potential to provide new avenues to develop much needed 
immunomodulatory treatments. 
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CHAPTER 2: Methods7 
2.1 Study design and population 
2.1.1 A1ATD cohort 
547 patients with severe A1ATD (with a level below the putative critical threshold of 11μM) 
were included in this retrospective observational study and were selected according to their 
genotype. Only patients with a severely deficient genotype who had a stored serum sample 
taken at the time of their baseline assessment were included. These participants were 
recruited from the ADAPT programme (Antitrypsin Deficiency Assessment and Programme 
for Treatment) which is a large cohort of highly characterised patients with A1ATD, who 
undergo annual follow up in a research clinic setting. As part of this research programme 
these patients have detailed lung function assessments and consented to the use of their 
medical records and stored biological samples for research purposes. Genotyping of all 
patients was performed by Heredi Lab Inc (Salt Lake City, USA). ADAPT was approved by the 
South Birmingham Research and Ethics Committee (Ethics approval number 3359a, see 
Appendix for consent form). Figure 2.1 shows the flow of participants through the study and 
the numbers of patients included in the subgroup analyses. For the purposes of this study 
patients were followed up to gain information on mortality. Our centre was informed of 
patient deaths even if they were no longer able to attend the research clinic and hence no 
patients were lost to follow up for this endpoint. 
7 Excerpts of this chapter have been previously published (202. Hampson JA, Stockley RA, Turner 
AM. Free light chains: potential biomarker and predictor of mortality in alpha-1-antitrypsin deficiency 
and usual COPD. Respir Res. 2016;17:34.) 
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Figure 2.1 Flow of patients through the A1ATD cohort  
A1ATD = alpha-1-antitrypsin deficiency, FLC = free light chain 
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2.1.2 Usual COPD cohort 
The usual COPD patients in this study were identified from two separate established cohorts 
which have now merged. The West Midlands COPD Collection (WMCC) is a cohort of 
patients with usual COPD who have given informed consent as part of a study investigating 
COPD phenotypes and progression. A diagnosis of COPD on the basis of spirometry was 
required for recruitment to this study and patients were then offered more detailed lung 
function testing and a CT thorax for more detailed phenotyping. The WMCC received ethical 
approval from the South Birmingham National Research Ethics Service (NRES) committee 
(REC ref no. 07/H1207/231).  
A second cohort of patients with COPD (excluding those with A1ATD) had been recruited 
through the Inflammatory Research Facility at Queen Elizabeth Hospital, Birmingham. This is 
a study examining clinical phenotypes, disease progression and epigenetics in patients with 
COPD and its associated co-morbidities. The study received ethical approval from the East 
Midlands NRES committee (REC ref no. 12/EM/0090). In both of these cohorts, patients 
consented to the use of their biological samples and access to their medical records for 
research purposes. Figure 2.2 shows the flow of patients through this cohort. Consent forms 
for both usual COPD cohorts are available in the Appendix. 
2.1.2.1 Exacerbation cohort 
Patients with an acute exacerbation of COPD were prospectively recruited into a sub-study 
aimed at examining the inflammatory response during these episodes. Recruitment occurred 
across two sites: Birmingham Heartlands Hospital and The Queen Elizabeth Hospital, 
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Birmingham.  Patients were consented within 24 hours of admission to hospital with an 
exacerbation and seen at four time points – day 1, 7, 14 and 56. Serum, plasma, sputum and 
urine samples were collected at each visit. In addition, patients completed the validated 
COPD assessment test (CAT) and were asked to keep a detailed symptom diary. Ethical 
approval for this study was granted by the West Midlands NRES committee – Coventry and 
Warwickshire (REC ref no. 09/H1210/75).
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Figure 2.2 Flow of patients through the usual COPD cohort  
COPD = chronic obstructive pulmonary disease, FLC = free light chain. 
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Figure 2.3 Flow of patients through exacerbation cohort 
COPD= chronic obstructive pulmonary disease, FLC= free light chain, MALT= mucosa-
associated lymphoid tissue. 
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2.1.3 Bronchiectasis cohort 
Patients were recruited to the non-CF bronchiectasis cohort from a larger study entitled “A 
study of clinical phenotypes, disease progression and genetic susceptibility in patients with 
chronic obstructive pulmonary disease and bronchiectasis”. Ethical approval for this study 
was granted by the Birmingham Ethics Committee (code RRK3404) and Newcastle and North 
Tyneside Research Ethics committee (code 12/NE/0248). This was a longitudinal study to 
investigate symptoms, quality of life, lung function, lung radiology, blood and sputum 
markers of disease. Patients were recruited from hospital practice and followed up for 3 
years. Baseline clinical data included demographics, medical history, current smoking status 
and pack years history, medications, presence of chronic bronchitis, exacerbation history 
and MRC and SQRQ scores. The flow of patients through this cohort is shown in Figure 2.4. 
Consent forms for this study population are available in the Appendix.  
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Figure 2.4 Flow of patients through the bronchiectasis cohort 
FLC = free light chain. The FACED score is a severity score based on FEV1, Age, Colonisation 
with pseudomonas, Extent of bronchiectasis and Dyspnoea (measured using the modified 
MRC score). 
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2.2 Clinical data 
Baseline demographic data including age, sex, body mass index (BMI), current smoking 
status and pack years history were collated for the A1ATD, usual COPD and bronchiectasis 
cohorts. Research notes and medical records were used to clarify symptom history (e.g. 
presence of chronic bronchitis), annual exacerbation frequency and mortality. The presence 
of chronic bronchitis was defined using the accepted MRC definition of a cough with sputum 
production for at least 3 months of 2 consecutive years (10). The exacerbation history was 
assessed using the criteria suggested by Anthonisen et al of increased breathlessness, 
sputum volume and sputum purulence (203). 
2.2.1 Colonisation data 
2.2.1.1 Quantitative sputum culture 
Patients in our A1ATD and bronchiectasis cohorts were asked to provide sputum samples for 
quantitative culture whilst in their stable state. This was performed by a research 
microbiologist. The first step in the quantitative culture process involved vortexing 1 gram of 
sputum sample with dithiothreitol (Sputasol, Oxoid Ltd, 100 µg/ml dithiothreitol) for 60 
seconds to homogenise it. The homogenised sample was then serially diluted 
(concentrations 1:10 (10-1) – 1:100000 (10-5)) using distilled water. The diluted samples were 
vortexed again before being plated on chocolate and blood agar plates. Figure 2.5 shows 
how the samples were plated. The plates were put in an incubator at 37◦C and checked for 
bacterial growth at 24 and 48 hours. An appropriate plate was then selected to count the  
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Figure 2.5 Streak plate method for preparing agar plate 
Figure A demonstrates the four quadrant zigzag technique for streaking the prepared 
sputum sample onto the agar plate. Figure B demonstrates how a culture plate prepared 
using this method may look after incubation. Note there are progressively fewer colonies 
across the four quadrants.  Individual colonies can be sampled from quadrant 4 for further 
testing or experiments as required.  
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number of colonies and this was then recorded as the number of colony forming units per 
millilitre (CFU/ml) of the original sputum sample as described previously (204). A number of 
routine techniques including microscopy, gram stain and functional tests (including oxidase 
and catalase tests) were then used to identify the cultured organisms.  
The research microbiology database was searched to find all stable state sputum culture 
results available for the patients in the cohort. A positive culture was defined as a growth ≥ 
105 colony forming units (CFU) per ml of sputum of a “potentially pathogenic organism” (see 
Appendix). There is no clear consensus in the literature regarding the definitions of chronic 
bacterial colonisation (205). Chronic colonisation was therefore defined as ≥3 isolations of  
the same organism from separate sputum samples taken over a minimum of 3 months in the 
stable clinical state, as used previously for defining pseudomonal colonisation in patients 
with bronchiectasis (206). 
2.2.2 Computed Tomography 
In the A1ATD cohort most patients had a high-resolution CT scan performed using a 
quantitative protocol (see Appendix). Routine practice was to look at the formal report and 
record documented emphysema and bronchiectasis; in addition, I interpreted CT scans 
imported from other trusts. During the initial phase all scans were also checked with one of 
my supervisors.  A random 10% of the quantitative protocol research scans were also 
examined to ensure consistency of reporting. Figure 1.7 (Chapter 1) demonstrates basal 
panlobular emphysema characteristic of severe alpha-1 antitrypsin deficiency.  In the usual 
COPD and bronchiectasis cohorts, reports were confirmed from routine CT scans performed 
in clinical practice.  
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2.2.3 Lung function tests 
See Appendix for a list of all lung function tests collated in this study (Appendix 1.4). All of 
the A1ATD patients undergo full lung function testing annually as part of the ADAPT 
research programme. Lung function data was taken from the ADAPT databases 
corresponding to the year the blood was taken for the baseline FLC sample.  
For the usual COPD patients, medical records were examined for lung function test results. 
Due to the acquisition of lung function data from several different hospitals for the usual 
COPD cohort, appropriate equations were used to calculate the predicted lung function 
values for each individual based on the age, sex and height (Appendix 1.5). This was to 
ensure consistency in the % predicted lung function values across different sites. Different 
hospitals use different lung function reference equations including the European Community 
of Steel and Coal (ECSC) (207) and  Global Lung Initiative (GLI) equations (208) which can 
cause small differences in interpretation. For the purposes of the current project all data was 
normalised to the ECSC. 
2.2.4 FACED score 
In the bronchiectasis cohort a combination of clinical data, CT data and colonisation 
information was used to calculate the FACED severity score. The score is calculated based on 
FEV1, Age, Colonisation with pseudomonas, the Extent of bronchiectasis (number of lobes of 
lung involved) and Dyspnoea (assessed using the modified MRC breathlessness score) (209) 
(See Appendix 1.6). The rationale for choosing this severity score is discussed in Chapter 
5.5.2.  
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2.2.5 Renal function analysis 
Due to the renal clearance of FLCs, the potential impact of a patient’s renal function needed 
to be accounted for in all regression and mortality analyses. Each patient’s creatinine and 
urea was therefore recorded. Where possible, results were taken from the same day as the 
sample was taken for FLC analysis. The estimated glomerular filtration rate (eGFR) was then 
calculated using the 4- variable abbreviated MDRD equation (= 186 x (Creat/88.4)-1.154 x 
(Age)-0.203x 0.742 (if female) x 1.210 (if black)) (210). The patients were then grouped 
according to their chronic kidney disease (CKD) stage. For the purposes of this study we 
classified patients into 5 groups (CKD stage 1 (eGFR ≥90), 2 (eGFR 60-89), 3 (eGFR 30-59), 4 
(eGFR 15-29), 5 (eGFR<15)) (211). Newer versions of the guidelines now split CKD stage 3 
into a (eGFR 45-69) and b (eGFR 30-44) however for the purposes of this study we grouped 
stage 3 patients together. 
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2.3 FLC analysis 
FLC analysis was performed on stored serum or plasma samples using the Freelite® 
immunoassay (Binding site Group Ltd, Birmingham, UK) on the SPAPLUS® turbidimeter (TBS). 
This is an automated nephelometric assay that was developed to quantify both kappa and 
lambda FLC with high sensitivity and specificity in the serum (147). As discussed in the 
introduction, the assay works by utilising antibodies that bind to epitopes on the FLCs (which 
are concealed on the interface between the heavy chain and the light chain in intact 
immunoglobulin molecules). Figure 2.6 demonstrates how a nephelometer is used to 
quantify FLC. 
2.3.1 Reference ranges 
The previously established reference ranges used were κ FLC 3.3 – 19.4 mg/L, λ 5.71 – 
26.3mg/L and κ/λ ratio 0.26 – 1.65 (176). κ and λ values were summated to give a combined 
FLC result (cFLC), as it is polyclonal FLC production that is of interest for this study. This 
combined FLC level has been utilised other studies of autoimmune and inflammatory 
diseases and in the general population. The accepted normal reference range for cFLC is 9.3–
43.3 mg/L (183). Patients with an abnormal κ/λ ratio suggestive of a possible underlying 
monoclonal gammopathy were then excluded from the analysis. For patients with chronic 
kidney disease there is an accepted higher ‘renal reference range’ for the κ/λ ratio of 0.37-
3.1. 
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Figure 2.6 Nephelometric FLC immunoassay 
The antibody and FLC antigen react to form a precipitate within a cuvette. Light is then 
shone through the cuvette and the precipitate causes the light to scatter. Antigen 
concentration is then quantified by the degree of light scatter. This method is used to 
quantify the number of kappa and lambda FLCs within the serum sample. 
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2.3.2 Usual COPD cohort –plasma and serum FLC matched samples 
analysis 
In a randomly selected subgroup of 82 patients from the usual COPD cohort, paired serum 
and plasma samples were analysed. Samples were collected from patients and assayed using 
Freelite® by the Binding Site Group Ltd (Birmingham, UK). 3 patients were excluded from the 
analysis due to an abnormal κ/λ ratio. 
2.3.3 Stability analysis 
In 19 A1ATD patients and 59 usual COPD patients with stable disease (according to both 
history and serial lung function) FLC analysis was performed on ≥2 samples collected over a 
period ranging from 1 to 4 years to determine whether levels were static in stable patients. 
2.4 Immunoglobulin analysis 
To see if FLCs had any utility over and above measuring intact immunoglobulins, IgA, IgG and 
IgM was measured in all the patients in the usual COPD cohort (n=327). The testing for this 
cohort was performed by the Binding Site Group Ltd (Birmingham, UK).  11 patients were 
excluded from the further analysis due to an abnormal κ/λ ratio. The reference ranges used 
were as follow: IgA 0.845-4.99 g/L, IgG 6.103-16.16 g/L, IgM 0.35-2.42 g/L. Immunoglobulins 
were also measured in a subgroup of 27 patients in the usual COPD exacerbation cohort. Day 
1 samples taken on admission to hospital and day 56 following resolution of their symptoms 
to determine any relationship to the episode.  
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In the bronchiectasis cohort, clinical database archives were searched to record 
retrospective immunoglobulin analysis results performed in usual clinical practice. 
2.5 Statistical analyses 
All analyses were performed using IBM SPSS statistics version 20. Use of appropriate 
statistical tests were determined by training and confirmed by liaising with the University 
statistician. 
Data was explored and assessed for normality using the Shapiro-Wilk test. Medians and 
interquartile ranges (IQR) were reported for non-normally distributed data and means and 
standard deviations (SD) used for normally distributed data. P values reported are for two-
tailed statistical tests. 
2.5.1 Univariate analyses 
2.5.1.1 Demographic factors, disease phenotypes and mortality 
Combined serum κ & λ free light chain (cFLC) concentrations were compared in subgroups 
according to sex, smoking status, presence or absence of emphysema and bronchiectasis, 
chronic bronchitis, mortality status and exacerbation frequency. The FLC results were not 
normally distributed therefore non-parametric tests (Mann Whitney U) were utilised. Results 
are reported as medians with IQR. 
Mann Whitney U tests were also used to compare cFLC levels in patients chronically 
colonised compared to those who were not in both the A1ATD and bronchiectasis cohorts. 
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Kruskall Wallis tests were used to determine whether cFLC levels were significantly different 
in patients grouped according to their CKD stage (renal function) or GOLD stage (severity of 
airflow obstruction). Post hoc analysis using Mann Whitney U tests were then performed to 
see the groups that were significantly different from each another and Bonferroni 
corrections were performed to calculate the significance of the statistical tests. 
2.5.1.2 Stability analyses 
Friedman Tests were utilised to examine cFLC levels across several time points in subgroups 
of the A1ATD and usual COPD cohorts. Bland-Altman plots were used to demonstrate the 
difference between cFLC levels at follow up compared to baseline. Linear regression analyses 
were also performed to exclude proportional bias of the follow up values. 
2.5.2 Correlations and partial correlations 
A cross-sectional analysis was performed to look for correlations between cFLC levels and 
demographic factors such as age as well as eGFR and lung function parameters in all three 
patient cohorts. Spearman’s Rho correlations were performed as the cFLC levels were not 
normally distributed. 
A Spearman’s Rho correlation was also performed on contemporaneous serum and plasma 
FLC levels in a sub-group of 80 patients in the usual COPD cohort. 
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2.5.2.1 Partial correlations 
Within each cohort, partial correlations were performed to look for any relationship 
between cFLC levels and lung function parameters controlling for other factors shown to 
influence cFLC levels (such as eGFR).  
2.5.3 Regression analyses 
Multivariate analytic techniques were used to adjust for covariates where needed; renal 
function (eGFR) was included in all regression analyses due to FLCs undergoing renal 
clearance.  
2.5.3.1 Logistic regression  
In the A1ATD cohort a multivariate logistic regression was performed to examine which 
variables predicted the presence of chronic bronchitis in the A1ATD cohort. Multiple factors 
are known to predict or relate to chronic bronchitis in patients with COPD including smoking 
status, sex, exacerbation history and severity of airflow obstruction so a multivariate analysis 
was performed to control for these. 
Logistic regression was also used to compare cFLC levels in patient with A1ATD and COPD. 
This was necessary to adjust for eGFR and a number of other factors relating to cFLC levels 
that differed between the cohorts. 
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2.5.3.2 Passing-bablock regression 
In addition to examining the correlation between the plasma and serum FLC levels in the 
subgroup of usual COPD patients, passing-bablock regression was performed to compare 
these analytical methods.   
2.5.3.3 Survival analyses 
In the A1ATD and usual COPD cohort, multivariate regression analyses were performed to 
examine the relationship between cFLC levels and survival. Survival time was calculated from 
the date the FLC sample was taken to confirmed date of death. Patients were divided into 
subgroups according to their serum cFLC level using 2 important threshold levels – the upper 
limit of normal (43.3 mg/L) and the threshold associated with death within 100 days (65 
mg/L (184)) and survival probabilities were plotted using Kaplan-Meier curves. The patients 
were also subdivided into cFLC quartiles and Kaplan-Meier curves were plotted to 
demonstrate the survival of patients in each quartile. Both Log Rank and Breslow tests were 
performed to assess the difference in survival of these groups. 
 In addition, both univariate and multivariate Cox proportional hazards regression analyses 
were performed to estimate the hazard ratios of individual predictors of mortality in both 
cohorts. Multivariate regression covariates were selected if p < 0.1 in the univariate analysis, 
and there was no significant collinearity with other variables. Cox regression was conducted 
using cFLC as a continuous variable, and also according to the thresholds described above. 
Receiver operating characteristic (ROC) curves were drawn to examine the specificity and 
sensitivity of cFLC for mortality prediction in the A1ATD and usual COPD cohorts. 
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In the usual COPD cohort, the same univariate and multivariate analyses were also 
performed to examine the relationship between immunoglobulin levels and demographic 
factors, disease severity and survival; Kaplan-Meier curves, univariate and multivariate cox 
regression and ROC curve analyses were conducted.  
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CHAPTER 3: FLCs as a biomarker in severe A1ATD8 
3.1 Introduction 
The primary aim of this chapter was to investigate the clinical utility of FLCs as a biomarker in 
patients with severe A1ATD. In order to be a useful biomarker there are a number of criteria 
that need to be fulfilled (128). Firstly, a biomarker needs to relate to the underlying disease 
pathology. Severe A1ATD is associated with the premature onset of COPD and immune 
activation may be one of the factors perpetuating inflammation in  COPD (212). The immune 
response seen in COPD incorporates cells from both the innate and adaptive immune 
systems (45); an essential component of adaptive immunity is the production of antibodies 
by mature B lymphocytes. During antibody production there is an excess of free light chains 
(FLCs) produced which are secreted into the circulation before undergoing renal clearance 
(145). FLCs have therefore been promoted as a potential biomarker of adaptive immune 
activation (145). There are two FLC isotypes: kappa (κ) and lambda (λ), which can be 
measured independently by a highly sensitive and specific assay (147). A polyclonal increase 
in combined κ and λ FLC levels (cFLC) has been observed in a number of other autoimmune 
and inflammatory conditions (126). To date there has been one study which reported raised 
polyclonal FLCs in a small number of patients with usual COPD compared to controls (168). 
There is evidence of adaptive immune activation in patients with A1ATD. Baraldo et al 
demonstrated increased numbers of CD4+, CD8+ T cells, B cells and lymphoid follicles in 
8 Excerpts of this chapter have been previously published (202. Hampson JA, Stockley RA, Turner 
AM. Free light chains: potential biomarker and predictor of mortality in alpha-1-antitrypsin deficiency 
and usual COPD. Respir Res. 2016;17:34.) 
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explanted lungs from patients with severe A1ATD compared to controls (125). In addition to 
protease inhibition it is now recognised that A1ATD has other anti-inflammatory roles and 
therefore its absence can promote inflammation and oxidative stress resulting in adaptive 
immune activation. Measuring FLCs as a surrogate marker of adaptive immune activation in 
patients with A1ATD therefore seems logical. 
In addition to relating to the pathophysiology of the disease, a useful biomarker should be 
stable, relate to disease activity and severity, identify clinically important phenotypes, 
respond to treatments which are known to be effective and be associated with clinically 
important outcomes such as disease progression and mortality (128). In order to establish 
whether FLCs could be a clinically useful biomarker, FLCs were measured in a large, highly 
characterised cohort of patients with A1ATD. This chapter gives a detailed outline of the 
demographics and other key patient characteristics of this cohort and also summarises the 
ability of FLCs to fulfil the criteria outlined above. 
3.2 Patient characteristics 
FLC analysis was performed on 547 patients with A1ATD. Seven patients were excluded from 
further analysis due to having an abnormal κ/λ ratio (repeat testing and referral to 
haematology for assessment was advised for these patients). The A1AT phenotypes of the 
remaining 540 patients were as follows: 517 PiZZ, 13 Znull, 8 MmaltonZ and 2 PiFZ. Median 
follow up time was 5.7 (3.9-7.7) years. The demographics of the cohort are outlined in Table 
3.1. Eighty-four % of patients had airflow obstruction (defined as a post-bronchodilator 
FEV1/FVC ratio <0.7); 8 of those without obstruction had emphysema on CT scan. 
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Variable A1ATD cohort (n=540) 
Age (years) 53.9 (45.0 – 60.9) 
Sex Male n = 311 (57.6%) 
Female n = 229 (42.4%) 
Pack years 11.6 (0.0 – 24.0) 
FEV1 (% predicted) 50.7 (35.1 – 85.1) 
KCO (% predicted) 62.3 (49.3 – 77.0) 
Chronic bronchitis 185 (34.3%) 
Emphysema 358 (66.3%) 
Bronchiectasis 142 (26.3%) 
Frequent exacerbator 129 (40.8%) 
eGFR (ml/min/1.73m2) 81.3 (70.6 – 93.9) 
CKD stage  
  1      eGFR ≥ 90 
  2      eGFR 60 - 89  
  3      eGFR 30 - 59 
  4      eGFR 15 - 29 
  5      eGFR < 15 
  Unknown (no eGFR) 
156(28.9%) 
279 (51.7%) 
41(7.6%) 
2 (0.4%) 
1 (0.2%) 
61 (11.3%) 
cFLC (mg/L) 25.7 (21.1 – 31.7) 
κ/λ 0.86 (0.71-1.08) 
Table 3.1: Patient demographics in the A1ATD cohort 
Continuous variables expressed as median (IQR); sex, chronic bronchitis, emphysema, 
bronchiectasis, exacerbators and CKD stage expressed as number in each group (%). A 
frequent exacerbator was defined as having 2 or more exacerbations per year. Number of 
patients with contemporaneous renal function = 479.  BMI = body mass index, FEV1 = forced 
expiratory volume in 1 second, KCO = corrected gas transfer, eGFR = estimated glomerular 
filtration rate, cFLC = combined (κ + λ) free light chain level and the κ/λ ratio is shown.
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3.2.1 FLCs and renal function 
FLCs undergo renal clearance. It was therefore important to take into consideration renal 
function when analysing polyclonal FLC levels. Contemporaneous renal function was 
available for 479/540 patients in the ADAPT cohort as assessed by eGFR. The number of 
patients in each CKD stage was outlined in Table 3.1. The serum cFLC concentrations were 
significantly different in the different CKD stage groups (Kruskall-Wallis test p = 0.006). A 
post hoc analysis (using Bonferroni correction to calculate significant p value cut off ≤ 0.005) 
revealed that patients with CKD stage 3 had significantly higher cFLC levels compared to 
those with CKD stage 1 (median 29.6 (23.0-39.0) v 24.5 (20.3-30.4) mg/L, p=0.003) (Figure 
3.1). 
A Spearman’s Rho correlation revealed a weak negative correlation between cFLC and eGFR 
(rs= -0.14, p=0.003) (Figure 3.1). A significant positive correlation between age and cFLC was 
also demonstrated (rs= 0.15, p=0.001), but this relationship disappeared after adjustment 
for eGFR (rp= 0.08, p=0.101), suggesting this was primarily due to worsening renal function 
with age. Given the renal clearance of FLCs, the relationship to eGFR was expected but 
important to confirm. 
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Figure 3.1: Stable state cFLC levels relationship to renal function in the A1ATD cohort 
Bar chart (A) shows the relationship between combined (κ & λ) FLC (cFLC) and chronic kidney 
disease (CKD) stage (each bar represents the median cFLC value and error bars represent the 
IQR).  Scatter plot (B) shows the relationship between cFLC and estimated glomerular 
filtration rate (eGFR). A post hoc analysis revealed that patients with CKD stage 3 had 
significantly higher cFLC compared to patients with CKD stage 1 (**p ≤ 0.01). A weak 
negative correlation between cFLC and eGFR was also seen (rs=-0.14, p=0.003). 
A 
B 
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3.2.2 Concurrent autoimmune disease prevalence 
Increase polyclonal FLCs have been observed in a number of autoimmune diseases (as 
discussed in section 1.4.1.4). It was therefore important to establish the prevalence of co-
existing autoimmune disease in our A1ATD cohort. The results showed that at least one 
autoimmune disease was present in 15.6% of patients (n=84), the most common being 
thyroid disease (4.1%, n=22), diabetes (3.1%, n=17), ulcerative colitis (2.1%, n=11), psoriasis 
(1.3%, n=7) and vasculitis (0.9%, n=5). However, cFLC levels did not differ between patients 
with and without a co-existing autoimmune disease (autoimmune 26.6mg/L IQR=22.3-34.4, 
versus no autoimmune disease 25.5mg/L IQR=20.8-31.5, p=0.125). There was no difference 
in the number of autoimmune conditions exhibited by the patients with cFLC levels outside 
the normal range (>43.3mg/L) compared to those with normal levels (Chi-squared test, 
p=0.320). 
3.3 Stability of FLCs as a biomarker in severe A1ATD 
In a subgroup of 19 patients within the A1ATD cohort, we analysed 3 further samples in 
addition to their baseline FLC sample with at least 1 year between sample collection time 
points to establish if FLC levels remained stable. All patients were clinically stable (i.e. 
minimum of 6 weeks post exacerbation) at the time of sample collection.  There was no 
significant difference in cFLC levels taken at 4 time points in stable disease (Friedman test, 
p=0.116). 
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Figure 3.2 shows Bland-Altman plots demonstrating the difference between cFLC levels at 
follow up compared to baseline. Linear regression analyses revealed no significant 
proportional bias of follow up cFLC values.  
In stability analyses of other biomarkers in COPD, the proportion of values within 25% of the 
baseline value is often quoted as a measure of stability (136). Within our A1ATD cohort 
44/57 of the follow up cFLC levels were within 25% of the baseline value (77.2%). When 
broken down to the different time-points, the percentage of cFLC values within 25% of the 
baseline were as follows: 84.2% at time-point 1, 78.9% at time-point 2 and 68.4% at time-
point 3.  
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Figure 3.2: Bland Altman Plots showing the differences between cFLC between baseline 
(cFLC1) and three follow up time-points (cFLC2,3,4) 
All cFLC values were log transformed before analysis. The solid horizontal line represents the 
mean difference between the Log10(cFLC) values. The dotted lines represent 95% 
confidence intervals. Linear regression analysis revealed no significant proportional bias 
between baseline and follow up cFLC values. A. Log10(cFLC)1 v 2, t=1.00, p=0.33 B. 
Log10(cFLC)1 v 3, t=1.94, p=0.07 C. Log10(cFLC)1 v 4, t=1.472, p=0.159.
A 
C 
B 
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3.4 FLCs and clinical phenotypes in severe A1ATD 
The results from the univariate analysis of serum cFLC levels in different patient subgroups 
are shown in Table 3.2 for total cFLC as well as κ & λ FLC results and the κ/λ ratio.  
Patients with chronic bronchitis had significantly higher cFLC levels compared to those 
without (median 27.0 v 25.0 mg/L, p = 0.019). This clinically important subgroup of 
patients with COPD suggests a greater adaptive immune response reflecting airway 
inflammation and/or airway colonisation. The λ FLC levels were also significantly higher 
(median 14.4 v 13.5 mg/L, p=0.02) and there was a trend towards the κ levels also being 
higher (median 12.2 v 11.4 mg/L, p=0.08). There was no significant difference in κ/λ ratio 
between the two groups. 
No significant differences were seen with respect to presence of bronchiectasis, 
emphysema, or a history of frequent exacerbations. λ FLCs were, however, significantly 
higher in smokers compared to non-smokers (median 15.6 v 13.7 mg/L, p= 0.044). 
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Group 1 Group 2 P value 
Emphysema Yes (n=358) No (n=145) 
cFLC 25.85 (21.1-31.5) 25.41 (21.3-32.1) 0.982 
κ 11.57 (9.1-15.6) 11.73 (9.2-15.0) 0.978 
λ 13.70 (11.0-16.9) 13.81 (10.6-17.5) 0.872 
κ/λ 0.88 (0.7-1.1) 0.85 (0.7-1.0) 0.646 
Bronchiectasis Yes (n=142) No (n=353) 
cFLC 26.30 (21.8-31.5) 25.41 (20.9-31.9) 0.350 
κ 12.33 (9.7-15.8) 11.55 (9.0-15.5) 0.136 
λ 14.22 (11.2-17.0) 13.80 (10.7-17.3) 0.656 
κ/λ 0.92 (0.7-1.1) 0.84 (0.7-1.1) 0.088 
Chronic bronchitis Yes (n=185) No (n=355) 
cFLC 26.98 (21.7-33.6) 25.02 (20.8-30.8) 0.019* 
κ 12.23 (9.5-16.4) 11.41 (9.0-14.8) 0.080 
λ 14.40 (11.2-17.7) 13.48 (10.6-16.8) 0.020* 
κ/λ 0.89 (0.7-1.1) 0.86 (0.7-1.1) 0.672 
Current Smokers Yes (n=45) No (n=495) 
cFLC 27.39 (22.2-34.3) 25.56 (21.1-31.6) 0.211 
κ 10.90 (9.3-17.1) 11.81 (9.1-15.4) 0.777 
λ 15.64 (12.1-19.9) 13.70 (10.7-17.1) 0.044* 
κ/λ 0.82 (0.7-1.0) 0.87 (0.7-1.1) 0.070 
Gender Male (n=311) Female (n=229) 
cFLC 25.69 (21.4-32.2) 25.75 (20.8-31.1) 0.455 
κ 11.84 (9.3-15.8) 11.41 (8.9-15.0) 0.343 
λ 13.88 (11.2-17.1) 13.54 (10.6-17.2) 0.425 
κ/λ 0.86 (0.7-1.1) 0.86 (0.7-1.1) 0.687 
Frequent exacerbations Yes (n=129) No (n=187) 
cFLC 24.69 (21.8-31.7) 26.36 (20.9-31.7) 0.703 
κ 11.32 (9.0-14.9) 12.23 (9.6-15.4) 0.393 
λ 13.46 (10.9-16.6) 13.84 (10.8-17.5) 0.865 
κ/λ 0.84 (0.7-1.0) 0.91 (0.7-1.1) 0.114 
Table 3.2: Comparing cFLC concentrations in different patient subgroups in the A1ATD 
cohort 
Median individual and combined κ & λ (cFLC) levels (mg/L) reported with inter-quartile range 
in brackets. Mann Whitney U Tests performed to determine any statistical differences 
between groups 1 and 2 (*p ≤ 0.05). Where statistical differences were found the p value is 
highlighted in bold red text. 
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3.4.1 Chronic bronchitis logistic regression analysis 
A logistic regression was performed to establish whether any specific variable predicts the 
presence of chronic bronchitis in the A1ATD cohort (Table 3.3). Chronic bronchitis has 
previously been shown to be more common in men and current smokers (213), associated 
with more severe airflow obstruction and an increased risk of exacerbations (214).  A 
multivariate analysis was therefore necessary, to adjust for these factors. The results 
showed that a three variable model with the following predictor variables: serum cFLC level, 
frequent exacerbations (≥ 2 per annum) and FEV1 (%predicted) was statistically significant 
(omnibus chi-square 16.2, df = 3, p= 0.001). However, the model only accounted for 5 – 7% 
of the variance, with a high negative predictive value (96.2%) but a poor positive predictive 
value - only successfully predicting the presence of chronic bronchitis in 9.7% of the patients. 
A higher cFLC and lower FEV1 were associated with an increased likelihood of having chronic 
bronchitis and frequent exacerbators were 1.7 times more likely to have chronic bronchitis.  
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Variable Univariate analysis 
P value 
Multivariate 
model 
cFLC 0.019* 0.032* 
Current smoking status 0.133 
Pack years 0.023* 
Gender 0.055 
Emphysema 0.553 
Bronchiectasis 0.487 
Frequent exacerbations (≥2) 0.007* 0.041* 
FEV1 (% predicted) <0.001* 0.020* 
KCO (% predicted) 0.010* 
FEV1/FVC 0.007* 
Table 3.3 Predictors of chronic bronchitis in the A1ATD cohort. Univariate analysis and 
multivariate logistic regression model. 
(*2p = ≤ 0.05). Variables with a 2p value of > 0.05 but <0.25 are highlighted in bold. Any 
variables with a p value <0.25 in the univariate analysis were included in the multivariate 
model to ensure no important variables are excluded.  Only one lung function parameter 
was included in the multivariate models to avoid collinearity between variables. The final 
model demonstrated that three variables significantly predicted chronic bronchitis in the 
A1ATD cohort – cFLC, frequent exacerbations, FEV1 (% predicted). 
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3.4.2 FLCs and chronic colonisation of the airways 
The driving force behind the adaptive immune activation seen in patients with COPD is not 
known. It has been hypothesised that colonisation of the airways by bacteria may be an 
important contributing factor. Prior studies looking at the prevalence of colonisation in 
patients with COPD report it to be as high as 48% (215). However, this in part depends on 
the criteria used to define colonisation (e.g. the cut off for airway bacterial load considered 
clinically significant) which appears to have no published consensus. In order to examine the 
relationship between airway colonisation and FLC levels in the A1ATD cohort a comparison 
of patients known to be chronically colonised and patients that had no evidence of 
colonisation (i.e. no positive sputum cultures in their stable state) was performed.  
Clear criteria were used to define which patients in the A1ATD cohort were chronically 
colonised with bacteria, based on the stored research sputum samples (2.2.1.1). Sputum 
specimens taken during stable disease state were available in 152/540 patients. A positive 
culture was defined as a growth ≥ 1 x 105 colony forming units (CFU) per ml of sputum of a 
“potentially pathogenic microorganism (PPM)”. We compared the FLCs of 53 patients who 
had no positive sputum cultures in their stable state and 12 patients who were chronically 
colonised with ≥1 PPM.  Within the chronically colonised group, two patients were colonised 
with pseudomonas, 4 with haemophilus influenza and 6 were chronically colonised with 
more than one organism. Patients who were chronically colonised had significantly higher 
cFLCs compared to patients with no positive cultures (Figure 3.3) (median cFLC 35.7 
(26.4-42.4) versus 26.3 (22.0-31.2) mg/L, p = 0.008). 
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Figure 3.3 Scatterplots showing FLC levels in chronically colonised and non-colonised 
patients. 
The figures show univariate comparisons between chronically colonised and non-colonised 
individuals with the A1ATD cohort. Each dot represents an individual patient and the lines 
represent median values per group. Mann-Whitney U tests were performed to compare the 
groups. A. Combined κ & λ FLC (cFLC) median 35.7 (26.4-42.4) v 26.3 (22.0-31.2) B. κ FLC 
median 18.5 (11.7-21.3) v 12.4 (9.5-15.7) C. λ FLC median 16.9 (14.6-21.2) v 13.7 (10.9-16.7). 
*p ≤ 0.05, **p ≤ 0.01. Graphs B and C show that both the κ and λ FLCs were significantly
higher in the chronically colonised group therefore demonstrating a polyclonal difference.
A 
B C 
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3.5 FLCs relationship to COPD disease severity and activity in 
severe A1ATD 
3.5.1 Disease severity 
FEV1 is the most commonly used marker of disease severity in COPD. Therefore, to establish 
if there was any relationship to COPD disease severity in the A1ATD cohort, the relationship 
of FLCs to baseline lung function parameters was investigated. Within the A1ATD cohort 
455/540 (84.3%) had airflow obstruction as measured by a post bronchodilator FEV1/FVC 
ratio of <0.7. There was no significant difference between the cFLC level in those with and 
without airflow obstruction (median 25.8 (21.2-31.6) v 24.9 (20.9-33.1) mg/L respectively, p 
= 0.937).  
As the FLC results were not normally distributed (Kolmogorov-Smirnov test p <0.001) 
Spearman’s Rho correlations with lung function parameters were performed to look for any 
significant relationships (Table 3.4). Weak positive correlations were seen between κ, κ/λ, 
cFLC and FEV1. A weak positive correlation was also seen between κ FLC levels and FEV1/FVC 
ratio and weak negative correlations between κ FLC levels and RV (residual volume % 
predicted) and κ/λ ratio and RV. Scatterplots (Figure 3.4, 3.5, 3.6) revealed 3 potential 
outliers with very high κ FLC levels (>60mg/L normal range = 3.3-19.4) and cFLC levels 
(>100mg/L normal range = 9.3-43.3). The clinical notes of these patients were examined to 
identify the possible cause for these high cFLC results. One patient had CKD stage 5 so partial 
correlations controlling for eGFR were then performed (see below). The two other patients 
had significant liver cirrhosis. Consideration as to whether these potential outliers should be 
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removed was given. The number of patients outside the 3 median absolute deviations from 
the median was calculated but given the broad range of cFLC results this approach resulted 
in many patients being excluded from analysis. Liver cirrhosis is a complication of A1ATD and 
therefore the condition potentially causing their increased polyclonal FLC level is also 
relevant to the disease cohort and on this basis and the lack of a robust statistical way of 
identifying outliers the decision was made not to exclude them from the analysis.  
As discussed in section 3.2.1, weak negative correlations between cFLC and age and renal 
function (as measured by eGFR) were present. Partial correlations controlling for these 
factors were then performed to determine the effect on the relationship between FLC levels 
and lung function measurements independent of age and eGFR (Table 3.5) Only cases where 
all the appropriate clinical information was available were therefore included in this 
correlation (n = 387). The results show that despite controlling for age and renal function the 
weak correlations between κ FLC levels and lung function remain. 
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FEV1 %p 
(n=539) 
FVC %p 
(n=539) 
FEV1/FVC 
(n=539) 
TLC %p 
(n=449) 
RV %p 
(n=449) 
KCO %p 
(n=455) 
TLCO %p 
(n=454) 
Κ        rs 
  p  
0.105 
0.015* 
0.063 
0.147 
0.087 
0.043* 
-0.055
0.241
-0.115
0.015*
0.034 
0.467 
0.032 
0.492 
λ        rs  
 p 
0.064 
0.140 
0.025 
0.557 
0.052 
0.227 
0.023 
0.633 
-0.020
0.679
-0.008
0.866
0.028 
0.553 
κ/λ    rs 
 p 
0.087 
0.044* 
0.070 
0.102 
0.068 
0.116 
-0.067
0.154
-0.108
0.022*
0.036 
0.444 
0.015 
0.755 
cFLC  rs 
 p 
0.086 
0.046* 
0.042 
0.330 
0.073 
0.092 
-0.019
0.682
-0.067
0.154
0.010 
0.825 
0.026 
0.582 
Table 3.4 Spearman’s Rho correlations between FLC levels and lung function parameters 
FEV1 = Forced expiratory volume in 1 second, FVC = Forced vital capacity, TLC = Total lung 
capacity, RV = Residual volume, KCO = Corrected gas transfer, TLCO = Transfer factor of the 
lung for carbon monoxide, cFLC = combined κ & λ FLC (mg/L), rs= correlation coefficient, %p 
= percentage predicted. (*Statistically significant p values are highlighted) 
Figure 3.4 Scatterplot of κ FLC against FEV1 (% predicted) in the A1ATD cohort 
FLC = free light chain, FEV1 = forced expiratory volume in 1 second. Each dot represents a 
single patient. (Spearman’s Rho rs=0.105, p=0.015) 
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Figure 3.5 Scatterplot of κ/λ ratio against FEV1 (% predicted) in the A1ATD cohort 
FEV1 = forced expiratory volume in 1 second. Each dot represents a single patient. 
(Spearman’s Rho rs=0.087, p=0.044) 
Figure 3.6 Scatterplot of cFLC (mg/L) against FEV1 (% predicted) in the A1ATD cohort 
cFLC = combined κ & λ free light chain (mg/L), FEV1 = forced expiratory volume in 1 second. 
Each dot represents a single patient. (Spearman’s Rho rs=0.086, p=0.046) 
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Cont. Age & 
eGFR 
FEV1 %p 
(n=389) 
FVC %p 
(n=389) 
FEV1/FVC 
(n=389) 
TLC %p 
(n=389) 
RV %p 
(n=389) 
KCO %p 
(n=389) 
TLCO %p 
(n=389) 
Kappa         rp   0.130 0.040 0.130 -0.101 -0.129 0.102 0.100 
 p 0.010* 0.427 0.010* 0.045* 0.011* 0.043* 0.049* 
Lambda      rp 0.058 -0.008 0.078 -0.058 -0.058 0.057 0.061 
 p 0.255 0.873 0.123 0.253 0.254 0.258 0.230 
κ/λ ratio    rp 0.116 0.050 0.103 -0.087 -0.108 0.082 0.058 
 p 0.022* 0.325 0.041* 0.084 0.033* 0.104 0.249 
cFLC     rp 0.099 0.016 0.111 -0.085 -0.099 0.085 0.085 
 p 0.050* 0.750 0.029* 0.094 0.051 0.094 0.092 
Table 3.5 Partial correlation (controlling for age and eGFR) between FLC levels and lung 
function parameters  
FEV1 = Forced expiratory volume in 1 second, FVC = Forced vital capacity, TLC = Total lung 
capacity, RV = Residual volume, KCO = Corrected gas transfer, TLCO = Transfer of the lung for 
carbon monoxide, eGFR = estimated glomerular filtration rate, cFLC = combined (κ & λ) free 
light chain (mg/L), rp = correlation coefficient, %p = percentage predicted. 
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3.5.1.1 FLCs according to GOLD guidelines classification of airflow obstruction in A1ATD 
Although no strong correlations between cFLC and FEV1 were demonstrated, when patients 
were sub-grouped according to the severity of their airflow obstruction (GOLD guidelines: 
mild FEV1 >80% predicted, moderate 50-80%, severe 30-50% and very severe <30%) 
significant differences between the groups were identified (Kruskall Wallis test (χ2(3) = 
11.26, p = 0.01). The median cFLC within the groups were as follows: mild 26.5, moderate 
27.8, severe 25.4, and very severe 23.2. A post-hoc analysis revealed the groups that were 
significantly different from one another (Figure 3.7). A Bonferroni calculation was used to 
calculate the cut off for significance (p ≤ 0.05/10 = 0.005). The only significant difference 
between individual groups was a higher cFLC in patients with moderate airflow obstruction 
compared to those with very severe airflow obstruction (p = 0.002).  
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Figure 3.7 Bar chart showing median cFLC levels in patients sub-grouped according to the 
severity of their airflow obstruction 
Bars represent median combined (κ & λ) FLC (mg/L) in each group. Error bars represent 
interquartile range. **p ≤ 0.005. 
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3.5.2 Disease activity 
In addition to relating to disease severity, an ideal biomarker should reflect ‘disease activity’ 
as a surrogate marker of the underlying pathophysiological process which ultimately causes 
end-organ damage (216). FEV1 decline (i.e. the degree of reduction in FEV1 per year) has 
previously been utilised as a marker of disease activity in COPD. It does have limitations 
however as it doesn’t directly reflect the underlying pathophysiology of the disease and a 
reduction in FEV1 is also reflective of the preceding disease process rather than suggestive of 
current disease activity. However, in the absence of another validated marker of disease 
activity the relationship of FLCs to lung function decline was explored.  
3.5.2.1 Lung function decline 
The relationship between cFLC levels and disease severity as measured by lung function 
parameters in the A1ATD cohort was weak. However, when patients were sub-grouped 
according to the severity of their airflow obstruction a significantly higher cFLC level was 
seen in the moderate versus the very severe group. It has been previously documented that 
FEV1 decline is faster in the earlier stages of COPD particularly GOLD stage 2 (217). To 
establish if this was true within the A1ATD cohort, the decline in FEV1 and KCO were 
calculated for all patients that had a minimum of 4 recorded lung function tests. There was 
adequate physiological data available to calculate FEV1 % decline in 373/540 (69%) and KCO 
% decline in 338/540 (62.6%) of patients. 
Figure 3.8 shows the median FEV1 and KCO % decline per year in the A1ATD cohort 
subdivided according to their degree of airflow obstruction. A significant difference between 
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the FEV1 decline in the different GOLD groups was found (Kruskall Wallis test χ2(4) = 11.7, p 
= 0.02). A post-hoc analysis demonstrated that patients with GOLD stage 2 (moderate) 
airflow obstruction had significantly greater FEV1 decline compared to those with no airflow 
obstruction p=0.002 (Bonferroni calculation was used to calculate the cut off for significance 
p ≤ 0.05/10 = 0.005).  A different pattern was seen in KCO decline (Figure 3.8 B) whereby the 
decline appeared to increase with worsening airflow obstruction. A significant difference in 
KCO decline between the different groups was also demonstrated (Kruskall Wallis test χ2(4) 
= 12.4, p = 0.015) and post-hoc analysis revealed the patients with GOLD stage 4 (very severe 
obstruction) had significantly faster decline in KCO than those with GOLD stage 1 (mild 
obstruction) p= 0.004. 
Despite cFLC being the highest in gold stage 2 patients who also have the greatest rate of 
FEV1 decline there was no significant correlation between FEV1 decline and cFLC (Spearman’s 
Rho rs= 0.087, p=0.095). 
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Figure 3.8 Bar charts showing lung function decline in the A1ATD cohort subdivided by 
GOLD stage of airflow obstruction 
Bars represent median FEV1 % decline per year (A) and KCO % decline per year (B). Error bars 
represent interquartile range.  FEV1 = forced expiratory volume in 1 second, KCO = corrected 
gas transfer. **p ≤ 0.005. 
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3.6 FLCs and longitudinal outcomes in A1ATD 
3.6.1 Mortality 
Sixty-nine (12.8%) patients died during the follow up period. Patients who died had 
significantly higher baseline cFLC levels compared to those still alive (median 29.18 
(22.7-39.9) v 25.17 (21.0-31.0) mg/L, p = 0.001).  Both κ and λ levels were significantly 
higher but there was no significant difference in the κ/λ ratio between the two groups 
suggesting that polyclonal FLC production was higher in those that died (Table 3.6). 
A univariate cox proportional hazards regression analysis identified important mortality 
predictor variables in the A1ATD cohort (Table 3.7). A multivariate analysis was then 
performed and 3 variables were found to significantly predict mortality in this population: 
serum cFLC, age and FEV1 (hazard ratios 1.04 p=0.001, 1.07 p= <0.001, and 0.97 p = 
<0.001 respectively). Only one lung function parameter was included in the multivariate 
analysis to avoid issues due to collinearity between variables.  
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Mortality Dead (n = 69) Alive (n=471) P value 
cFLC 29.18 (22.7-39.9) 25.17 (21.0-31.0) 0.001* 
κ 14.07 (9.8-17.7) 11.55 (9.0-14.8) 0.003* 
λ 15.40 (11.8-20.1) 13.6 (10.7-16.9) 0.005* 
κ/λ 0.94 (0.7-1.2) 0.85 (0.7-1.1) 0.259 
Table 3.6 FLCs and mortality in the A1ATD cohort 
Median individual and combined κ & λ (cFLC) levels (mg/L) reported with inter-quartile range 
in brackets. Mann Whitney U Tests performed to determine any statistical differences 
between the groups (*p ≤ 0.05). Where statistical differences were found the p value is 
highlighted in bold red text. 
Variable Univariate HR (CI) P value Multivariate HR (CI) P value 
Serum cFLC 1.03 (1.01 - 1.04) <0.001* 1.04 (1.01 - 1.06) 0.001* 
Pack years 1.02 (1.00 - 1.03) 0.056 1.01 (0.99 - 1.03) 0.518 
Current smoker 1.02 (0.47 - 2.24) 0.957 
Gender 1.22 (0.74 - 2.01) 0.431 
Emphysema 1.85 (1.01 - 3.39) 0.045* 1.03 (0.47 - 2.25) 0.947 
Bronchiectasis 1.26 (0.75 - 2.13) 0.389 
Frequent 
exacerbator 
1.72 (0.87 - 3.42) 0.120 
Age 1.07 (1.04 - 1.09) <0.001* 1.07 (1.04 - 1.11) <0.001* 
Chronic bronchitis 1.90 (1.17 - 3.08) 0.010* 1.21 (0.67 - 2.17) 0.531 
BMI 0.91 (0.86 - 0.97) 0.002* 0.94 (0.88 - 1.02) 0.137 
eGFR 0.98 (0.97 - 1.00) 0.020* 0.99 (0.98 - 1.00) 0.104 
FEV1 (% predicted) 0.97 (0.96 - 0.99) <0.001* 0.97 (0.96 - 0.99) <0.001* 
KCO (% predicted) 0.97 (0.95 - 0.98) <0.001* 
FEV1/FVC 0.04 (0.01 - 0.18) <0.001* 
Table 3.7 Predictors of mortality in the A1ATD cohort: univariate and multivariate cox 
proportional hazards regression analysis 
HR = hazard ratio, CI = 95% confidence intervals, cFLC = combined κ & λ free light chain level 
mg/L, BMI = body mass index, eGFR = estimated glomerular filtration rate, FEV1 = forced 
expiratory volume in 1 second, KCO = corrected gas transfer, FVC = forced vital capacity. A 
frequent exacerbator was defined as having 2 or more exacerbations per year. (*p ≤ 0.05).
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3.6.1.1 Mortality in cFLC subgroups 
Multivariate cox regression analysis was repeated using 2 important threshold cFLC levels – 
the upper limit of normal (43.3mg/L) and the threshold previously associated with death 
within 100 days (65mg/L) (184) (Table 3.8). The hazard ratio (HR) for death for patients with 
a cFLC level greater than the upper limit of normal in the A1ATD cohort was 2.89 (95% CI 
1.47-5.70, p=0.002). The multivariate analysis demonstrates that this increased risk is 
independent of age and FEV1. When the higher cut of 65mg/L was utilised the HR for death 
increased to 14.97 (95% CI 4.25 – 52.72, p<0.001 Table 3.8). The Kaplan-Meier plots showed 
significant differences in the survival curves according to both these levels (Figure 3.9).  
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Table 3.8 Predictors of mortality in the A1ATD cohort: cox proportional hazards regression 
analysis models 
Model 1 shows that a combined κ & λ free light chain level (cFLC) of greater than 43.3mg/L, 
age and forced expiratory volume in 1 second (FEV1) are independent risk factors for 
mortality in the A1ATD cohort. Model 2 uses a higher cFLC cut off of 65 mg/L. Hazard ratios 
(HR) reported with 95% confidence intervals (CI) in brackets. *p≤0.05 highlighted in red.  
Model 1 Model 2 
Variable Multivariate HR 
(95%CI) 
P value Multivariate HR 
(95%CI) 
P value 
cFLC ≥ 43.3 mg/L 2.89 (1.47-5.70) 0.002* 
cFLC ≥ 65 mg/L 14.97 (4.25-52.72) <0.001* 
Age 1.07 (1.04-1.10) <0.001* 1.07 (1.040-1.10) <0.001* 
FEV1 (% predicted) 0.97 (0.96-0.98) <0.001* 0.97 (0.96-0.98) <0.001* 
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Figure 3.9 Kaplan-Meier curves according to cFLC thresholds in the A1ATD cohort 
Blue line represents patients with a combined κ & λ free light chain (cFLC) of less than A. 
43.3mg/L (the upper limit of normal), n=507, B. 65mg/L, n=533. Red line represents those 
with a cFLC level above these thresholds, n= 33 and n =7 and respectively. The Kaplan-Meier 
plots showed significant differences in the survival curves according to both these levels, A. 
p = 0.001, B. p<0.001 by Log Rank test.
A
B
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3.6.1.2 Mortality according to cFLC quartiles 
The patients were subdivided into cFLC quartiles. The Kaplan-Meier plot demonstrating 
survival of patients in each quartile (Figure 3.10) shows that during the initial period of 
follow up an increase in cFLC quartile was associated with a higher mortality (Breslow test p 
= 0.003). However, as the survival curves cross at later time points the log rank test was not 
statistically significant (p= 0.115). 
 
 
 
Figure 3.10 Kaplan-Meier curves according to cFLC quartiles in the A1ATD cohort 
Patients were subdivided into combined κ & λ free light chain (cFLC) quartiles. The coloured 
lines represent each quartile: blue represents quartile 1 (cFLC 10.2 - 21.2 mg/L), orange 
represents quartile 2 (cFLC 21.12 - 25.7mg/L), green represents quartile 3 (cFLC 25.7 - 
31.7mg/L) and red represents quartile 4 (cFLC 31.7 – 151.2mg/L), n = 135 in each group. 
Breslow p=0.003, Log Rank p = 0.115. 
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3.6.2 ROC curve analysis 
Figure 3.11 shows a receiver operating characteristic (ROC) curve which examines the 
specificity and sensitivity of cFLC for mortality prediction in the A1ATD cohort. The area 
under the curve was 0.62 (95% CI 0.5-0.69, p=0.001). The overall accuracy of cFLC in 
identifying patients who die subsequently is therefore poor.  
Figure 3.11 Receiver operating characteristics (ROC) curve assessing the sensitivity and 
specificity of combined κ & λ FLC for mortality prediction in severe A1ATD  
Area under the curve = 0.62 (95% CI 0.5-0.69, p=0.001). 
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3.7 Discussion 
The results presented in this chapter report the ability of FLCs to fulfil the criteria of a useful 
clinical biomarker in A1ATD related COPD.  
3.7.1.1 FLC Stability 
No significant difference was seen in cFLCs taken from patients with stable disease at 
different time points over several years, suggesting that cFLCs are reproducible in stable 
disease. FLC stability compares well to other biomarkers in COPD. For example Dickens et al 
looked at the repeatability of biomarkers in the ECLIPSE cohort (136) including the 
percentage of subjects in which the 3-month follow up sample was within 25% of the 
baseline for 16 biomarkers. CC-16 and fibrinogen were the only biomarkers with superior 
stability to FLCs (with 90% and 89% within 25 % of baseline respectively compared to 84.2% 
for FLC at the first follow up). However, the results are not entirely comparable as their 
follow up time frame was shorter in the ECLIPSE cohort and therefore less variability may be 
expected. Nevertheless, overall the stability of FLCs is similar to that of other promising 
COPD biomarkers.  
3.7.1.2 FLC relationship to disease phenotypes 
Useful biomarkers should help identify disease phenotypes which may help stratify 
treatment strategies. For example, a prior study demonstrated that AαVal360 (a NE specific 
fibrinogen cleavage product) was higher in patients with severe A1ATD and visible 
emphysema compared to those without (218). Within the A1ATD cohort a number of 
differences in cFLC between various patient subgroups were identified.  
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Patients with chronic bronchitis were found to have significantly higher cFLC levels 
compared to those without. Chronic bronchitis is recognised to be a clinically relevant 
subgroup within airways disease being associated with more rapid FEV1 decline (219), 
increased exacerbation frequency (220) and a greater risk of death (221). However, the 
difference between cFLCs in patients with chronic bronchitis compared to those without was 
relatively small, thus the result must be interpreted with clinical caution. 
The prevalence of other autoimmune diseases was low in our A1ATD cohort, and no 
relationships were seen between cFLC levels and autoimmune disease burden. However, 
prior studies suggest that cFLCs change during periods of disease ‘activity’ (e.g. in 
rheumatoid arthritis (159) and systemic lupus erythematosus (157)) such that presence of 
well controlled (inactive) autoimmune conditions might explain the lack of association 
observed.  
Many questions regarding the role B cells play in the development of COPD remain 
unanswered. For example, which antigens drive the B cell response? Is the response specific 
to the lung or not? Commonly hypothesised antigen sources are microbes colonising the 
airways, smoke constituents and breakdown products of the extracellular matrix (222). In 
the A1ATD cohort we found that chronically colonised patients had significantly higher cFLC 
levels, supporting the hypothesis that colonisation itself may be an important factor in 
adaptive immune activation. Another theory is that infection or colonisation with bacteria 
leads to a breakdown in self – tolerance, promoting an immune reaction to self-antigens. 
This concept is well established in a number of autoimmune diseases (223). In support of this 
theory, Calabrese et al have shown that the novel cytokine Interleukin-32 (IL-32) is 
expressed within the lungs of patients with COPD and may play a role in amplifying the 
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adaptive immune response to antigens by promoting the production of other pro-
inflammatory cytokines such as TNFα (224). IL-32 has been shown to be upregulated in other 
autoimmune conditions such as rheumatoid arthritis and inflammatory bowel disease (225, 
226). 
The results also showed that current smokers had significantly higher λ FLC levels compared 
to non-smokers or ex-smokers. Smoking is known to affect the adaptive immune response 
within the lung. Interestingly several studies have shown smoking to be associated with a 
systemic reduction in immunoglobulin levels (227-231) however the mechanism by which 
this occurs is unknown. Mili et al observed lower immunoglobulin levels but 37% higher B 
cell counts in smokers versus non-smokers in a large cohort of middle aged men (230). 
However, higher autoantibody levels in smokers have also been reported (232).  
3.7.1.3 FLC relationship to disease severity 
There was no difference in cFLC in patients with and without airflow obstruction in the 
A1ATD cohort. From previous studies the median cFLC in a healthy population is ≈ 20mg/L 
(176) which is lower than that of our A1ATD cohort even in the absence of airflow
obstruction. This may suggest that patients with A1ATD show evidence of a greater adaptive 
immune response even when they have not developed airflow obstruction. However, to 
confirm this and determine its course we would need to measure FLCs in an age and renal 
function matched healthy population.  
The fact that A1ATD patients with normal lung function have a cFLC comparable to those 
with airflow obstruction may reflect the likelihood that some of these patients may have 
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early lung disease with lung function still within the normal range. Indeed, eight patients 
who did not have airflow obstruction still had emphysema seen on their CT scan. Within the 
group with normal spirometry there was a trend toward those with emphysema having a 
higher cFLC level although this did not meet statistical significance (median 30.1 v 24.6, 
p=0.063).  An alternative explanation is that an increase in FLC production may occur as a 
result of inflammation caused by the unopposed action of proteases, Z A1AT polymerisation 
within the liver or lung (ER stress) and other immune modulatory effects resulting from the 
lack of A1AT (125). 
Other biomarkers show a relationship to disease severity however there was not a strong 
relationship between cFLC and FEV1 in A1ATD. When patients were sub-grouped according 
to the severity of their airflow obstruction, a significantly higher cFLC level was, 
nevertheless, seen in the moderate (GOLD stage 2) versus the very severe group (GOLD 
stage 4). This is somewhat counterintuitive since the number of B cell follicles in the lung of 
patients with COPD increases with worsening airflow obstruction however (49). A 
contemporaneous increase in excess FLC production with increasing lymphoid follicle 
number would therefore seem more likely and a clear relationship (at least with severity) 
might be expected. However, FLC was assessed in the blood and not the lung. The concept of 
systemic inflammation and circulating inflammatory markers resulting from an ‘overspill’ 
from the lung remains an area of debate (233). If this is true of FLCs in COPD then measuring 
FLCs as a marker of B cell activation within the lung may be expected to be a measure of 
current local disease ‘activity’ rather than ‘severity’. The data may therefore suggest that 
although there are a greater number of B cells within the lung of A1ATD patients with more 
severe COPD (125) it does not necessarily reflect the degree of B cell activation in terms of 
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immunoglobulin and FLC production. This may explain the lack of relationship between cFLC 
and FEV1. It is also possible that patients with more severe COPD may have been more likely 
to be taking immunomodulatory drugs such as high dose inhaled or oral steroids. Treatment 
with corticosteroids has been shown to reduce the lymphocytic infiltration of the small 
airways in COPD (234) and reduce the number of lymphoid follicles in severe COPD (235).  
3.7.1.4 FLC relationship to disease activity 
In other autoimmune and inflammatory conditions such as rheumatoid arthritis and 
systemic lupus erythematosus, FLCs have been shown to relate to disease activity as 
measured by disease activity scores such as the Disease Activity Score S28 (DAS28) and the 
SLE disease activity index (SLEDAI) (157, 159).  
Disease activity in COPD is generally regarded as low with slow progression. FEV1 decline is 
often used as a surrogate marker for disease activity in patients with COPD. 
It is recognised that average FEV1 decline is faster in the earlier stages of COPD particularly 
GOLD stage 2 (217). Within the A1ATD cohort, patients with GOLD stage 2 (moderate) 
airflow obstruction had significantly faster annual FEV1 decline compared to those without 
airflow obstruction. However, despite GOLD stage 2 patients also having a significantly 
higher cFLC level compared to GOLD stage 4 patients no significant correlation between cFLC 
and FEV1 decline was evident.  
FLCs have a short half-life of around 2-3 hrs for κ FLCs and 5-6hrs for λ FLCS (236). In a study 
examining the use of FLCs as a biomarker in RA and primary Sjogren’s syndrome this was 
promoted as a potential benefit as they were deemed to reflect short term disease activity 
better than other markers of B cell activity with a longer half-life such as total 
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gammaglobulin or IgG levels (159). FEV1 decline has disadvantages as a marker of disease 
activity in COPD as it could be considered as more reflective of rate of end organ damage 
rather than short term disease activity. The relationship between circulating FLCs and 
disease activity in A1ATD related COPD may be better assessed by looking at FLCs during 
COPD ‘exacerbations’ where there is a temporary worsening of symptoms requiring 
additional treatment.  This was not possible within the A1ATD cohort but was performed 
within a usual COPD cohort (See Chapter 4.6.2). 
3.7.1.5 FLC relationship to longitudinal outcomes 
Patients who subsequently died during the period of follow up were found to have a 
significantly higher baseline FLC level compared to those who remained alive. This is 
consistent with the finding that a high FLC level is a risk factor for mortality within the 
general population (183). Multivariate analysis by Cox regression, to assess whether cFLC 
associated with mortality, showed that cFLC, increasing age and lower FEV1 (all p<0.001) 
significantly predicted death, with a cFLC level above the normal range conferring an odds 
ratio for death of 2.89 (1.47 - 5.70) p=0.002. The Kaplan-Meier plots showed significant 
differences in the survival curves according to both this level and the higher figure of 
65mg/L. 
The fact that the ROC curve c-statistic was 0.62 does not preclude cFLC as a useful prognostic 
test in severe A1ATD. For mortality prediction, a number of combined variables is often 
utilised and it is recognised that the use of single c-statistics could cause important risk 
factors to be excluded from cumulative risk prediction scores (237). A large study 
investigating the ability of inflammatory biomarkers to improve mortality prediction in COPD 
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found the best predictive model utilised the following variables: age, BODE and 
hospitalisation history (C statistic of 0.686, p<0.001) but the addition of a panel of 
inflammatory biomarkers increased that to 0.726 (p=0.003) (133). The ability of cFLC to 
improve mortality prediction as part of a model of both clinical risk factors and blood 
biomarkers is therefore worthy of further investigation.  
3.7.1.6 Conclusions 
Overall FLCs do fulfil some criteria of a useful biomarker demonstrated by their stability 
during the stable disease state, relationship to certain phenotypes (chronic bronchitis 
and chronic colonisation) and mortality. The strongest feature is the ability to predict 
mortality and this could be useful in risk stratifying patients with the aim of early 
intervention to improve outcomes. 
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CHAPTER 4: FLCs as a biomarker in usual COPD9 
4.1 Introduction 
In Chapter 3, the ability of polyclonal free light chains to fulfil the criteria of a useful clinical 
biomarker in severe A1ATD was examined. In order to establish whether the associations 
found were also true in “usual” (non A1ATD) COPD and therefore applicable to a larger 
patient population, FLC analysis was performed in a cohort of 327 patients and the following 
criteria were again assessed: 
1. Relationship to underlying disease pathophysiology
2. Stability
3. Ability to identify clinically important phenotypes
4. Relationship to disease severity and activity
5. Ability to predict longitudinal outcomes
In addition to the criteria listed above an ideal biomarker should also be sensitive to 
treatments that are known to be effective however (as discussed in Chapter 1) this is difficult 
as at present there is a lack of pharmacological interventions that have been unequivocally 
proven to impact on disease progression in COPD (201).  
9 Excerpts of this chapter have been previously published (202. Hampson JA, Stockley RA, Turner 
AM. Free light chains: potential biomarker and predictor of mortality in alpha-1-antitrypsin deficiency 
and usual COPD. Respir Res. 2016;17:34.) 
111 
Braber et al first linked FLCs and their association with neutrophils to the underlying 
pathogenesis of usual COPD (168). They found increased serum FLC levels in three smoke-
exposed murine models and in a small number of usual COPD patients (n=6) compared to 
controls. Immunohistochemical staining using κ and λ specific antibodies was performed on 
lung specimens from patients with COPD and an increase in FLC expression around large 
airways and within follicles was observed compared to specimens from healthy control 
subjects. In addition, in vitro experiments demonstrated that FLCs could bind to neutrophils 
and promote IL8 production and treating mice with F991 (an FLC antagonist) reduced the 
BAL neutrophil counts of the smoke exposed murine lungs (168). This highlighted the 
potential pathogenic role FLCs may have in COPD as well as being a surrogate marker of 
adaptive immune activation within the lung. 
Baraldo et al found a similar degree of adaptive immune activation in the lungs of patients 
with A1ATD related and usual COPD as evidenced by the number of lymphocytes and 
lymphoid follicles (125). Similar levels of polyclonal FLCs might therefore be expected.  In 
addition to examining the clinical utility of FLCs as a biomarker in usual COPD in this chapter, 
a comparison with the A1ATD cohort was also undertaken.   
4.2 Patient Characteristics 
FLC analysis was performed in 327 patients with usual COPD. Eleven patients were excluded 
from final analysis due to an abnormal κ/λ ratio (repeat testing and referral to haematology 
for assessment was advised for these patients). The median follow up time was 2.5 (1.5-4.7) 
years. Clinical features and demographic data are shown in Table 4.1.
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Variable Usual COPD cohort (n=316) 
Age 68.8 (61.5 – 75.1) 
Sex Male n = 182 (57.6%) 
Female n = 134 (42.4%) 
Pack years 44.1 (29.5 – 62.2) 
FEV1 (% predicted) 46.4 (35.0 – 61.0) 
KCO (% predicted) 59 (47.5 – 77.0) 
Chronic bronchitis 198 (62.7%) 
Emphysema 257 (81.3%) 
Bronchiectasis 96 (30.3%) 
Frequent exacerbator 193 (61.1%) 
eGFR 85.8 (69.7 – 101.1) 
CKD stage  
  1      eGFR ≥ 90 
  2      eGFR 60 - 89  
  3      eGFR 30 - 59 
  4      eGFR 15 - 29 
  5      eGFR < 15 
  Unknown (no eGFR) 
119 (37.6%) 
130 (41.1%) 
35 (11.1%) 
4 (1.3%) 
0 (0%) 
28 (8.9%) 
cFLC (mg/L) 31.9 (24.0 – 43.3) 
κ/λ 0.86 (0.72-1.06) 
Table 4.1: Patient demographics in the usual COPD cohort 
Continuous variables expressed as median (IQR); sex, chronic bronchitis, emphysema, 
bronchiectasis, exacerbators and chronic kidney disease (CKD) stage expressed as number in 
each group (%). A frequent exacerbator was defined as having 2 or more treated 
exacerbations per year. Number of patients with contemporaneous renal function = 288.  
BMI = body mass index, FEV1 = forced expiratory volume in 1 second, KCO = corrected gas 
transfer, eGFR = estimated glomerular filtration rate, cFLC = combined (κ + λ) free light chain 
level and the κ/λ ratio is shown. 
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4.2.1 FLCs and renal function 
Contemporaneous renal function was available for 288/316 patients within the usual COPD 
cohort. The number of patients at each CKD stage is outlined in Table 4.1. There was a 
similar relationship between cFLC level, eGFR and CKD stages (Figure 4.1) to that observed in 
A1ATD. Significant differences in cFLC were seen between the different CKD groups (Kruskall 
Wallis test χ2(3) =17.81, p<0.001). A post hoc analysis (Bonferroni correction to calculate 
significant p value cut off 0.05/5=0.008) revealed that patients with CKD stage 4 had 
significantly higher cFLC levels than those with CKD stage 1 (p=0.006). FLC levels correlated 
negatively with eGFR (rs=-0.24, p<0.001). The strength of this correlation was reduced by 
adjustment for age, but remained statistically significant (rp=-0.13, p=0.021). 
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Figure 4.1: Stable state cFLC levels relationship to renal function in the usual COPD cohort 
Bar chart (A) shows the relationship between combined (κ & λ) FLC (cFLC) and chronic kidney 
disease (CKD) stage (each bar represents the median cFLC value and error bars represent the 
IQR).  Patients with CKD stage 4 had significantly higher cFLC compared to patients with CKD 
stage 1 (**p ≤ 0.01). Scatter plot (B) shows the negative correlation between cFLC and 
estimated glomerular filtration rate (eGFR) (rs=-0.24, p<0.001). 
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4.3 Plasma and serum FLC matched samples analysis 
The Freelite assay was developed for use with serum samples. However, for the purposes of 
this study there was a requirement to determine levels in plasma, when serum was 
unavailable. There is limited data for the use of plasma samples (238) with the Freelite assay. 
Therefore, matched serum and plasma samples were analysed in a subgroup of 82 patients 
from the usual COPD cohort to determine whether the results were equivalent. Three 
patients were then excluded from the analysis due to an abnormal κ/λ ratio. 
The FLC results were not normally distributed therefore non-parametric statistical tests were 
utilised. There was a significant correlation between serum and plasma κ and λ values 
(Spearman’s Rho: 0.96 and 0.98 respectively, p = <0.001) (Figure 4.2). The results from both 
matrices were also equivalent using Passing-Bablok analysis (κ: y=0.94x -0.32 and λ: y=0.92x 
- 0.05) and linear regression analysis (κ: y=0.90x - 0.5 and λ y=0.92x - 0.11).
Figure 4.3 shows a Bland-Altman plot demonstrating the difference between the serum and 
plasma cFLC values. The assay showed good agreement whether plasma or serum samples 
were tested: κ: positive predictive value (PPV): 89%, negative predictive value (NPV): 93% 
and λ: PPV: 100%, NPV: 93%. The results therefore showed there was good analytical 
agreement between FLC values in plasma and serum samples. All FLC results were therefore 
grouped together in the usual COPD cohort (whichever sample was used) for subsequent 
statistical analyses
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Figure 4.2: Scatterplots demonstrating the correlation between serum and plasma FLC 
values in n=79 usual COPD patients 
A. Serum κ versus plasma κ (rs =0.96, p<0.001), B. Serum λ versus plasma λ (rs=0.98,
p<0.001), C. Serum κ/λ ratio versus plasma κ/λ ratio (rs=0.95, p<0.001).
A 
C 
B 
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Figure 4.3 Bland Altman plot demonstrating the variability between serum and plasma 
cFLC in the matched analyses 
All cFLC values were log transformed before analysis. The solid horizontal line represents the 
mean difference between the Log10(cFLC) values. The dotted lines represent 95% 
confidence intervals. Linear regression analysis revealed no significant proportional bias 
between matched serum and plasma cFLC values (t=-1.065, p=0.29). 
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4.4 Stability of FLCs as a biomarker in usual COPD 
In a subgroup of 51 patients with usual COPD a repeat FLC analysis was performed on 
samples obtained after a 1 year interval to establish the stability of FLC within this patient 
population. There was no significant difference between baseline and follow up cFLC values 
(Wilcoxon signed rank test Z=-1.91, p=0.056). Seventy one percent of follow up cFLC values 
were within 25% of the baseline value. Figure 4.4 shows a Bland-Altman plot demonstrating 
the agreement between the baselines and follow up cFLC levels.  
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Figure 4.4 Bland Altman plot showing difference between cFLC at baseline and 1 year 
follow up in n=51 usual COPD patients. 
All cFLC values were log transformed before analysis. The solid horizontal line represents the 
mean difference between the Log10(cFLC) values. The dotted lines represent 95% 
confidence intervals. After removal of one influential observation (circled in blue) linear 
regression provided no evidence of proportional bias (t =-1.52, p=0.136). 
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4.5 FLCs and clinical phenotypes in usual COPD 
Table 4.2 shows the univariate analysis of FLCs in different subgroups within the usual COPD 
cohort. The men were found to have significantly higher FLC levels than the women (cFLC 
35.35 v 29.51 mg/L p<0.001). This finding could not be explained by a difference in 
demographic factors such as age and eGFR (median men v women: age 69.4 v 68.1, 
p=0.129, eGFR 87.2 v 83.8, p=0.354) or smoking habit.  
Current smokers were found to have a significantly lower κ/λ ratio with a trend towards 
higher κ levels than non-smokers. A weak positive correlation between λ FLC levels and pack 
years was identified (rs=0.13, p=0.027). 
Although patients with stable COPD were asked to provide sputum samples, as for the 
A1ATD group, there were too few for meaningful analysis therefore the relationship of FLCs 
to chronic colonisation in usual COPD was not investigated.  
No significant differences in cFLC were seen with respect to presence of chronic bronchitis, 
bronchiectasis, emphysema, or a history of frequent exacerbations (defined as ≥2 treated 
episodes per year). 
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Group 1 Group 2 P value 
Emphysema Yes (206) No (47) 
cFLC 31.92 36.42 0.131 
κ 14.73 (10.8-19.7) 17.23(11.6-23.6) 0.063 
λ 17.43 (12.6-24.7) 19.54 (13.5-25.0) 0.331 
κ/λ 0.85 (0.7-1.0) 0.93 (0.7-1.2) 0.086 
Bronchiectasis Yes (73) No (169) 
cFLC 33.33 (25.1-47.5) 32.36 (23.7-44.5) 0.643 
κ 15.99 (10.7-20.8) 14.92 (10.8-20.1) 0.565 
λ 18.52 (12.5-24.7) 17.71 (12.8-24.3) 0.830 
κ/λ 0.86 (0.7-1.1) 0.87 (0.7-1.0) 0.387 
Chronic bronchitis Yes (189) No (116) 
cFLC 33.29 (25.0-45.0) 30.89 (22.2-39.7) 0.111 
κ 15.40 (11.3-21.3) 14.66 (10.2-18.3) 0.119 
λ 18.06 (12.9-24.5) 16.04 (12.3-22.1) 0.163 
κ/λ 0.88 (0.7-1.1) 0.84 (0.7-1.0) 0.419 
Current Smokers Yes (121) No (188) 
cFLC 31.5 (22.9-42.4) 33.66 (24.7-44.5) 0.271 
κ 14.25 (10.2-18.3) 15.58 (11.6-20.5) 0.066 
λ 16.86 (12.9-23.7) 18.01 (12.2-23.8) 0.777 
κ/λ 0.82 (0.7-1.0) 0.90 (0.7-1.1) 0.031 
Gender Male (182) Female (134) 
cFLC 35.35 (27.4-47.2) 29.51 (21.6-38.8) <0.001 
κ 16.40 (12.3-21.6) 13.50 (9.6-16.8) <0.001 
λ 19.15 (13.6-25.4) 15.05 (11.5-21.5) <0.001 
κ/λ 0.88 (0.8-1.1) 0.87 (0.7-1.0) 0.363 
Frequent exacerbations Yes (193) No (82) 
cFLC 31.15 (22.9-39.9) 32.52 (26.6-45.8) 0.081 
κ 14.26 (10.0-17.8) 15.5 (11.7-20.8) 0.085 
λ 16.32 (12.1-22.7) 18.16 (13.6-24.2) 0.070 
κ/λ 0.86 (0.7-1.1) 0.85 (0.7-1.0) 0.942 
Table 4.2: Comparison of cFLC in 2 patient subgroups within the usual COPD cohort 
Median individual and combined κ & λ (cFLC) levels (mg/L) reported with inter-quartile range 
in brackets. Mann Whitney U Tests performed to determine any statistical differences 
between groups 1 and 2 (*p ≤ 0.05). Where statistical differences were found the p value is 
highlighted in bold red text. 
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4.6 FLCs relationship to COPD disease severity and activity 
4.6.1 Disease severity 
To establish if there was any correlation between FLCs and disease severity in usual COPD, a 
cross sectional analysis with lung function parameters was undertaken. FEV1 percentage 
predicted is the current standard way of classifying severity of airflow obstruction in COPD. 
As the FLC results were not normally distributed non-parametric Spearman’s Rho 
correlations with lung function parameters was undertaken (Table 4.3). Within this cohort 6 
patients had radiological emphysema but no evidence of airflow obstruction. Weak positive 
correlations were found between κ FLC and FEV1 and both κ and cFLC levels and the 
FEV1/FVC ratio. 
FLC levels correlated positively with age (κ rs=0.3, p<0.001, λ rs=0.25 p<0.001, cFLC rs=0.28 
p<0.001). Correlations were therefore performed controlling for age and eGFR (Table 4.4). 
Only patients with all the appropriate information were included (n=131) and no significant 
correlations remained between lung function parameters and FLCs. 
There are a number of validated symptom scores which are utilised assessing the 
symptomatic burden of COPD as a measure of disease severity. The medical research council 
(MRC) breathlessness score was recorded for 283/316 (69%) of the patients in the usual 
COPD cohort at the time the sample for FLC was taken. When the patients were grouped 
according to their MRC score no significant difference in cFLC between the groups was seen 
(Kruskall Wallis test χ2(2) =2.81, p=0.590, Figure 4.6). 
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FEV1 %p 
(n=308) 
FVC %p 
(n=306) 
FEV1/FVC 
(n=309) 
TLC %p 
(n=153) 
RV %p 
(n=152) 
KCO %p 
(n=167) 
TLCO %p 
(n=157) 
Κ        rs 
  p  
0.131 
0.022* 
-0.010
0.856
0.132 
0.020* 
0.010 
0.903 
-0.031
0.700
0.055 
0.482 
-0.005
0.952
λ        rs  
 p 
0.073 
0.204 
-0.057
0.317
0.095 
0.094 
-0.009
0.914
0.002 
0.985 
0.018 
0.815 
-0.019
0.810
κ/λ    rs 
 p 
0.105 
0.067 
0.046 
0.422 
0.108 
0.059 
-0.010
0.902
-0.056
0.494
0.039 
0.617 
0.011 
0.891 
cFLC  rs 
 p 
0.100 
0.080 
-0.038
0.511
0.113 
0.047* 
0.006 
0.940 
-0.007
0.929
0.033 
0.675 
-0.012
0.885
Table 4.3 Spearman’s’ Rho correlations between FLC levels and lung function parameters 
in the usual COPD cohort 
FEV1 = Forced expiratory volume in 1 second, FVC = Forced vital capacity, TLC = Total lung 
capacity, RV = Residual volume, KCO = Corrected gas transfer, TLCO = Transfer factor of the 
lung for carbon monoxide, cFLC = combined κ & λ FLC (mg/L), rs= correlation coefficient, %p 
= percentage predicted. (*Statistically significant 2p values are highlighted) 
Figure 4.5 Scatterplot of κ FLC against FEV1 (% predicted) in the usual COPD cohort 
FLC = free light chain, FEV1 = forced expiratory volume in 1 second. Each dot represents a 
single patient. (Spearman’s Rho rs= 1.31, p=0.02) 
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Cont. Age & 
eGFR 
FEV1 %p 
(n=131) 
FVC %p 
(n=131) 
FEV1/FVC 
(n=131) 
TLC %p 
(n=131) 
RV %p 
(n=131) 
KCO %p 
(n=131) 
TLCO %p 
(n=131) 
Kappa         rp   0.073 -0.025 0.097 0.056 0.076 -0.088 -0.110
 p 0.406 0.776 0.268 0.522 0.387 0.313 0.208 
Lambda      rp 0.061 -0.048 0.107 0.034 0.072 -0.056 -0.078
 p 0.487 0.583 0.221 0.694 0.407 0.521 0.373 
κ/λ ratio    rp 0.009 -0.012 0.033 -0.041 -0.044 0.047 -0.034
 p 0.920 0.894 0.705 0.637 0.615 0.590 0.694 
cFLC     rp 0.069 -0.039 0.107 0.046 0.077 -0.074 -0.097
 p 0.428 0.655 0.221 0.597 0.377 0.397 0.268 
Table 4.4 Partial correlation (controlling for age and eGFR) between FLC levels and lung 
function parameters in the usual COPD cohort 
FEV1 = Forced expiratory volume in 1 second, FVC = Forced vital capacity, TLC = Total lung 
capacity, RV = Residual volume, KCO = Corrected gas transfer, TLCO = Transfer of the lung for 
carbon monoxide, eGFR = estimated glomerular filtration rate, cFLC = combined (κ & λ) free 
light chain (mg/L), rp = correlation coefficient, %p = percentage predicted. 
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Figure 4.6: Box plot showing cFLC levels according to MRC breathlessness score in the 
usual COPD cohort 
Horizontal lines represent medians, boxes represent interquartile ranges and whiskers 
represent minimum to maximum values. MRC = Medical Research Council, cFLC = combined 
κ & λ free light chain levels (mg/L). 
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4.6.1.1 FLCs according to severity of airflow obstruction in usual COPD 
When patients were sub-grouped according to their severity of airflow obstruction (GOLD 
stages: mild FEV1 >80% predicted, moderate 50-80%, severe 30-50% and very severe <30%) 
significant differences between the groups were identified (Kruskall Wallis test (χ2(4) = 
12.35, p=0.015). The median cFLC (mg/L) within the groups were: no airflow obstruction 
28.52, mild 32.8, moderate 34.8, severe 33.3, and very severe 26.5.  A post-hoc analysis 
found cFLC levels were significantly higher in patients with moderate airflow obstruction 
compared to those with very severe airflow obstruction (Mann Whitney U test p = 0.002). A 
Bonferroni calculation was used to calculate the level for significance (p ≤ 0.05/10 = 0.005) 
(Figure 4.7). The same relationship was seen between cFLCs and GOLD group of airflow 
obstruction in the A1ATD cohort (Figure 3.7). 
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Figure 4.7 Bar chart showing median cFLC levels in usual COPD patients sub-grouped 
according to the severity of their airflow obstruction 
Bars represent median combined (κ & λ) FLC (mg/L) in each group. Error bars represent 
interquartile range. **p ≤ 0.005. 
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4.6.2 Disease activity 
To establish if polyclonal FLCs increased during periods of disease activity in usual COPD, 
they were measured in a separate cohort of 68 patients admitted to hospital with an 
exacerbation of COPD. FLC levels were measure on day 1 of the admission and at day 56 
following resolution of their symptoms. One patient was excluded from analysis due to a 
diagnosis of MALT lymphoma and 12 other patients were excluded due to an abnormal κ/λ 
ratio (these patients were recalled for repeat testing and referral to haematology for 
investigation as appropriate). The demographics and other patient characteristics on 
admission are outlined in Table 4.5. There was a significant polyclonal increase in FLCs from 
day 1 to day 56. There were concurrent decreases in white cell count (WCC), COPD 
assessment test (CAT) score and respiratory rate (Table 4.6). 
As expected there was a negative correlation between cFLC levels and eGFR taken on day 1 
(Figure 4.8). At day 1 cFLC levels were also found to correlate positively with CRP and age 
and there was a weak negative correlation between κ/λ ratio and pack year history (Figure 
4.9). 
The positive correlation between cFLC and CRP was also evident at day 56 but interestingly, 
a negative correlation with WCC was seen at this timepoint (rs=-0.51, p=0.009, Figure 4.10). 
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Variable Exacerbation cohort (n=55) 
Age 68.2 (62.4-75.2) 
Sex Male n=31 (56.4%) 
Female n=24 (43.6%) 
Pack years 42.5 (29.3-60.0) 
FEV1 (% predicted) 40.0 (29.5-55.5) 
KCO (% predicted) 64.0 (49.5-75.5) 
BMI (kg/m2) 24.1 (20.6-31.3) 
Chronic bronchitis 25/51 (49.0%) 
Emphysema 44/53 (83.0%) 
Bronchiectasis 14/53 (26.4%) 
Frequent exacerbator 55/55 (100%) 
Annual exacerbation frequency 3 (2.0-5.0) 
eGFR 82.1 (65.0-101.5) 
CKD stage  
  1      eGFR ≥ 90 
  2      eGFR 60 - 89  
  3      eGFR 30 - 59 
  4      eGFR 15 - 29 
  5      eGFR < 15 
25 (45.5%) 
18 (32.7%) 
11 (20.0%) 
1 (1.8%) 
0 (0%) 
cFLC (mg/L) 33.1 (23.8-52.7) 
κ/λ ratio 1.13 (0.88-1.37) 
CRP 29 (9.0-69.0) 
WCC 12.3 (8.6-15.2) 
CAT score 31 (25-35) 
Table 4.5: Exacerbation cohort patient demographics and baseline characteristics 
Continuous variables expressed as median (IQR); sex, chronic bronchitis, emphysema, 
bronchiectasis, exacerbators and chronic kidney disease (CKD) stage expressed as number in 
each group (%). A frequent exacerbator was defined as having 2 or more exacerbations per 
year. FEV1 = forced expiratory volume in 1 second, KCO = corrected gas transfer, BMI = body 
mass index, eGFR = estimated glomerular filtration rate, cFLC = combined (κ + λ) FLC, CRP =C 
reactive protein, WCC = white cell count, CAT = COPD assessment test. 
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Variable Day 1 Day 56 Z P value 
κ 17.63 (11.4-28.2) 17.87 (11.50-30.5) -1.97 0.048* 
λ 15.23 (11.5-24.3) 18.31 (12.3-25.1) -2.77 0.006** 
cFLC 33.09 (23.8-52.7) 34.32 (25.7-52.1) -2.44 0.015* 
κ/λ 1.13 (0.88-1.37) 1.10 (0.84-1.36) -1.52 0.129 
CRP 29.0 (9.0-69.0) 11.5 (4.8-39.0) -1.62 0.104 
WCC 12.25 (8.6-15.2) 8.8 (8.0-11.2) -2.06 0.040* 
CAT score 31 (25-35) 25 (19-31) -3.57 <0.001** 
Pulse 94.3 (84.0-102.5) 82.5 (72.0-92.3) -1.46 0.145 
Systolic BP 134.0 (117.0-143.3) 130.5 (114.0-142.8) -0.526 0.599 
Diastolic BP 72.5 (67.5-82.3) 75.5 (70.3-988.8) -1.411 0.158 
RR 20 (18-22) 18 (16-20) -2.53 0.011* 
Table 4.6: Clinical variables at day 1 and day 56 in the exacerbation cohort 
Variables highlighted in yellow increased and variables highlighted in blue decreased. 
Median values quoted with interquartile range in brackets. Wilcoxon signed rank test used 
to identify significant differences in variables between day 1 and day 56. Significant p valued 
highlighted in red with an asterisk. cFLC= combined (κ & λ) FLC level, CRP = c-reactive 
protein, WCC= white cell count, BP = blood pressure, RR = respiratory rate. 
Figure 4.8 Scatterplot showing relationship between day 1 cFLCs and renal function in the 
exacerbation cohort 
Spearman’s Rho rp=-0.48 p=<0.001. cFLC= combined κ & λ (mg/L), eGFR = estimated 
glomerular filtration rate. 
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Figure 4.9: Scatterplots demonstrating relationship of FLCs to CRP, WCC, age and smoking 
in usual COPD patients on day 1 of an exacerbation 
Spearman’s Rho correlations- A: rp= 0.37 p=0.005**, B: rp=0.37. p=0.005** C: rp=-0.147, 
p=0.283 D: rp=-0.29, p=0.036*. cFLC = combined κ & λ FLC level (mg/L), CRP = C reactive 
protein, WCC= white cell count. 
A B 
C D 
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Figure 4.10 Scatterplots showing relationship of cFLC to CRP and WCC day 56 post 
exacerbation 
Spearman’s rho correlation A: rp= 0.59, p=0.004 B: rp=-0.51, p=0.009. cFLC = combined κ & λ 
FLC level (mg/L), CRP= C reactive protein, WCC= white cell count. 
A B 
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4.6.2.1 Immunoglobulin analysis  
To explore the relationship between FLCs and immunoglobulin production during 
exacerbations, 3 major classes: IgA, IgG and IGM were measured in a subgroup of 27 
patients at day 1 and day 56. No significant changes in immunoglobulin levels were seen 
during the course of the exacerbation (Figure 4.11). At day 1, cFLC levels correlated 
positively with IgG levels but not IgA or IgM but at day 56 cFLC correlated positively with 
both IgA and IgG levels (rp=0.45, p=0.022* and rp=0.56, p=0.003** respectively, Figure 4.12). 
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Figure 4.11 Box plots showing immunoglobulin levels at day 1 and 56 in n=27. 
Horizontal line represents median value, box represents interquartile range and whiskers 
represent minimum and maximum values. No significant difference change in levels was 
seen (Wilcoxon signed rank test IgA p=0.657, IgG p=0.501, IgM p=0.581) 
Figure 4.12: Scatterplots showing correlations between cFLC and immunoglobulin levels at 
day 1 and 56 in n=27  
Significant positive correlations highlighted with red dots. Blue dots represent parameters 
that did not correlate.
rp=0.17, p=0.387 rp=0.51, p=0.007** rp=0.11, p=592 
rp=0.45, p=0.022* rp=0.56, p=0.003** rp=-0.05, p=0.807 
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4.6.2.2 FLCs and longitudinal outcomes in the exacerbation cohort 
The median follow up time for this cohort was 2.37 years (1.51-2.58). During this time 13 
patients died (23.6%). However, there was no significant difference in day 1 or day 56 cFLC 
levels in the patients who died compared to those who survived (median 34.1 v 31.9, p= 0.80 
and 34.9 v 34.2, p=0.91 respectively).  
135 
4.7 FLCs and longitudinal outcomes in usual COPD 
4.7.1 Mortality 
Within the stable usual COPD cohort ninety-one (28.8%) patients died during the follow up 
period. The patients who died had significantly higher baseline cFLC levels compared to 
those who remained alive (36.4 (26.0-51.5) v 31.5 (23.3-41.3) mg/L, p=0.014, Table 4.7. 
Univariate cox regression analysis was performed to identify any variables that significantly 
predicted mortality within this cohort. All variables with a p value ≤ 0.1 in the univariate 
analyses were included in the initial multivariate analyses. Non-significant variables (with a p 
value > 0.05) were then removed to build a final multivariate model. In the final model, the 
variables that were found to independently predict mortality were cFLC and FEV1 % 
predicted (hazard ratios: 1.02 p<0.001, 0.97 p<0.001 respectively). These tables are 
summarised below (Table 4.7 and Table 4.8) 
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Mortality Dead (n = 91) Alive (n = 225) P value 
cFLC 36.42 (26.0-51.5) 31.47 (23.3-41.3) 0.014* 
κ 15.97 (11.6-23.3) 14.81 (10.50-19.0) 0.046* 
λ 19.22 (13.3-27.9) 16.3 (12.4-22.8) 0.008* 
κ/λ 0.82 (0.7-1.0) 0.88 (0.7-1.0) 0.117 
Table 4.7 FLCs and mortality in the usual COPD cohort 
Median individual and combined κ & λ (cFLC) levels (mg/L) reported with inter-quartile range 
in brackets. Mann Whitney U Tests performed to determine any statistical differences 
between the groups (*p ≤ 0.05). Where statistical differences were found the p value is 
highlighted in bold red text. 
Variable Univariate HR (CI) P value Multivariate HR (CI) P value 
cFLC 1.02 (1.01 - 1.03) <0.001* 1.02 (1.01-1.02) <0.001* 
Pack years 1.01 (1.00 - 1.01) 0.161 
Current smoker 0.97 (0.63 - 1.49) 0.872 
Gender 1.46 (0.95 - 2.24) 0.087 
Emphysema 1.05 (0.60 - 1.85) 0.861 
Bronchiectasis 0.83 (0.51 - 1.38) 0.478 
Frequent 
exacerbator 
1.20 (0.71 - 2.02) 0.503 
Age 1.02 (1.00 - 1.05) 0.065 
Chronic bronchitis 1.22 (0.77 - 1.92) 0.403 
BMI 0.95 (0.91 - 0.98) 0.002* 
eGFR 1.01 (1.00 - 1.01) 0.113 
FEV1 (% predicted) 0.98 (0.96 - 0.99) <0.001* 0.97 (0.96-0.99) <0.001* 
KCO (% predicted) 0.98 (0.97 - 1.00) 0.010* 
FEV1/FVC 0.04 (0.01 - 0.19) <0.001* 
Table 4.8: Predictors of mortality in the usual COPD cohort: univariate and multivariate cox 
proportional hazards regression analysis 
HR = hazard ratio, CI = 95% confidence intervals, cFLC = combined κ & λ free light chain level 
mg/L, BMI = body mass index, eGFR = estimated glomerular filtration rate, FEV1 = forced 
expiratory volume in 1 second, KCO = corrected gas transfer, FVC = forced vital capacity. A 
frequent exacerbator was defined as having 2 or more exacerbations per year. (*p ≤ 0.05) 
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4.7.1.1 Mortality in cFLC subgroups  
The patients were sub-grouped according to two cFLC thresholds – 43.3mg/L (the upper limit 
of normal) and 65mg/L (previously shown to be a risk factor for mortality within 100 days 
(184)) and multivariate cox regression analyses were then repeated. Within the usual COPD 
cohort, the hazard ratio for mortality associated with a cFLC greater than 43.3mg/L was 1.8 
(p=0.009) and increased to 2.39 for patients with a cFLC of greater than 65mg/L (Table 4.9). 
Significant differences between the survival curves were seen at both of these thresholds 
(Figure 4.13). 
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Table 4.9: Predictors of mortality in the usual COPD cohort: cox proportional hazards 
regression analysis models 
Model 1 shows that a combined κ & λ free light chain level (cFLC) of greater than 43.3mg/L 
and forced expiratory volume in 1 second (FEV1) are independent risk factors for mortality in 
the A1ATD cohort. Model 2 uses a higher cFLC cut off of 65 mg/L. Hazard ratios (HR) 
reported with 95% confidence intervals (CI) in brackets. *p≤0.05 highlighted in red 
Model 1 Model 2 
Variable Multivariate HR 
(95%CI) 
P value Multivariate HR 
(95%CI) 
P value 
cFLC ≥ 43.3 mg/L 1.80 (1.16-2.80) 0.009* 
cFLC ≥ 65 mg/L 2.39 (1.29-4.40) 0.005* 
FEV1 (% predicted) 0.98 (0.96-0.99) <0.001* 0.98 (0.96-0.99) <0.001* 
139 
Figure 4.13: Kaplan-Meier curves according to cFLC thresholds in the usual COPD cohort 
The blue line represents patients with a combined κ & λ free light chain (cFLC) of less than A. 
43.3mg/L (the upper limit of normal), n=237, B. 65mg/L, n=292. Red line represents those 
with a cFLC level above these thresholds, n= 79 and 24 respectively. The Kaplan-Meier plots 
showed significant differences in the survival curves according to both these levels, A. p = 
0.013, B. p=0.012 by Log Rank test. 
A
B
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4.7.2 ROC curve analysis 
ROC curve analysis was performed to assess the sensitivity and specificity of cFLC in 
predicting mortality within the usual COPD cohort. The area under the curve was 0.59 (95% 
CI 0.52-0.66, p=0.015 Figure 4.14). 
Figure 4.14 Receiver operating characteristics (ROC) curve assessing the sensitivity and 
specificity of combined κ & λ FLC for mortality prediction in usual COPD.  
Area under the curve = 0.59 (95% CI 0.52-0.66, p=0.015). 
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4.8 Immunoglobulin analysis 
4.8.1 Introduction 
In order to establish if measuring FLCs has any benefit over performing immunoglobulin 
analysis – IgA, IgG and IgM was measured in all 316 patients in the usual COPD cohort. The 
immunoglobulin results were not normally distributed therefore non-parametric statistical 
tests were utilised.  
4.8.2 Results 
Positive correlations were found between FLC levels and IgA and IgG but not IgM (Table 
4.10). The strongest correlation was between cFLC and IgA levels (rs = 0.492, p<0.001, Figure 
4.15). A partial correlation controlling for eGFR (n=283) strengthened this relationship 
further (rp= 0.545, p<0.001). 
Significant differences in immunoglobulin levels according to gender were seen. Women 
were found to have lower median IgA and IgG levels (2.14 v 2.57 g/L, p<0.001 and 8.48 v 
9.29 g/L, p=0.029 respectively) and higher median IgM levels compared to men (0.8 v 0.67 
g/L, p=0.007). Scatterplots were drawn to identify any outliers contributing to the 
differences seen (Figure 4.16). One outlier with a significantly raised IgM level was 
identified but removal of this patient did not influence the overall results.   
IgM levels were also found to have a weak negative correlation with both age (rs= -0.12, 
p=0.037) and BMI (rs=-0.14, p=0.017).  
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κ λ κ/λ cFLC 
IgA      rs 
p 
0.445 
<0.001** 
0.493 
<0.001** 
-0.078
0.168
0.492 
<0.001** 
IgG      rs 
p 
0.484 
<0.001** 
0.408 
<0.001** 
0.130 
0.021* 
0.458 
<0.001** 
IgM     rs 
p 
0.056 
0.324 
0.098 
0.082 
-0.094
0.097
0.087 
0.122 
Table 4.10: Spearman’s Rho correlations between FLC levels and immunoglobulin levels 
rs = correlation coefficient. (*Statistically significant 2p values are highlighted in red) 
Figure 4.15: Scatterplot showing correlation between IgA and cFLC levels in the usual COPD 
cohort 
IgA = Immunoglobulin A, cFLC = combined κ & λ FLC level (mg/L). Spearmen’s Rho rs=0.49, 
p<0.001. 
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Figure 4.16: Scatterplots of immunoglobulin levels according to gender  
Horizontal red lines represent median values. IgM outlier highlighted with blue circle.
IgA IgG 
IgM IgM outlier removed 
p<0.001 p=0.028 
p=0.007 p=0.006 
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4.8.2.1 Immunoglobulin and disease phenotypes in usual COPD 
Previous studies have found smoking to cause a systemic reduction in immunoglobulin levels 
(227-231) however that was not evident within this cohort. There was no significant 
difference in IgA, IgG or IgM levels between current smokers and non-smokers (median IgA 
2.36 v 2.44 g/L, p=0.344, IgG 8.73 v 9.03 g/L, p=0.628, IgM 0.74 v 0.70 g/L, p=0.344).  
There was a trend of patients having ≥ 2 exacerbations annually having lower IgA levels 
(median 2.27 v 2.56 g/L, p=0.056) and there was a weak but statistically significant negative 
correlation between IgG and the number of annual exacerbations (rs=-0.112, p=0.041). There 
were no significant differences in any of the immunoglobulin results with respect to the 
presence of emphysema, bronchiectasis or chronic bronchitis.  
4.8.2.2 Immunoglobulin relationship to disease severity in usual COPD 
There was a weak positive correlation between IgG levels and FEV1 (% predicted) (rs =0.138, 
p=0.015). No other significant correlations between immunoglobulin levels and lung function 
parameters were found.  
4.8.2.3 Immunoglobulin relationship to longitudinal outcomes in usual COPD 
IgA levels were significantly higher in patients who died compared to those remaining alive 
(median 2.66 v 2.33 g/L, p=0.014, Table 4.11). Univariate cox regression analysis 
demonstrated that only IgA levels significantly predicted mortality (HR 1.32, p<0.001). 
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The whole cohort (n=316) was therefore subdivided into IgA quartiles and Figure 4.17 
shows the associated difference in survival curves. There is some overlap of quartile 1 and 2 
but the increased risk of mortality associated with IgA results in the top 2 quartiles is 
apparent.  
Univariate cox regression analysis shows the hazard ratio for death for patients with IgA 
results in the top quartile (≥3.18g/L) was 1.9 (1.24-2.92), p=0.003). Figure 4.18 shows the 
significant difference in the survival curves above and below this threshold. Multivariate cox 
regression was then undertaken to determine whether this relationship was independent of 
other factors that predicted mortality within this cohort. Table 4.12 outlines the results 
which show that IgA is an independent risk factor for mortality, which is not influenced by 
gender despite men having higher IgA levels than women (corrected HR in the final 3 
variable model (IgA>3.18g/L, BMI and FEV1% predicted) of 1.78 (p=0.014)). A ROC curve 
analysis was performed to assess the sensitivity and specificity of IgA in the prediction of 
mortality within this cohort. The area under the curve was 0.59 (p=0.014, Figure 4.19) 
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Dead (n =91 ) Alive (n=225) P value Univariate HR (CI) P value 
IgA 2.66 (1.71-3.17) 2.33 (1.65-3.04) 0.014* 1.32 (1.16-1.51) <0.001* 
IgG 8.68 (7.14-11.39) 8.94 (7.25-10.68) 0.685 1.04 (0.98-1.11) 0.234 
IgM 0.74 (0.51-1.03) 0.70 (0.5-1.07) 0.992 0.94 (0.76-1.17) 0.595 
Table 4.11: Immunoglobulin levels and mortality in the usual COPD cohort 
Median immunoglobulin (g/L) reported with inter-quartile range in brackets. Mann Whitney 
U Tests performed to determine any statistical differences between the groups (*p ≤ 0.05). 
Univariate cox regression analysis performed to establish if immunoglobulin levels predict 
mortality. Where statistical differences were found the p value is highlighted in bold red 
text. HR= hazard ratio, CI= confidence interval. 
Figure 4.17: Kaplan-Meier graph according to IgA quartiles in the usual COPD cohort 
Patients were subdivided into IgA quartiles. The coloured lines represent each quartile: blue 
represents quartile 1 (IgA <1.67g/L), orange represents quartile 2 (IgA 1.67-2.40g/L), green 
represents quartile 3 (IgA 2.40-3.18g/L) and red represents quartile 4 (≥3.18), n = 79 in each 
group. Breslow p=0024, Log Rank p =0.016. 
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Figure 4.18: Kaplan-Meier plot according to IgA levels in the usual COPD cohort 
Blue line represents patients with an IgA level <3.18g/L (the threshold for the upper quartile 
within the usual COPD cohort, n=237). Red line represents those with an IgA level ≥3.18g/L 
(n= 79). Log Rank p = 0.003.  
Figure 4.19 Receiver operating characteristics (ROC) curve assessing the sensitivity and 
specificity of combined IgA for mortality prediction in usual COPD.  
Area under the curve = 0.59 (95% CI 0.52-0.66, p=0.014).
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Variable Univariate HR (CI) P value Multivariate HR (CI) P value 
IgA >3.18g/L 1.9 (1.24-2.92) 0.003 1.71 (1.07-2.72) 0.024* 
Pack years 1.01 (1.00 - 1.01) 0.161 
Current smoker 0.97 (0.63 - 1.49) 0.872 
Gender 1.46 (0.95 - 2.24) 0.087 1.19 (0.74-1.90) 0.474 
Emphysema 1.05 (0.60 - 1.85) 0.861 
Bronchiectasis 0.83 (0.51 - 1.38) 0.478 
Frequent 
exacerbator 
1.20 (0.71 - 2.02) 0.503 
Age 1.02 (1.00 - 1.05) 0.065 1.01 (0.98-1.04) 0.400 
Chronic bronchitis 1.22 (0.77 - 1.92) 0.403 
BMI 0.95 (0.91 - 0.98) 0.002* 0.96 (0.92-0.99) 0.009* 
eGFR 1.01 (1.00 - 1.01) 0.113 
FEV1 (% predicted) 0.98 (0.96 - 0.99) <0.001* 0.98 (0.96-0.99) 0.001* 
KCO (% predicted) 0.98 (0.97 - 1.00) 0.010* 
FEV1/FVC 0.04 (0.01 - 0.19) <0.001* 
Table 4.12: Predictors of mortality in the usual COPD cohort: univariate and multivariate 
cox proportional hazards regression analysis 
HR = hazard ratio, CI = 95% confidence intervals, cFLC = combined κ & λ free light chain level 
mg/L, BMI = body mass index, eGFR = estimated glomerular filtration rate, FEV1 = forced 
expiratory volume in 1 second, KCO = corrected gas transfer, FVC = forced vital capacity. A 
frequent exacerbator was defined as having 2 or more exacerbations per year. (*p ≤ 0.05)
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4.9 Comparison with severe A1ATD cohort 
The primary purpose of this analysis was to compare the cFLC levels between the severe 
A1ATD and usual COPD groups, rather than their clinical features, as cohorts were recruited 
in different settings, and differences between A1ATD and usual COPD are well known. 
The patient demographics and significant differences between the two cohorts are outlined 
in Table 4.13. In comparison to the severe A1ATD cohort, the usual COPD patients were 
significantly older, had a greater number of pack years, more severe COPD as measured by 
FEV1 (% predicted) but better renal function. The presence of chronic bronchitis and a history 
of frequent exacerbations (defined as ≥ 2 per year) were also more common in the usual 
COPD cohort. In the univariate analysis, usual COPD patients were found to have 
significantly higher cFLC levels (31.9 v 25.7 mg/L, p<0.001). However, since cFLC related to 
several clinical features in both A1ATD and usual COPD it was necessary to adjust by 
regression analysis for these features prior to comparing cFLC levels; this was particularly 
important because most of these also differed between A1ATD and our usual COPD cohort 
as outlined above (Table 4.13).  
This was achieved by forced entry of eGFR, FEV1 % predicted, presence of chronic bronchitis 
and age as covariates in a linear regression seeking associations of cFLC levels, to which the 
presence of A1ATD was then added as a final variable. Since cFLCs were non-normally 
distributed the values were logged prior to regression analysis, which resulted in normal 
distribution of the subsequent standard residuals. A significant model was created (F (5,543) 
=14.67, p<0.001) although it only counts for 11.1% of the variance seen (adjusted R2 = 0.11). 
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It did however show that A1ATD was a significant predictor of a lower cFLC level 
independent of eGFR, FEV1, chronic bronchitis and age (p<0.001, Table 4.14). 
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Variable A1ATD cohort (n=540) Usual COPD cohort (n=316) P value 
Age 53.9 (45.0 – 60.9) 68.8 (61.5 – 75.1) <0.001* 
Sex Male n = 311 (57.6%) 
Female n = 229 (42.4%) 
Male n = 182 (57.6%) 
Female n = 134 (42.4%) 
0.999 
Pack years 11.6 (0.0 – 24.0) 44.1 (29.5 – 62.2) <0.001* 
FEV1 (% predicted) 50.7 (35.1 – 85.1) 46.4 (35.0 – 61.0) <0.001* 
KCO (% predicted) 62.3 (49.3 – 77.0) 59 (47.5 – 77.0) 0.533 
Chronic bronchitis 185 (34.3%) 198 (62.7%) <0.001* 
Emphysema 358 (66.3%) 257 (81.3%) 0.002 
Bronchiectasis 142 (26.3%) 96 (30.3%) 0.678 
Frequent exacerbator 129 (40.8%) 193 (61.1%) <0.001* 
eGFR 81.3 (70.6 – 93.9) 85.8 (69.7 – 101.1) 0.063 
CKD stage  
  1      eGFR ≥ 90 
  2      eGFR 60 - 89  
  3      eGFR 30 - 59 
  4      eGFR 15 - 29 
  5      eGFR < 15 
  Unknown (no eGFR) 
156(28.9%) 
279 (51.7%) 
41(7.6%) 
2 (0.4%) 
1 (0.2%) 
61 (11.3%) 
119 (37.6%) 
130 (41.1%) 
35 (11.1%) 
4 (1.3%) 
0 (0%) 
28 (8.9%) 
0.002* 
cFLC (mg/L) 25.7 (21.1 – 31.7) 31.9 (24.0 – 43.3) <0.001* 
κ/λ 0.86 (0.71-1.08) 0.86 (0.72-1.06) 0.967 
Table 4.13: Comparison of patient demographics in the severe A1ATD and usual COPD 
cohorts 
Number of patients with contemporaneous renal function = 479 A1ATD, 288 usual COPD. 
Continuous variables expressed as median (IQR); sex, chronic bronchitis, emphysema, 
bronchiectasis, exacerbators and CKD stage expressed as number in each group (%). A 
frequent exacerbator was defined as having 2 or more exacerbations per year. BMI = body 
mass index, FEV1 = forced expiratory volume in 1 second, KCO = corrected gas transfer, eGFR 
= estimated glomerular filtration rate, cFLC = combined (κ + λ) free light chain level (mg/L). 
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Variable B (95% CI) Std error B P value 
eGFR -0.001 (-0.002- -0.001) <0.001 <0.001 
Age 0.001 (0 – 0.003) 0.001 0.023 
Chronic bronchitis 0.033 (0.007 - 0.06) 0.013 0.013 
FEV1% predicted 4.8 x 10-4 (0 – 0.001) <0.001 0.021 
A1ATD -0.09 (-0.133 - -0.053) 0.020 <0.001 
Table 4.14: Linear regression analysing log cFLC in all stable patients in the severe A1ATD 
and usual COPD cohorts 
The table shows the regression coefficients (B) and significance of variables. The two most 
important variables in the model were eGFR and A1ATD. 
153 
4.10 Discussion 
4.10.1.1 FLC Stability  
The results show that polyclonal FLCs are static in the stable disease state in usual COPD. 
There was no significant difference between the baseline and one year follow up samples 
however only 71% were within 25% of the baseline value compared to 84.2% in the A1ATD 
cohort. The usual COPD patients are older and are likely to have a greater burden of other 
comorbidities, which may have had an influence on the stability of their FLC levels (239).  
4.10.1.2 FLC and immunoglobulin relationships to disease phenotypes in usual COPD 
Similarly to the A1ATD cohort, the patients with chronic bronchitis had a higher median 
cFLC value compared to those without (33.29 v 30.89 mg/L) although this did not achieve 
statistical significance (p=0.11) in usual COPD which may perhaps reflect the greater degree 
of airways inflammation in the former group (240) and a potential immune modulatory role 
of AAT 
(241).  
Current smokers were found to have a significantly lower κ/λ ratio with a trend towards 
higher κ levels than non-smokers. This differs from the A1ATD cohort where the current 
smokers (though few) had significantly higher λ FLC levels. Baraldo et al assessed the 
clonality of B-cells found within lymphoid follicles within lungs of A1ATD and usual COPD 
patients (125). Oligoclonal and monoclonal B-cell populations were seen in 3/3 patients 
with severe A1ATD and 2/3 patients with usual COPD. They therefore felt that the immune 
activation was to ‘specific’ antigens. As B cells only produce κ or λ FLCs it is possible that an 
adaptive immune response to smoking could promote an oligoclonal/monoclonal B cell 
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proliferation resulting in excess κ/λ FLCs. Thus, the findings in both cohorts are potentially 
reflective of a smoking effect on FLC production, although a reason for the difference in 
clonality between A1ATD and COPD will require further investigation. 
Males were found to have significantly higher cFLC levels compared to females, which was 
an unexpected finding and could not be accounted for by any documented demographic 
differences between them. There is known to be a male predominance of haematological 
conditions associated with monoclonal overproduction of FLCs such as monoclonal 
gammopathy of undetermined significance (MGUS) and multiple myeloma (242). However, 
any patient with an abnormal κ/λ was excluded from the analysis, hence undetected 
gammopathies should not have influenced our results. A difference in immunoglobulin levels 
was also demonstrated, with the males having significantly higher IgA and IgG levels but 
significantly lower IgM levels.  A previous study investigating the effects of demographic 
factors on immunoglobulin levels found male sex to be positively associated with IgA levels 
and negatively associated with IgG and IgM levels (243). The reason for the differences seen 
was thought to relate to the effects of sex hormones, which have been shown to influence 
immunoglobulin production in vitro (244, 245) and in animal models (246) and hence 
remains the most likely explanation.  
As in the A1ATD cohort, no significant difference in cFLC levels was seen between frequent 
and non-frequent exacerbators. However, there was a trend towards patients with a lower 
IgA having more exacerbations and a weak negative correlation between IgG levels and 
annual exacerbation frequency. IgG subclass deficiency is relatively common in patients with 
COPD (247) and has been shown to increase the susceptibility of patients to respiratory tract 
infections (248) which may explain the finding that patients with a lower IgG level had a 
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higher number of annual exacerbations although subclass levels have yet to be measured. 
IgA is essential in the mucosal defence of the body to infective insults with the ability to 
inhibit bacteria from adhering to epithelial cells (249). It is tempting therefore to hypothesise 
that the trend towards frequent exacerbators also having lower IgA levels may also have 
reduced respiratory tract mucosal defence resulting in an increased susceptibility to 
infections. However, there are two IgA isotypes within the body: IgA1 and IgA2 with the 
former predominating in the serum and the latter in mucosal secretions (secretory IgA). 
Despite there being lower levels of IgA in serum than IgG, more IgA is produced within the 
body compared to all other antibody isotypes combined emphasising its importance in the 
humoral immune defence (250). It is important to recognise however the distinct differences 
in the production, structure and function of secretory and serum IgA. Serum IgA is produced 
in the bone marrow whereas secretory IgA is synthesised by plasma cells within mucosal 
membranes. Serum IgA, which was measured in this study, is predominantly monomeric 
IgA1 and its immune functions are not fully understood. It has been shown to bind other 
serum proteins including A1AT and albumin (251)  as well as monocytes and granulocytes 
and is thought to have an anti-inflammatory role  (252). Secretory IgA is predominantly 
dimeric in form linked by a secretory component and provides an important defence against 
pathogens by protecting mucosal surfaces within the body (250). In terms of what is already 
known about IgA production in COPD, Burnett et al found an increase in the number of cells 
containing IgA (both IgA1 and IgA2 subclasses) in lung tissue specimens from patients who 
had died from ‘chronic bronchitis’ and bronchiectasis compared to controls. Interestingly, 
the proportion of IgA1 and IgA2 was the same in patients with bronchiectasis and controls 
but patients with chronic bronchitis had significantly higher IgA1 levels (253). In a small study 
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of patients with COPD infected sputum samples were shown to contain more IgA than non-
infected samples but no significant difference in serum IgA levels (254). More recently 
Ladjemi et al demonstrated that incubating bronchial epithelium from COPD patients with B 
cells from healthy donors promotes IgA1 production. However, IgA was also shown to 
accumulate in sub-epithelial layers in COPD lung tissue and did not necessarily result in an 
increase in secretory levels (255).  
4.10.1.3 FLC relationship to disease severity 
FLC levels did not correlate with disease severity. However, when patients were sub-grouped 
according to the severity of their airflow obstruction, patients with moderate (GOLD stage 2) 
obstruction were found to have significantly higher FLC levels than those with severe (GOLD 
stage 4) obstruction. The same pattern was also seen in the A1ATD cohort.  As discussed in 
Chapter 3.7.1.3, FEV1 decline is known to be greatest in patients with moderate airflow 
obstruction and this is sometimes viewed as a surrogate marker of disease ‘activity’. It is 
possible that cFLC levels therefore relate better to disease activity than disease severity. 
Alternatively, it is possible that this reflects a treatment effect as a greater proportion of 
GOLD stage 4 patients are likely to be treated with high dose inhaled steroids which have 
been shown to modulate the adaptive immune system response within the lung in COPD 
(234, 235). 
4.10.1.4 FLC and disease activity in usual COPD 
In order to establish whether FLCs varied according to episodes of increased disease activity 
in COPD they were measured in a separate cohort of patients at day 1 and day 56 of an 
exacerbation. A significant polyclonal increase in cFLC levels from day 1 to day 56 was 
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observed although the absolute difference in median values was small. This could suggest 
that FLCs alter with acute changes in disease activity which more likely represents an 
immune stimulus reflecting an infective nature of the exacerbation episodes associated with 
bacteria or viruses. It was not possible as part of this study to obtain sufficient samples to 
determine the infective nature of the episodes but would clearly be important in a future 
project.   
There was no significant difference in the day 1 or day 56 cFLC levels in the patients who 
subsequently died compared to those who survived although the numbers were small. 
Previous studies have shown that exacerbations are associated with a worse quality of life, 
greater speed of FEV1 decline and an increased risk of mortality (15-17) and this could be 
explored in more detail within a follow up study powered for such an outcome.  
In order to establish whether FLCs could be a clinically useful biomarker of disease activity in 
COPD they would also need to be measured in a larger cohort with a longer period of follow 
up. Overall there was a significant increase in group cFLC levels from day 1 to day 56 
however not all patients had an increase. It would be important to determine whether a rise 
in FLC level during such episodes was associated with a worse short-term prognosis given 
the association between FLC levels and mortality within the larger usual COPD cohort 
demonstrated here. It may be that a high-risk subgroup of patients who have unresolved 
inflammation resulting in chronic adaptive immune activation and a greater risk of mortality 
could be predetermined however further work is needed to investigate this possibility.  
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4.10.1.5 FLC and immunoglobulin relationships to longitudinal outcomes 
The results show that cFLC levels are an independent risk factor for mortality in patients with 
usual COPD with a level above the upper limit of normal conferring a hazard ratio of 1.8 
(corrected for severity of COPD as measured by FEV1 in a multivariate analysis). Polyclonal 
FLC levels have previously been shown to be a risk factor for mortality within both the 
general population and in patients with CKD (183, 187-189). 
Serum IgA levels were also found to significantly predict mortality in this patient population 
supporting the concept that adaptive immune activation is an important identifying factor 
for mortality in patients with COPD. Hurme et al found IgA levels to significantly predict 
mortality within a cohort of 285 nonagenarians (256). This is consistent with an ‘immune risk 
phenotype’ where specific parameters including: CD4:CD8 ratio of <1, poor T-cell 
proliferative responses to mitogens, increased CD8+, CD28−, CD57+ cells, low B cells and 
cytomegalovirus (CMV) seropositivity which predicts mortality in a healthy aged population 
(257, 258). The authors hypothesised that the chronic antigenic stimulation caused by 
viruses such as CMV and other organisms lead to an increase in senescent T cells and other 
immune system changes which result in immunoparesis and an increased risk of death. A 
significant proportion of COPD patients suffer from recurrent infective exacerbations or are 
colonised with specific bacteria which may similarly cause chronic antigenic stimulation of 
the adaptive immune system resulting in dysregulation and thereby increase the risk of 
mortality. To investigate this further we could establish a similar cohort including the 
bacterial colonisation status and follow their immune response and prognosis. 
Other inflammatory biomarkers have previously been shown to be risk factors for mortality 
in patients with COPD. For example baseline C reactive protein is a risk factor for mortality in 
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patients with mild to moderate COPD (259, 260) but not in patients with more severe COPD 
(261). The ECLIPSE study found several other inflammatory biomarkers to be independent 
risk factors for mortality including: white cell count, neutrophil count, interleukin 6, CCL-18, 
PARC and SP-D and showed that adding a panel of biomarkers to clinical predictive models 
improved their predictive value (133). The increased risk of death associated with having a 
high polyclonal FLC level or IgA is a novel finding as no recognised mortality prediction tool 
currently used in usual COPD includes markers of adaptive immune activation. Further work 
is therefore needed to establish whether adding cFLC and/or IgA levels to existing mortality 
prediction tools could increase their prognostic accuracy. Within the current cohort a 
positive correlation was seen between IgA and cFLC levels. Having a cFLC level >43.3mg/L 
(the upper limit of normal) or and IgA level or >3.18g/L (the cut off of the upper quartile) 
conferred similar hazard ratios for death (1.80, p=0.009 and 1.71, p=0.024 respectively). 
Neither test was superior at ROC curve analysis as the area under the curve was 0.59 for 
both. Measuring FLCs alone may therefore have no benefit over measuring IgA levels for this 
specific utility as Immunoglobulin testing is available in all hospitals and less expensive to 
perform. 
4.10.1.6 Conclusions 
FLCs show some characteristics consistent with the criteria for a useful biomarker in usual 
COPD. 
1. Relationship to underlying disease pathophysiology: FLCs have been shown to be
increased in murine models of emphysema and in a small number of usual COPD
patients compared to controls. They can interact with neutrophils to promote IL8
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production and prevent their apoptosis which could potentiate inflammation within 
the lung. 
2. Stability: FLCs are static in the stable disease state in usual COPD
3. Ability to identify clinically important phenotypes: cFLCs were found to be higher in
males within this cohort and a significant difference in the κ/λ ratio was observed in
smokers but cFLCs were unable to differentiate important clinical phenotypes such as
chronic bronchitis.
4. Relationship to disease severity and activity: cFLCs do not have a linear relationship
with disease severity as measured by FEV1 however when patients were sub-grouped
according to their GOLD severity, patients with moderate airflow obstruction were
found to have significantly higher FLC levels than those with very severe impairment.
The same relationship was seen within the A1ATD cohort. FLCs significantly rise
during COPD exacerbations but the influence of this on longitudinal outcomes is
currently unknown.
5. Ability to predict longitudinal outcomes: cFLC levels measured in the stable state are
an independent risk factor for mortality in patients with usual COPD.
In addition to the findings above we found that cFLC levels correlate positively with IgA and 
IgG levels and that IgA levels are similarly associated with mortality within this cohort. This 
supports the findings of Chapter 3 regarding the importance of adaptive immune activation 
as a risk factor for mortality in patients with COPD. The utility of adding FLCs as a biomarker 
to mortality prediction models is worthy of further investigation. 
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CHAPTER 5: FLCs and colonisation in a bronchiectasis 
cohort 
5.1 Introduction 
Bronchiectasis is the permanent dilatation of the airways, which may or may not be 
associated with airway thickening. It is diagnosed radiologically by high-resolution computed 
tomography scanning. The hallmark clinical features of bronchiectasis are chronic cough with 
sputum production, bacterial airway colonisation and frequent lower respiratory tract 
infections (262). 
A significant proportion of patients with A1ATD related and usual COPD have co-existent 
bronchiectasis. Earlier reports of the incidence of bronchiectasis in A1AT deficient individuals 
were as high as 43% although based on small study populations (66, 71).  In a larger study of 
74 (PiZ) subjects, Parr et al reported the incidence of “clinically relevant” bronchiectasis to 
be 27%, which is similar to the reported incidence in usual COPD (72). The incidence of 
bronchiectasis in our larger A1ATD and usual COPD cohorts reported in Chapter 3 and 4 
were 28.6% and 30.2% respectively and therefore in line with previous studies.  
A recent Meta-Analysis found the presence of bronchiectasis in patients with COPD to be 
associated with a higher exacerbation frequency, isolation of pathogenic organisms, more 
severe airflow obstruction and an increased risk of mortality (263).  
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In Chapter 3, the potential utility of polyclonal FLCs as a biomarker in severe A1ATD was 
examined. In addition to predicting mortality within this patient population, patients who 
were known to have chronically colonised airways were found to have higher FLC levels than 
those without evidence of colonisation. This raised the issue of whether colonisation could 
be driving a chronic adaptive immune response in certain individuals. To explore this 
relationship further, FLCs were measured in a small cohort of patients with bronchiectasis.  
5.2 Patient Characteristics 
FLC analysis was performed in 53 patients with non-cystic fibrosis (CF) related 
bronchiectasis. Six patients were then excluded from analysis for the following reasons: 2 
patients had abnormal ratios, 1 patient had a known paraproteinaemia, 1 patient had an IgG 
and IgM deficiency and 2 patients were on long-term oral steroids. Demographic data for the 
remainder is shown in Table 5.1. Median follow up time was 5.6 years (IQR 4.8-5.7) and the 
underlying aetiology of bronchiectasis of patients within this cohort is shown in Table 5.2. 
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Variable Bronchiectasis cohort (n=47) 
Age (years) 68 (61.8-72.4) 
Sex Male n = 9 (19.1%) 
Female n = 38 (80.9%) 
Pack years 0 (0-2) 
FEV1 (% predicted) 68.8 (24.9) 
KCO (% predicted) 101.0 (94.0-107.0) 
Chronic bronchitis 36/41 (87.8 %) 
Emphysema 2/43 (0.05%) 
Frequent exacerbator 26/41 (63.4%) 
eGFR (ml/min/1.73m2) 85.0 (72.8 – 91.1) 
CKD stage  
  1      eGFR ≥ 90 
  2      eGFR 60 - 89  
  3      eGFR 30 - 59 
  4      eGFR 15 - 29 
  5      eGFR < 15 
  Unknown (no eGFR) 
12 (25.5%) 
29 (61.7%) 
3 (6.4%) 
1 (2.1%) 
0 (0%) 
2 (4.3%) 
cFLC (mg/L) 29.9 (25.6-39.4) 
κ/λ 0.89 (0.29) 
Table 5.1: Patient demographics in the bronchiectasis cohort 
Continuous variables are expressed as median (IQR); sex, chronic bronchitis, emphysema, 
exacerbators and chronic kidney disease (CKD) stage expressed as number in each group (%). 
A frequent exacerbator was defined as having 2 or more treated exacerbations per year. 
Number of patients with contemporaneous renal function = 45. FEV1 = forced expiratory 
volume in 1 second, KCO = corrected gas transfer, eGFR = estimated glomerular filtration 
rate, cFLC = combined (κ + λ) free light chain level and the κ/λ ratio is shown. 
Bronchiectasis aetiology (n=47) 
Idiopathic 15 (31.9%) 
Sequelae to childhood infection 22 (46.8%) 
Primary ciliary dyskinesia 2 (4.3%) 
ABPA 1 (2.1%) 
Aspiration pneumonia 2 (4.3%) 
Pink disease 2 (4.3%) 
Airways disease 3 (6.4%) 
Table 5.2 Bronchiectasis aetiology 
Aetiology of bronchiectasis within the cohort expressed as number in each group (%). ABPA 
= Allergic Broncho Pulmonary Aspergillosis 
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5.3 Concurrent autoimmune disease 
Thirteen patients (27.7%) had at least one concurrent autoimmune disease (Positive ANCA 
(n=5), Thyroid disease (n=4) rheumatoid arthritis (n=2), vitiligo (n=1), polymyalgia 
rheumatica (n=1), ulcerative colitis (n=1), one patient had 3 conditions). There was no 
significant difference in cFLC levels between patients with and without a concurrent 
autoimmune disease (median 28.4 v 31.2 mg/L, p=0.20). 
Twenty-five patients have been tested for antinuclear antibodies (ANA). There were no 
significant differences in cFLC levels in patients with and without a positive ANA (median 
28.43 v 40.32 mg/L, p=0.095). 
5.4 FLCs and clinical phenotypes 
Table 5.3 shows the results of the univariate analysis of FLC levels (κ, λ and cFLC) in the 
bronchiectasis cohort grouped according to their gender, smoking history and clinical 
phenotype. No significant differences between the groups were seen.  
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Group 1 Group 2 P value 
Current Smokers Yes (n=11) No (n=33) 
cFLC 30.5 (27.5-38.6) 29.9 (25.5-41.3) 0.728 
κ 14.3 (12.5-15.3) 14.9 (11.4-18.0) 0.847 
λ 15.4 (14.5-21.8) 15.4 (12.9-20.7) 0.417 
κ/λ 0.95 (0.68-0.98) 0.94 (0.750-1.11) 0.545 
Gender Male (n=9) Female (n=38) 
cFLC 31.3 (26.6-44.2) 29.8 (25.5-39.8) 0.570 
κ 15.1 (11.4-18.6) 14.4 (11.8-17.7) 0.766 
λ 15.4 (13.7-25.8) 15.7 (13.2-20.5) 0.665 
κ/λ 0.97 (0.62-1.02) 0.93 (0.78-1.05) 0.746 
Frequent exacerbations Yes (n = 26) No (n = 15) 
cFLC 31.9 (27.0-46.1) 27.7 (24.0-34.6) 0.144 
κ 15.6 (12.7-19.4) 14.3 (10.3-15.1) 0.137 
λ 16.1 (13.6-25.1) 14.4 (12.0-19.5) 0.151 
κ/λ 0.90 (0.69-1.14) 0.94 (0.77-0.98) 0.871 
Chronic bronchitis Yes (n=36) No (n=5) 
cFLC 30.2(24.9-41.8) 25.9 (22.2-33.5) 0.202 
κ 14.8 (11.6-17.6) 13.1 (9.3-16.8) 0.339 
λ 15.4 (13.3-21.8) 14.1 (11.6-17.3) 0.202 
κ/λ 0.94 (0.72-1.03) 0.91 (0.71-1.10) 0.905 
Table 5.3 Comparison of FLCs in subgroups according to phenotype and gender in the 
bronchiectasis cohort 
Median individual and combined κ & λ (cFLC) levels (mg/L) reported with inter-quartile range 
in brackets. Mann Whitney U Tests performed to determine any statistical differences 
between groups 1 and 2 (*p ≤ 0.05).  
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5.4.1 FLC relationship to colonisation status and sputum purulence 
5.4.1.1 FLC relationship to airway colonisation 
The prevalence of bacterial colonisation in patients with non-cystic fibrosis related 
bronchiectasis has been reported to be as high as 64% (264). All the patients within the 
current bronchiectasis cohort were asked to provide sputum samples during their stable 
state to establish whether they were colonised with any potentially pathogenic 
microorganisms (PPMs – see Appendix 1.3). For the purposes of this study a positive culture 
was defined as a growth ≥ 1 x 105 colony forming units (CFU) per ml of sputum of a PPM. 
Chronic colonisation was defined as ≥3 isolations of same organism from separate sputum 
samples over minimum of ≥3 months (206). Patients were then sub-grouped according to 
the colonising organism (pseudomonas, haemophilus influenzae, other/mixed growth of 
multiple PPMs). Figure 5.1 A shows the breakdown of the cohort according to their 
colonisation status. Nine patients did not provide an adequate number of sputum samples 
for colonisation status to be confirmed. Figure 5.1 B shows the cFLC levels in patients sub-
grouped according to their colonising organism. No significant difference between the 
groups was seen (Kruskall Wallis test χ2(4) = 3.79, p=0.435). 
Additionally, when patients were simply grouped according to whether they were colonised 
or not, no significant difference in FLC levels was seen (median cFLC mg/L 31.3 (26.6-42.5) 
versus 29.2 (22.9-35.6) mg/L respectively, p = 0.29) Figure 5.2. 
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Figure 5.1 The colonisation status of the patients in the bronchiectasis cohort and 
relationship to cFLCs 
A. Pie chart showing the proportion of patients according to colonisation status. B. Bar chart
showing median FLC levels (error bars represent interquartile range) in the different groups.
There was no significant relationship to colonisation status (Kruskall Wallis test p=0.435).
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Figure 5.2: Box plot showing cFLC levels in bronchiectasis patients who are chronically 
colonised or not with potentially pathogenic organisms  
Univariate comparison of the combined κ & λ free light chain (cFLC) levels between the non-
colonised (n=5) versus the chronically colonised (n= 33) patients in the bronchiectasis 
cohort. Horizontal lines represent medians, boxes represent interquartile ranges and 
whiskers represent minimum to maximum values.  There was no significant difference 
between the combined κ & λ free light chain (cFLC) levels (median cFLC mg/L 31.3 (26.6-
42.5) versus 29.2 (22.9-35.6), p = 0.29). 
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5.4.1.2 FLC relationship to sputum purulence  
Sputum purulence has previously been shown to correlate with markers of airway 
inflammation in patients with bronchiectasis (265). Nineteen patients had sputum cultures 
taken at the same time as their FLC sampling. The sputum samples were categorised by a 
research microbiologist as mucoid, mucopurulent or purulent according to their appearance. 
There was a trend towards patients with purulent sputum having higher serum FLC levels 
compared those with mucopurulent sputum although this did not achieve conventional 
statistical significance (median cFLC 36.0 (29.5-38.4) versus 29.8 (23.2-30.6) mg/L 
respectively p=0.065, Figure 5.3). 
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Figure 5.3 Scatter plot showing the relationship of cFLC to sputum purulence in patients 
with bronchiectasis 
Comparison between combined κ & λ free light chain (cFLC) levels of patients sub-grouped 
according to their sputum purulence within the bronchiectasis cohort. Each 
dot/square/triangle represents an individual patient and the lines represent median values 
per group. The groups were compared using the Mann-Whitney U test. There was a trend 
towards patients with purulent sputum having higher cFLC levels compared to those with 
mucopurulent sputum although this did not achieve statistical significance (median cFLC 
(mg/L) 36.0 (29.5-38.4) versus 29.8 (23.2-30.6) respectively, p=0.065).  
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5.5 FLCs relationship to bronchiectasis disease severity 
5.5.1 FLC relationship to airflow obstruction 
In patients with bronchiectasis, chronic airway inflammation results in structural damage of 
the airways and mucus plugging which can be associated with an accelerated decline and 
FEV1 resulting in airflow obstruction (266, 267). Greater systemic inflammation, colonisation 
with pseudomonas and a high exacerbation frequency have been shown to be risk factors 
for lung function decline in patients with non-CF bronchiectasis (266). 
The relationship of FLCs to lung function parameters within this cohort was therefore 
examined. However, no correlation with FEV1 (rs=-0.10, p=0.49), FEV1/FVC (rs=-0.10, p=0.49) 
or gas transfer (KCO rs=-0.17, p=0.33) was identified (Figure 5.4). In addition, when patients 
were sub-grouped according to the severity of their airflow obstruction there was no 
significant differences between the groups (Kruskall Wallis test χ2 (4) =1.60, p=0.81, Figure 
5.5).  
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Figure 5.4 Scatterplot showing the relationship between cFLC and airflow obstruction in 
the bronchiectasis cohort. 
cFLC = combined (κ & λ) free light chain, FEV1 = forced expiratory volume in 1 second. Each 
dot represents a single patient. (Spearman’s Rho rs=-0.10, p=0.49). 
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Figure 5.5 Bar chart showing cFLC levels in bronchiectasis patients grouped according to 
the severity of their airflow obstruction 
Bars represent median combined (κ & λ) FLC (mg/L) in each group. Error bars represent 
interquartile range.
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5.5.2 FLCs relationship to the FACED severity score in bronchiectasis 
There is no agreed severity index used routinely in the assessment of bronchiectasis, 
however in recent years a number of scoring systems to assist with prognostication have 
been proposed. HRCT scan changes correlate poorly with lung function impairment limiting 
the utility of HRCT severity scores alone (268). This prompted the need for more detailed 
validated scoring systems taking into account other clinical parameters to help assess 
severity in bronchiectasis.  Martinez-Garcia et al described the ‘FACED’ tool to predict 
mortality in a cohort of patients with bronchiectasis based on a score calculated from the 
following variables: FEV1, Age, Colonisation with pseudomonas, the Extent of bronchiectasis 
(number of lobes of lung involved) and Dyspnoea (assessed using the modified MRC 
breathlessness score) (209). Another widely used severity scoring system is the 
‘Bronchiectasis Severity Index’ which contains many of the same variables as the FACED tool 
but also includes BMI, previous hospital admissions and the number of exacerbations within 
the last year (269). However this data was not available for our retrospective cohort analysis 
and the FACED score has been shown to be superior in predicting 15 year mortality (270) so 
this severity score was chosen for the purposes of the current study.  
The FACED score was calculated for 39/47 of the patients within the bronchiectasis cohort 
(see Appendix 1.6); eight patients did not have all the data available to calculate the score so 
were excluded from the analysis (MRC scores not recorded at the time of sample collection). 
No significant difference between cFLC levels was seen between the patients grouped 
according to their FACED scores (Kruskall Wallis (χ2(6) = 5.77, p=0.450) Figure 5.6. 
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Figure 5.6 Box plot showing the relationship of cFLC levels to FACED severity score in 
patients with bronchiectasis  
The FACED score was calculated for n=39 patients based on their FEV1, Age, Colonisation 
with pseudomonas, Extent of bronchiectasis and Dyspnoea (measured using the modified 
MRC score). Horizontal lines represent medians, boxes represent interquartile ranges and 
whiskers represent minimum to maximum values. FACED score of 0 = least severe, 7 = most 
severe. cFLC = combined (κ & λ) free light chain. 
 n = 3        n = 7    n = 9        n = 10       n = 6    n = 3    n = 1   
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5.6 FLCs and longitudinal outcomes 
Four patients died during the follow up period. There was no significant difference between 
the cFLC levels in the patients who died compared to those still alive (median cFLC 23.9 
(27.1-39.8) versus 30.5 (19.7-41.2) mg/L, p=0.214). A survival analysis was not conducted 
within this cohort as there were too few deaths for this to be statistically robust (271).  
5.7 Immunoglobulin analysis 
Immunoglobulin results were recorded for 41/47 patients (87.2%) within the bronchiectasis 
cohort. Positive correlations were identified between FLC levels (κ, λ and cFLC) and IgA and 
IgG levels. The strongest correlation was between cFLC and IgA levels (rs= 0.702, p<0.001** 
Figure 5.7) There was no significant correlation between FLC levels and IgM.  
A positive correlation between IgA levels and BMI was also seen (rs = 0.42, p=0.006*). No 
significant differences in immunoglobulin levels was seen between current smokers and 
non-smokers (IgG median 10.91 v 10.74 g/L, p=0.914, IgA median 3.02 v 2.49 g/L, p=0.30, 
IgM 0.72 v 1.03 g/L, p=0.106). No significant differences in immunoglobulin levels were 
seen with respect to gender, frequent exacerbator status (≥ 2 per year) or chronic 
bronchitis.  
Patient who subsequently died were found to have significantly lower IgM levels than those 
still alive (Median 0.39 v 0.99 g/L, p=0.038*), however as only four patients died during the 
follow up period the clinical significance of this result is uncertain.  
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κ λ κ/λ cFLC 
IgA     rs 
p 
0.685 
<0.001** 
0.697 
<0.001** 
0.014 
0.929 
0.702 
<0.001** 
IgG     rs 
p 
0.411 
0.008* 
0.313 
0.046* 
0.17 
0.287 
0.373 
0.016* 
IgM    rs 
p 
-0.189
0.237
0.012 
0.938 
-0.29
0.066
-0.093
0.563
Table 5.4 Spearman’s Rho correlation of FLC levels and Immunoglobulin levels in the 
bronchiectasis cohort 
rs =correlation coefficient. (*Statistically significant 2p values are highlighted in red) 
Figure 5.7 Scatterplot showing correlation between IgA and cFLC levels in the 
bronchiectasis cohort. 
IgA = Immunoglobulin A, cFLC = combined κ & λ FLC level (mg/L). Spearmen’s Rho rs=0.70, 
p<0.001** 
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5.8 Discussion 
The main aim of this chapter was to explore the relationship of FLC levels and bacterial 
colonisation of the airways. This small bronchiectasis cohort was utilised due to the detailed 
information on their colonisation status. However, no significant difference was seen 
between FLC levels of bronchiectasis patients colonised with different organisms. In 
addition, there was no significant difference in FLC levels between those who were 
chronically colonised compared to those patients who were not.  
Although no direct relationship of FLC to colonisation status was seen there was a trend 
towards patient with purulent sputum having higher cFLC levels. Purulent sputum occurs as 
a result of neutrophil recruitment to the airways indicating activation of the adaptive 
immune response (265). In addition to being a marker of colonisation (215) studies have 
demonstrated that sputum colour (measured using a sputum colour chart) is associated with 
active proteolytic enzymes and increased inflammatory cytokine levels within the airways 
(265, 272). As sputum purulence is therefore a marker of airway inflammation it seems 
logical that patients with purulent sputum may have a greater adaptive immune response 
reflected in higher serum FLC levels.  
There are a number of potential reasons why we did not see the same relationship of FLCs to 
chronic colonisation within this cohort. As previously discussed in Chapter 4, it has been 
hypothesised that FLCs could play a role in the pathogenesis of COPD and it is possible that 
this is not the case for non-CF bronchiectasis. Bronchiectasis is a very heterogeneous 
condition with many different potential aetiologies. Ideally a sub-group analysis should be 
performed according to the underlying cause of the bronchiectasis as it is possible that FLCs 
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may be relevant to some aetiologies and not others. Unfortunately, the number in this 
cohort was too small to draw conclusions from subgroup analyses according to aetiology. 
Although some pathological processes are common to both bronchiectasis and COPD, there 
are also some differences. In both, the airways are infiltrated with neutrophils, macrophages 
and lymphocytes and there is a vicious cycle of infection and inflammation (43, 273). As 
previously described in Chapter 1 lymphoid follicles are seen in the lungs of patients with 
COPD (49) and this has also been reported in a subgroup of patients with ‘follicular’ 
bronchiectasis (274). This was first described by Whitwell in 1952 and was so named due to 
the prominent pathological feature being excessive lymphoid tissue formation within the 
walls of the affected airways and surrounding alveoli. This pathological subtype corresponds 
to the commonest form of bronchiectasis whereby ‘cylindrical’ or ‘tubular’ bronchiectasis is 
seen radiologically. It would also be interesting to look at FLC levels according to pathological 
and radiological subtype however when reviewing the CT reports of the patients within this 
cohort the radiologists had not consistently reported the type of bronchiectasis that was 
seen, so it was not possible to perform this analysis robustly and would clearly be an 
important issue for any future studies.  
In COPD, it is recognised that chronic inflammation and disease progression occurs despite 
smoking cessation, and may be driven by periods of exacerbation, which can also be non-
infective in nature. This was the reason for the emergence of the autoimmune hypothesis in 
the pathogenesis of COPD. It is possible that FLC production could in part be driven by an 
autoimmune phenomenon and exacerbated by infection. This prompted me to look at the 
antinuclear antibody (ANA) titres within this cohort but no relationship to FLC levels was 
seen. ANA testing was inconsistently performed within this cohort and the number of 
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patients with ANA sampled was likely too small to enable robust conclusions. Interestingly 
the proportion of patients with concurrent autoimmune disease was higher in this cohort 
than in the A1ATD and COPD cohorts.  
5.8.1 Immunoglobulin analysis 
The British Thoracic Society guidelines on non-CF bronchiectasis advocate that all patients 
with bronchiectasis have serum immunoglobulin levels checked due to the possibility of an 
underlying antibody deficiency as the cause of their bronchiectasis (262). Similar to the 
findings in the usual COPD cohort, the FLC levels in this cohort of bronchiectasis patients 
were found to correlate positively with both IgA and IgG levels but not IgM.  
In this cohort patients who died were found to have significantly lower IgM levels than those 
still alive. However only 4 died during the follow up period so the importance of this finding 
remains uncertain. IgM is the first antibody response when foreign antigen is encountered. 
Circulating serum IgM also contains so-called ‘natural’ antibodies that are considered 
important modulators of immune homeostasis (275) in addition to IgM antibody produced in 
response to antigen stimuli. Selective IgM deficiency is associated with increased risk of 
potentially life-threatening infections including upper and lower respiratory tract infections 
and bronchiectasis. IgM deficiency has also been linked to a number of autoimmune 
diseases but the cause and effect relationship has not been differentiated (276).  
Given that immunoglobulins are routinely tested in all patient with bronchiectasis it would 
be important to examine immunoglobulin levels in a larger cohort of bronchiectasis patients 
with respect to longitudinal outcomes. The main purpose of measuring immunoglobulin 
levels is to rule out an abnormally low value, however, in view of our findings in usual COPD 
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that high cFLC levels and IgA levels significantly predict mortality it would be important to 
determine whether the same relationship exists in bronchiectasis or whether low IgM levels 
predict mortality as this could be easily added to existing mortality prediction scores such as 
the FACED tool.  
5.8.2 Limitations 
There were a number of limitations that may have influenced the results within this chapter. 
Patients were recruited from secondary care bronchiectasis clinics. This was a strength, as 
patients under routine follow up are more likely to be chronically colonised and have a high 
exacerbation frequency and hence more likely to determine the relevance of colonisation to 
FLC levels. However, it could also be a weakness as this would add an element of selection 
bias such that results may not be generally representative of patients with bronchiectasis. 
The primary aim of assessing FLCs in this cohort was to look for a relationship to colonisation 
rather than examining the utility of FLCs as a biomarker in patients with bronchiectasis. 
However, the data was far from clear and a much larger cohort would need to be studied in 
order to determine such a utility. 
Only one sample of serum was taken from the patients so it was not possible to determine 
the stability of FLCs over time within this cohort. There was also a relatively small number of 
patients compared to the A1ATD and usual COPD cohorts.  It is likely that larger cohorts of 
patients will be needed to assess such phenotypic trends. As this was a retrospective cohort 
analysis there were also some gaps in the data which reduced the sample size further for 
analyses such as the relationship of cFLC to the FACED bronchiectasis severity score. It was 
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also not possible to undertake survival analyses due to the small number of patients who 
died during the follow up period. 
182 
CHAPTER 6: Conclusions and future work10 
6.1 Conclusions 
The main objective of this study was to investigate the utility of polyclonal FLCs as a clinical 
biomarker in severe A1ATD and usual COPD. As previously discussed, key properties of a 
clinically useful biomarker are that it is reproducible in stable disease, relates to disease 
severity and relates to outcome. The results demonstrate that cFLCs meet many of these 
criteria, notably being associated with subsequent mortality in both cohorts. No significant 
difference was seen in cFLCs taken from patients with stable disease at different time points, 
suggesting that cFLCs are reproducible in stable disease. A strong relationship between cFLC 
levels and disease severity was not seen, although there was a difference observed between 
patients with and without chronic bronchitis, which is recognised to be a clinically relevant 
subgroup within airways disease (277). Chronic bronchitis is associated with more rapid FEV1 
decline (219), increased exacerbation frequency (278) and a greater risk of mortality (279). 
However, the difference between cFLCs in patients with chronic bronchitis compared to 
those without was relatively small, thus the result must be interpreted with caution in terms 
of clinical relevance. 
The most significant finding in this study was that in both the A1ATD and usual COPD 
cohorts, cFLC levels were a predictor of mortality, independent of age and severity of renal 
impairment with cFLC levels above the normal range conferring a hazard ratio of 2.89 (1.47-
5.70, p=0.002) and 1.8 (1.16-2.8, p=0.009) respectively. In addition, cFLC levels were found 
10 Excerpts of this chapter have been previously published (202. Hampson JA, Stockley RA, Turner 
AM. Free light chains: potential biomarker and predictor of mortality in alpha-1-antitrypsin deficiency 
and usual COPD. Respir Res. 2016;17:34.) 
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to positively correlate with IgA and IgG levels in the usual COPD cohort and IgA levels 
similarly predicted mortality. Several studies have shown a link between immune system 
activity, inflammation and risk of death: an increase in polyclonal cFLCs predicted mortality 
in the general population (183) and cFLC >65 mg/L was a risk factor for death within 100 
days (184). The association between inflammation and cardiovascular death is well 
recognised (280), and 41 % of the deaths in those with cFLC>65 mg/L was from 
cardiovascular disease (183). A recent systematic review supported the concept that the 
relationship between cardiovascular disease and COPD goes beyond common aetiological 
factors such as smoking (281); cFLCs could be partly a factor in this association. 
Furthermore, many important questions regarding the role B cells play in the development 
of COPD remain unanswered. As previously discussed it is not known what drives the B cell 
response in COPD or whether this response is specific to the lung or not. If it were lung 
specific, then this might account for the lack of relationship to co-morbid systemic diseases 
linked to immune activation. Commonly hypothesised antigen sources are microbes 
colonising the airways, smoke constituents and breakdown products of the extracellular 
matrix (222). In the A1ATD cohort we found that chronically colonised patients had 
significantly higher cFLC levels, supporting the hypothesis that colonisation may be an 
important driving factor of adaptive immune activation. Alternatively there has been much 
research about the interaction of microorganisms and the associated immune response 
triggering a response to self-antigens resulting in autoimmunity through a number of 
different mechanisms (223). These include so-called “molecular mimicry” (where the 
microorganism has a peptide epitope similar to a self-protein), through the production of 
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superantigens by microorganisms themselves or are due to other modifications of self-
antigens brought about by infection related tissue injury and oxidative stress (223). 
The difference in cFLC observed between usual COPD and A1ATD imply that this is a more 
important pathogenic theme in usual COPD, although this does not exclude immune 
activation also contributing to the disease process in A1ATD. This result is contrary to the 
recent report of equivalent levels of lymphoid follicles in lung tissue from a small cohort of 
A1ATD patients with very severe lung disease, compared to usual COPD (125). It is possible 
that immune activation represents a feature of advanced disease in both conditions, as most 
of our patients had severe disease, thus further studies are indicated.  
cFLC levels were also examined in a cohort of patients with bronchiectasis to examine the 
relationship between cFLC and colonisation further. Within this cohort, no meaningful 
relationship was seen. However, this may be due the heterogeneous nature of patients with 
bronchiectasis in compared to the more homogenous nature of disease in A1ATD. The 
variation in aetiology, differing severity and clinical phenotypes means that a larger cohort 
was needed to identify any clear relationships with colonisation and to examine the 
relationship between FLC, immunoglobulin levels and longitudinal outcomes in this 
bronchiectatic population. 
In summary polyclonal FLCs are a feature of severe A1ATD related and usual COPD. Levels 
relate to chronic bronchitis and the presence of colonisation in A1ATD, rise during periods of 
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exacerbation in usual COPD and predict mortality in both. Suggesting an association of these 
features with disease activity, colonised disease states and late stage disease. However, 
these preliminary results raise many issues and further questions that need to be answered 
namely: 
1. Cause and effect: are FLCs simply a marker of adaptive immune activation or are they
pathogenic in COPD?
2. Is it only bacterial colonisation driving the adaptive immune response or are other
factors involved?
3. Relationship to mortality: are polyclonal FLCs simply a marker of mortality risk or a
cause of increased mortality?
4. Are FLCs present within the airways of patients with COPD and how does this relate
to their serum level and other factors including bacterial colonisation?
In order to clarify the studies reported here further areas of research need to be 
followed or consolidated.   
6.2 Future epidemiological work 
It is important to establish whether the link to mortality seen within these cohorts is a 
reproducible finding. Further work is warranted to investigate the role of adding biomarkers 
of adaptive immune function, such as cFLC and IgA, to mortality prediction tools in usual 
COPD. The Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints 
(ECLIPSE) study was a prospective study designed to identify novel biomarkers that may help 
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phenotype patients or predict disease progression. As previously discussed in Chapter 3, the 
group found that the addition of a panel of inflammatory biomarkers to a number of clinical 
variables (age, BODE and hospitalisation history) increased the C statistic from 0.686 
(p<0.001) to 0.726 (p=0.003) (133).  If samples have been stored from this cohort of more 
than 1800 patients, FLC and IgA levels could be measured in these patients to determine 
whether their addition added further to the predictive value of the model.   
In healthy aging populations, other adaptive immune system markers of the so called 
‘immune risk phenotype’ (CD4:CD8 ratio <1, inadequate T cell responses, high numbers of 
CD8+, CD28- and CD57+ T cells, low B cell number) have been shown to increase risk of 
mortality (256, 258). More recently IgA levels were also found to predict mortality in a 
cohort of Finnish nonagenarians (256). It has been hypothesised that the cause of this 
immune risk phenotype in the elderly may be due to chronic stimulation of the immune 
system by infections such as CMV resulting in immunosenescence (257). It may also be of 
value to examine these other parameters of adaptive immune function in the ageing COPD 
patient population. Of particular interest would be the effects of chronic bacterial 
colonisation of the lung and whether this relates to or is the cause of the change to these 
markers (including IgA) and hence the association/cause of longitudinal outcomes. 
It is important that the relationship of polyclonal FLCs to bronchiectasis and colonisation is 
further elucidated. As discussed in Chapter 1, a significant proportion of patients with COPD 
have co-existent bronchiectasis. As immunoglobulin levels are routinely assessed in patients 
with bronchiectasis in the diagnostic pathway advised by the British Thoracic Society, it 
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should be possible to do this retrospectively in a further and larger cohort of patients with 
bronchiectasis thereby consolidating the association (262). One way to facilitate this would 
be to utilise an established bronchiectasis cohort such as the EMBARC (a European 
Bronchiectasis Registry) (282). If a biomarker of adaptive immune function was shown to 
predict poor outcome in chronically colonised patients with bronchiectasis, it would be 
important to see if targeting these patients with prophylactic antibiotics affected outcome 
by reducing the bacterial load within the lungs and the subsequent persistent systemic 
inflammatory response. 
The A1ATD cohort is similar in disease severity to the American A1ATD registry (283), thus 
results are likely to be generalisable to other A1ATD populations. However, the usual COPD 
group generally had severe COPD, and exhibited a high prevalence of emphysema, thus our 
results may be less generalisable to milder usual COPD cohorts and those without 
emphysema. This is in part due to the inclusion of family screened, non-index cases in 
A1ATD, not undertaken in usual COPD. Consequently, future work in milder COPD 
populations, perhaps recruited from primary care, could be undertaken to ensure wider 
generalisability and a better comparison to the A1ATD group. For this purpose, the local 
BLISS cohort (a prospectively recruited primary care cohort composed of patients diagnosed 
with COPD by their GP and identified through a linked case finding trial) could be a suitable 
source to widen work (284). 
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6.3 Future work to examine the effects of FLCs on neutrophil 
function 
In order to investigate a more direct relevance of FLCs to the pathogenesis of COPD, further 
functional laboratory work is necessary. The first question to answer is to confirm whether 
FLCs have a pathogenic effect in COPD through polymorphonuclear (PMN) activation. Braber 
et al previously demonstrated that in vitro, FLCs can bind to human neutrophils causing their 
activation and production of IL8 (168). Antagonising FLCs (using F991) was also shown to 
inhibit this binding capability and reduce neutrophilia within the BAL fluid in a smoke 
exposed mouse model (168). Mechanistically cFLCs have biological properties that could 
therefore potentially damage lung tissue through interaction with neutrophils (168, 177, 
178). It has also been shown previously that migratory accuracy of neutrophils is lower in 
COPD than A1ATD (285); it is possible that cFLCs might be partly responsible since cFLCs 
were significantly higher in COPD in this study and have been previously shown to inhibit 
migration of PMNs towards chemoattractants in vitro (177). Furthermore, several case 
reports detail nodular and cystic lung disease associated with cFLC overproduction in light 
chain deposition disease (LCDD) (191-194).  This condition is characterised by the deposition 
of non-amyloid κ or λ light chains, and presents with progressive cystic lung disease 
ultimately leading to respiratory failure necessitating lung transplantation (193). It is possible 
to therapeutically antagonise cFLCs using the compound F991 in animals (168, 286, 287). 
Thus, it remains important to clarify whether the pro-inflammatory effects of cFLCs play a 
role in COPD, and represent a suitable target for an anti-inflammatory strategy. 
189 
6.3.1 FLC neutrophil stimulation assays 
In order to confirm the work of Braber et al, neutrophils (extracted from patient samples 
using Percol density centrifugation) (288) would be stimulated with physiological 
concentrations of FLCs in vitro, and IL8 release measured by ELISA. Inter patient variability 
will be measured to validate this further. For this purpose, neutrophils will be isolated from 
the peripheral blood of 5 healthy controls, 5 usual COPD and 5 A1ATD patients on 3 different 
days and IL8 release in response to FLCs measured. These results will provide evidence that 
it represents a stable process. 
To characterise the neutrophil response to FLCs, additional markers of neutrophil function, 
specifically phagocytosis, the oxidative burst, degranulation and chemotaxis should be 
measured following stimulation with FLCs. The effect of FLCs on ROS production and 
phagocytosis can be measured using the Phagoburst and Phagotest assays respectively (BD 
Biosciences) (289). The Phagoburst assay measures neutrophil ROS production in response 
to stimulation with E.coli via the reduction of dihydrorhodamine (DHR) which is measured 
using flow cytometry. Similarly, the Phagotest assay uses flow cytometry to measures the 
phagocytosis of fluorescently labelled E. coli. ROS production and phagocytosis will be 
measured in response to stimulation with either vehicle control or varying concentrations of 
FLCs. In addition, the effect of FLCs on neutrophil degranulation will be measured using an 
MPO release assay which utilises TMB as a chromogenic substrate in order to measure the 
release of enzymatically-active MPO from activated phagocytes. 
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Finally, in order to examine whether FLCs are chemoattractant in their own right 
experiments will be performed to see their effects on neutrophil migration using an Insall 
chamber. All the above assays are well established in our department (289, 290). 
6.4 Develop a FLC sputum assay 
The next question to answer is whether FLCs are present in the airways of patients with 
COPD and examine how this relates to their serum levels. Do they play a local role in 
inflammation and how does this reflect response to bacterial colonisation? 
One of the advantages of measuring FLCs in serum is that this is a routinely performed test 
in hospital laboratories for the diagnosis of haematological conditions. However, sputum 
biomarkers in COPD directly assess airway inflammation. In addition to cell counts such as 
neutrophil, macrophage and eosinophil counts other molecules such as cytokines, proteases, 
anti-proteases and markers of oxidative stress have been measured in the sputum of 
patients with COPD (291). As with all biomarkers, validation is key to ensuring that sputum 
markers are clinically useful (see Chapter 1.3).  
To examine whether FLCs can be measured accurately in sputum as well as serum and 
plasma, a study has been planned in collaboration with the Binding Site to validate a sputum 
FLC assay.  
So far, testing has been performed on 5 samples of sputum sol taken from patients with 
usual COPD. Linearity was confirmed and all 5 showed doubling dilutions, starting with an 
initial dilution of 1 in 50 into assay sample diluent remained as predicted. Six independent 
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assays were then performed over several days using fresh sample dilutions, which by the 
final assay involved testing samples that had been frozen and thawed from -80°C on 4 
occasions, also giving an indication of sample stability. 
The inter-assay reproducibility was comparable to that obtained with the internal reference 
thus indicating a 1/50 sputum dilution gives an acceptable level of reproducibility (κ sample 
mean coefficient of variance (CV) 7.22 versus internal reference (IR) CV 5.72, lambda mean 
sample CV 7.34 versus IR CV 7.47). Interestingly, the mean kappa FLC value was higher than 
lambda for all 5 samples, which is different to that seen in respective serum. No marked 
lowering of values occurred as the assays were performed, suggesting that stability to freeze 
thaw cycles was good. 
Spike recovery was then performed using 10µL of nephelometric Kappa Free or Lambda Free 
kit calibrator added to 700µL of 1/50 dilution of 2 sputum samples. Samples were assayed 
and the recovery of the added free light chain assessed (mean recovery 100% and 95.8% 
respectively). A 1/50 sputum sol dilution therefore appears to provide a suitable matrix for 
the quantitation of free light chains. 
Having established that FLCs can be accurately assayed in sputum, further work will aim to 
quantify the levels of FLC in larger cohorts of patient with both A1ATD and usual COPD and 
not only look at correlation with serum values but also clinical parameters such as lung 
function, inflammatory markers, chronic bronchitis, bacterial colonisation and outcomes. 
Sample collection is currently ongoing. It would also be important to measure sputum FLCs 
during periods of exacerbations. The studies in this thesis found that in usual COPD that 
there is a significant rise in serum cFLCs from day 1 to day 56 during exacerbations but did 
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not assess local changes within the lung during this time. This would be of particular 
importance when considering targeted therapy, such as FLC inhibition (section 6.3) which 
could prove to be of value either in chronic care or as part of exacerbations only. 
In summary polyclonal FLC predict mortality in patient with severe A1ATD and usual COPD 
and may be an important biomarker for risk stratification. Further work is needed to 
establish if they are pathogenic in these conditions and could be responsible in part for the 
aberrant neutrophil functions previously described in COPD and hence a useful drug target.
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APPENDIX 1: Methods supplements 
1.1 Consent forms 
Consent forms are included for the following patient cohorts who were utilised for the 
purposes of this research 
1. Assessment for Alpha-1 Antitrypsin Deficiency
2. A study of clinical phenotypes, disease progression and epigenetics in patients with
chronic obstructive pulmonary disease and its associated co morbidities.
3. A study of clinical phenotypes, disease progression and genetic susceptibility in
patients with chronic obstructive pulmonary disease
4. An open study to investigate the measurement and variability of inflammatory cells,
mediators and erythrocyte abnormalities in spontaneously produced sputum, blood
and urine from patients with COPD who present with acute exacerbations
5. An open study to investigate the measurement and variability of inflammatory cells,
mediators and erythrocyte abnormalities in spontaneously produced sputum, blood
and urine from patients with COPD who present with acute exacerbations
6. A study of clinical phenotypes, disease progression and genetic susceptibility in
patients with chronic obstructive pulmonary disease, cystic fibrosis bronchiectasis
and non-CF bronchiectasis
Queen Elizabeth Hospital Birmingham 
Patient Information Leaflet and Consent Form Version 4.1, 5 February 2014 
University Hospital Birmingham
     NHS Foundation Trust
Queen Elizabeth Hospital Birmingham 
Edgbaston 
Birmingham 
B15 2WB 
PATIENT INFORMATION SHEET 
Assessment for Alpha1 Antitrypsin Deficiency 
What is the study about? 
You or a member of your family has been identified as having alpha1 antitrypsin deficiency.  This is an 
inherited condition that is believed to increase the risk of development of lung health problems.  However 
very little detailed information has been collected on the way this deficiency affects patients and some 
studies have suggested that lung disease may run in families even without the deficiency.  It is likely 
however that the deficiency highlights the tendency to develop these diseases and when present will make 
them worse. 
We wish to learn as much as possible about the deficiency and its relationship to lung disease and for this 
reason invite you to participate in our alpha1 antitrypsin deficiency assessment programme. 
Sub-study: As part of a recently awarded National Institute for Health Research Rare Diseases 
Translational Research Collaboration it is important to be able to perform more detailed tests and 
assessments on a group of patients that includes both those with milder disease and those at the more 
severe end of the spectrum.  This project will enable a critical comprehensive assessment of the health 
economic burden of alpha-1-antitrypsin deficiency which has never been undertaken.  It will also 
specifically develop and apply new laboratory tests to measure enzymes in blood and secretions which can 
contribute to damage to the lung.  This will help to identify those individuals at risk of progression and 
hence most likely to benefit from alpha-1-antitrypsin replacement therapy. 
What will I have to do? 
In broad terms you will undergo all the routine questioning, examination and tests that we normally 
undertake when assessing somebody who presents with lung disease.  However we hope to do this more 
carefully and in more detail than is routinely carried out by your own doctor or specialist. 
We will ask many questions about your past and present symptoms, health and wellbeing.  In addition you 
will be examined thoroughly to determine the presence of signs related to lung disease.  You will be asked 
to perform some lung function testing which assesses how your lungs work and their ability to take 
oxygen in and out of your body.  We may also perform a specialised CT scan of your lungs (if you have 
not had one) which is a very sensitive technique of detecting damage that has occurred.  Finally we will 
ask you to provide blood samples and if you have a cough productive of sputum we will arrange for you to 
collect this over several hours on one day before coming to see us. 
Once all these tests have been performed we will be able to determine whether you have lung disease 
related to alpha1 antitrypsin deficiency.  This will be explained to you and any modifications in your 
treatment that are indicated will be communicated to both yourself and your own doctor. 
It is our general clinical routine to follow patients with established lung disease on a long-term basis.  
Patients are usually seen annually to assess their wellbeing and follow any progress in the condition.  If 
you have alpha1 antitrypsin deficiency we would wish to see you once a year to assess your symptoms,  
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clinical signs and repeat the extensive lung function tests.  After the first year the lung function may be 
repeated less frequently (2 or 3 yearly) depending on whether these are changing or are stable. 
Sub-study: An abdominal ultrasound scan to assess any liver abnormalities may also be performed. 
NOTE The CT scan exposes you to a small degree of radiation – about the equivalent of 6 months 
background radiation in the UK.  Although this dose is safe (it is the same as a single x-ray of the 
abdomen), it is important that you inform us if you are likely to be pregnant as we will not carry out the 
test in these circumstances.   
Study Flow Chart 
PROCEDURE 
Consultation  
Screening Visit 
Baseline Visit Follow-up Visits 
(annually)  
Written informed consent X 
Demographic and medical history X 
Fingerprick blood test to confirm AAT 
level, genotype and phenotype 
Xa 
Routine haematology and chemistry X X 
Serum and plasma for inflammatory 
markers 
X X 
Optional DNA blood sample Xb 
Sputum sample for microbiology, cell 
count and inflammatory markers c 
X X 
Abdominal ultrasound scan Xd 
Health Status Questionnaires X X 
 Pre-bronchodilator lung function tests X 
Post-bronchodilator lung function tests X X 
Oxygen saturation X X 
Vicorder measurements X X 
CT scan of chest e X 
Physical examination X X 
Record of exacerbation history X X 
Record of current medication X X 
a Only if this has not been previously confirmed 
b Can be performed at either baseline or follow-up visit 
c Only if produces spontaneous sputum 
d Sub-study only and performed within the first 12 months 
e To confirm presence and distribution of emphysema and bronchiectasis if patient has not previously had 
  a CT scan of the chest 
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What are the benefits? 
The major purpose of the study is to find out as much as possible about the lung disease and other health 
problems associated with alpha1 antitrypsin deficiency.  This will provide the background information that 
enables us to manage the disease appropriately and design studies to assess the role of alpha1 antitrypsin 
replacement therapy in both the short and long term.  The investigations that we undertake will allow us to 
advise upon the degree of lung disease that you have and simple measures that you can undertake with 
your current treatment in order to try and stabilize the lung disease.  In addition the lung function tests that 
we will perform will help us to optimize your current treatment in order to improve your breathlessness 
where possible. 
What are the risks? 
All the investigations that are taking place are entirely routine in the assessment of patients with lung 
disease.  As such they are repeated on many occasions in the same patient without any adverse effects.  
The only minor problem that is likely to occur is a slight degree of bruising in some patients when they 
have their blood taken. 
What are the alternatives? 
There are currently no alternatives to finding the information that is required other than the assessment 
programme outlined above. 
What happens if I do not wish to take part? 
If you do not wish to participate in the assessment programme this will be fully understood.  Your own 
general practitioner, or the consultant chest physician who normally looks after you, will be informed of 
the diagnosis and provided with advice on how to assess and manage your follow up along the lines 
outlined above.  If for any reason they or you require further advice from us in the future we will be only 
too pleased to see you.  It is important to emphasize that your overall management by your doctor will not 
be affected by your decision. 
What happens to the samples? 
All biological samples will be processed and stored locally using a unique ID number known only to 
research staff at the local site.  
Sub-study: Anonymised samples will be sent to the main site in Birmingham and used in their entirety for 
subsequent biomarker analysis. 
What happens to the information? 
The important information that we collect will help in the understanding of variation and progression of 
health in alpha1 antitrypsin deficiency.  The research information obtained from the samples collected will 
be the basis for future studies on the role of alpha1 antitrypsin replacement therapy or use of newer 
treatments to help the disease.  Neither your name or any details relating to you personally will be released 
to any other person outside the research programme. 
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Your anonymised clinical information will be entered onto the Alpha One International Registry (A.I.R).  
The worldwide database contains valuable information regarding the incidence and distribution of alpha1 
antitrypsin deficiency between countries, helping to advance knowledge and understanding of the 
condition.  Access to the database is strictly limited and password protected. 
Sub-study: CT scans performed in connection with the National Institute for Health Research Rare 
Diseases Translational Research Collaboration will be anonymised and sent to the main site in 
Birmingham for data analysis. 
Who is taking part? 
All subjects that we identify with alpha1 antitrypsin deficiency and in some cases members of their family 
will be asked to take part.  At present we know of over 800 such patients as yourself and it is likely that 
there are several thousand similar people yet to be identified.   
Sub-study: The study is being conducted at up to 10 centres in the UK where leading consultants have an 
interest in alpha-1-antitrypsin deficiency.  They include major research centres at hospitals based in 
Birmingham, London, Cambridge, Leicester, Manchester, Nottingham and Southampton. A total of 200 
patients with either mild or severe disease will be recruited to the sub-study.  
What if something goes wrong? 
Since the study involves only simple tests that could form part of your routine care and is not a clinical 
trial, we do not expect any harm to come to you. Whatever part of the study you choose or decide not to 
take part in will not affect your future care. If you are harmed by taking part in this research project there 
are no special compensation arrangements. In between visits to the assessment centre your own doctor 
will be largely responsible for your care but (depending on where you live) we may collaborate with your 
doctor and help by seeing you if you become unwell. 
What happens at the end of a study? 
There is no fixed end point to the assessment programme and it will provide a unique opportunity to learn 
a great deal about alpha1 antitrypsin deficiency.  We will keep you informed of your own progress how the 
assessment programme is going and how our understanding is developing by means of patient meetings 
and newsletters.   
What if I have more questions or do not understand something? 
The doctors, co-ordinator and nurse involved in the alpha1 antitrypsin assessment programme will happily 
answer your questions on any occasion when you visit.  If questions arise between visits you will be able 
to contact the centre and either speak to somebody at that time or arrange to do so. 
What happens now if I decide to take part? 
If you decide to take part in the programme now we will arrange an appointment in the not too distant 
future for you to come to the assessment centre for the investigations outlined above.  This will be 
arranged to suit everybody’s convenience and all the assessment will be completed where possible on a 
single visit. 
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What happens if I change my mind during the study? 
If you change your mind during the study, it is important that you notify the assessment centre.  This will 
enable any investigations that have been organized or visits to be cancelled.  Your decision will be passed 
on to both your own doctor and where appropriate your own specialist in order that they can arrange for 
appropriate appointments to monitor your progress.  Providing you are agreeable we would like to contact 
your own doctor or specialist from time to time in order to find out how you are progressing.  However if 
in the future you once again decide to join the programme, we would be only too pleased to see you. 
ADAPT (Antitrypsin Deficiency Assessment and Programme for Treatment), Lung Function and 
Sleep Department, ADAPT Office (office 4), Queen Elizabeth Hospital, Mindelsohn Way, 
Edgbaston, Birmingham.  B15 2WB 
Professor R. A. Stockley, Director - ADAPT Project 
Mrs. Rebecca Bray, Co-ordinator, Registry Office  
Research Team  
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CONSENT FORM FOR PARTICIPATION IN RESEARCH 
Assessment for Alpha1 Antitrypsin Deficiency 
Version and date of Patient Information Leaflet: V 4.1, 5 February 2014 Please Initial 
Yes No 
I have been given a full explanation of the programme and read the patient 
information sheet and have had all my questions answered and voluntarily agree to 
participate in the alpha1 antitrypsin deficiency assessment programme. 
Yes No 
I understand that that if I suffer from any unexpected problems that it may be 
important to contact both my own doctor and the research staff at the alpha-1-
antitrypsin study centre. 
Yes No 
I understand fully that I am free to withdraw from the programme at any time 
without giving a reason and that this will not adversely affect my future 
management. 
Yes No 
I understand that my medical records will be examined by study team and possibly 
regulatory authorities, however my records will remain confidential 
Yes No 
I agree to have my anonymised CT data and biological samples transferred to the 
main study site in Birmingham for subsequent analysis. 
Yes No 
I agree to have my name and clinical information added to the National registry for 
alpha-1-antitrypsin deficiency.  
Yes No 
I agree to have my anonymised clinical information added to the International 
registry for alpha1 antitrypsin deficiency. 
Yes No 
I understand that my General Practitioner and any local hospital consultants 
involved with my care will be informed of my participation in the assessment 
programme 
………………………………………………………………………………………..      
Patient’s signature    Date 
Name in BLOCK CAPITALS……………………………………………………… 
Responsible investigator: I have explained the nature and purpose of this study 
…………………………………………………………………………………………      
Responsible investigator/representative signature          Date 
Name in BLOCK CAPITALS……………………………………………….. 
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NHS Foundation Trust 
Queen Elizabeth Hospital Birmingham 
Edgbaston 
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Title:  A study of clinical phenotypes, disease progression and epigenetics in patients 
with chronic obstructive pulmonary disease and its associated co morbidities. 
You have been asked to participate in a clinical study for research purposes. Before you 
decide to take part it is important that you understand why the study is being performed, 
what it involves, and any possible risks and benefits for you. Take your time reading the 
following information and discuss it with others if you wish. 
Introduction to the research & invitation to take part 
You have been diagnosed as having the symptoms or signs of chronic obstructive 
pulmonary disease (COPD) which is a chronic disease that usually progresses slowly. At 
present there is no specific therapy for COPD and it is also being appreciated that having 
COPD means it is more likely that you will develop other diseases such as heart disease, 
diabetes, kidney disease, gum disease and osteoporosis (thinning of the bones). The 
purpose of the study is to learn as much about COPD and how it affects you and your 
general health so that we can develop new understanding of the disease and hence 
develop new treatment strategies.  
This study is being carried out by the research department in the Chronic Diseases 
Resource Centre, which is part of University Hospitals Birmingham NHS Foundation 
Trust, and is led by Professor RA Stockley. The department has a special interest in 
understanding and treating chronic lung disease, in particular COPD. You have been 
contacted because you already have evidence of COPD and we believe that you are 
suitable to take part in the study. 
In summary 
 The research aims to determine your symptoms and how they affect you. This
includes a full general examination, and all the routine breathing tests, blood sputum
tests (if you produce some) and scans (only if you have not had one before as part of
your routine assessment and if clinically indicated) that we normally undertake when
assessing patients with COPD as well as tests to detect other health problems known
to be associated with COPD including but not limited to heart disease, diabetes, and
osteoporosis.
 If you take part, you will be seen once a year in this special clinic (which will replace
one of your routine appointments if you regularly attend outpatients) asked to provide
routine blood, sputum and urine samples, undergo breathing tests and scans (if you
have not already had them), a limited dental examination by a dentist and a hygienist
will be performed with collection of plaque and saliva samples and answer questions
about yourself, your quality of life, work experience and your chest problems
 All information will be stored in such a way that you cannot be identified by anyone
without Professor Stockley’s permission
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What is the study about? 
The main purpose of the study is to learn as much as possible about your lung disease.  
We wish to study in detail how chest infections, smoking and various other factors 
influence your lung condition and how this progresses over time. Recent research 
suggests that COPD also has effects elsewhere in the body, chiefly but not limited to heart 
disease, diabetes, joint problems etc. and we wish to study this in more detail. This 
knowledge will help in developing newer forms of treatment. All the information obtained 
from you will be stored on a secure database and will be used in this study and in future 
research involving COPD. 
What will I have to do? 
In broad terms you will undergo all the routine questioning, examination and tests that we 
normally undertake when assessing somebody who presents with lung disease.  However 
we hope to do this in more detail than is routinely carried out by your own doctor or 
specialist. 
 We will ask many questions about your past and present symptoms, health and
wellbeing.
 you will be examined thoroughly
o to determine the presence of signs associated with lung disease.
o for presence of other health problems known to be associated with COPD.
 you will be asked to perform routine lung function testing which assesses how
your lungs work and their ability to take oxygen in and out of your body.
 we will ask you to provide 50mls blood (approximately 3 tablespoons) and urine
samples and if you have a cough productive of sputum we will arrange for you to
collect this over several hours on the day before coming to see us.
 You will undergo a limited dental examination by a dentist and a hygienist and
both plaque and saliva samples will be collected.
 We may also perform a specialised CT scan of your lungs (only if it is clinically
indicated and if you have not had one already as part of your routine assessment)
which is a very sensitive technique of detecting lung damage that has occurred.
 We may perform a DEXA scan (only if it is clinically indicated and if you have
not had one already) which is a technique to detect the extent of thinning of your
bones.
We know that COPD is influenced by your genes which have made you susceptible to 
developing the disease. To determine the influence of genes, (if you agree), we will 
collect and store a sample of your blood from which we can extract your DNA. No 
information about the genetic data on you, can or will be released as we will not be able to 
link this with your name as the sample will be coded once it is processed and separated 
from any information that identifies it as yours.  As medical science progresses new ideas 
and new genes related to lung disease are likely to become known and for this reason we 
will store the sample for such future studies.  It is important to emphasise that the whole 
study will be confidential and specific procedures have been put in place to separate all 
confidential information that could help identify you from the results of genetic DNA 
analysis.   
It is our general clinical routine to follow patients with established lung disease on a long-
term basis.  We would wish to see you at least once but thereafter we would also wish to 
review you once year in the CDRC, which will replace any routine clinic appointment, to 
assess your symptoms, clinical signs and repeat the comprehensive tests and lung function 
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tests so that we can identify any factors that cause progression of the COPD. After the 
third year the lung function may be repeated less frequently (2 or 3 yearly) depending on 
whether these are changing or are stable. After 4 years we will also re assess the presence 
or progression of any of the complicating conditions associated with COPD and ensure 
you are on the right treatment. 
NOTE The routine CT and DEXA scans expose you to a small amount of radiation. The 
total dose will be equivalent to about 6 months (to 2 years) of background radiation in the 
UK. Although this dose is safe, it is important that you inform us if you are likely to be 
pregnant as we will not carry out the CT scan in these circumstances.   
What are the benefits? 
The major purpose of the study is to find out as much as possible about COPD.  The 
investigations that we undertake will allow us to advise upon the degree of lung disease 
that you have and simple measures that you can undertake with your current treatment in 
order to try and stabilise the lung disease.  In addition the breathing tests that we will 
perform will help us to optimise your current treatment in order to improve your 
breathlessness where possible. Finally we will help you and your doctor to identify and 
manage any associated health problems affecting other parts of your body that we detect. 
What are the risks? 
All the investigations that are taking place are entirely routine, used in the assessment of 
patients with lung disease.  As such they are repeated on many occasions in the patients 
without any adverse effects.  The only minor problem that is likely to occur is a slight 
degree of bruising in some patients when they have their blood taken. 
What are the alternatives? 
There are currently no alternatives to finding the information that is required other than 
the assessment programme outlined above. 
There are many ways of looking at blood and sputum samples, but relating them to lung 
scans, breathing tests, symptoms and genes has not been done together before. It is 
therefore a new area of research, and there are no similar studies being done in the UK at 
present. Also the association of COPD with heart disease, diabetes, osteoporosis and other 
health care issues is a new area of research and there is a lot to be learnt from this study 
and how they should be managed. 
What happens if I do not wish to take part? 
The study is entirely voluntary and if you do not wish to participate it will not affect your 
current or future care.  It is important to emphasize that your overall management by your 
doctor will not be affected if you do not wish to take part.  
What happens to the information? 
If you decide to take part you will need to allow access to your medical records. They 
may be looked at by the research team, by the hospital Research and Development 
department and by regulatory authorities who check that the study is being carried out 
properly. By signing this form you are giving permission for this to be done and all 
information will be kept confidential. However the results of any tests we carry out will 
be provided to your own doctors if it influences your health or management together with 
any suggestions about changing your treatment 
The information collected will be stored on a secure computer, but your name will not. 
This is known as linked anonymised data, meaning that only Professor Stockley or a 
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delegated deputy will be able to link any of the information to your name. He or a 
delegated deputy will have sole access to a written record of your information, stored in a 
secure facility at University Hospitals Birmingham. All the data collected, samples you 
provide, and their results, including any information about your genes, will be coded with 
a number. The results of tests on your samples and about your genes will not be available 
to anyone outside of the research team and our collaborators. The link to your name will 
be destroyed 15 years after the study ends according to national guidelines.  
Once the data is collected it will be the property of the research department. The data will 
be used for future research into COPD. Research undertaken will involve observational 
assessment, quantification of impact on health care and studies of factors that affect the 
outcome in COPD.  
Future Research 
If you agree, your hospital number will be held on a registry of COPD patients that are 
involved in research. Only the research team involved in this study will have access to 
this registry and it will be held on a secure NHS computer.   If you agree, we will contact 
you about other research projects or studies that we think you might be suitable for.  You 
can choose not to have your name on this registry.  If you agree to be on the registry, you 
do not have to take part in any studies we tell you about, that would be your choice.  You 
can also choose to have your name removed from the registry at any time, and without 
giving a reason, by telephoning or in writing to the address given at the end of this 
information sheet.  
Who will have access to the data? 
Members of the research team led by Prof Stockley will have full access to the database. 
Access will be built on a role based model, with registered users having graded levels of 
access to the data. They will have unique user names and passwords and there will be a 
record of anyone logging in to the database ensuring we have a record of users accessing 
the system. 
The results of the study may be published in a medical journal, but your identity will not 
be revealed. The results may be used in statistical tests, in the development of new 
treatments and diagnostic tests. 
Who is taking part? 
About 1000 other patients with COPD will be asked to take part at the University Hospital 
Birmingham and Heart of England hospitals. 
What if something goes wrong? 
Since the study is not a clinical trial and involves only simple tests that could form part of 
your routine care, we do not expect any harm to come to you. Whatever part of the study 
you choose or decide not to take part in will not affect your future routine care.  
What happens at the end of a study? 
Throughout the study, and when it ends, your hospital doctor and general practitioner will 
continue to treat your chest problems and be kept informed of the results of our tests, so 
they will not need to repeat them unnecessarily. 
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What if I have more questions or do not understand something? 
The doctors and nurses involved in the research study will happily answer your questions 
on any occasion when you visit.  If questions arise between visits you will be able to 
contact the centre and either speak to somebody at that time or arrange to do so if for any 
reason if it is inconvenient. 
What happens now if I decide to take part? 
If you decide to take part in the programme now we will arrange an appointment in the 
not too distant future for you to come to the assessment centre for the investigations 
outlined above.  This will be arranged to suit everybody’s convenience and all the 
assessment will be completed where possible on a single visit. 
Will my General Practitioner (GP) be informed? 
If you give your permission, your GP and usual hospital doctor will be informed of your 
participation in the study.  
What happens if I change my mind during the study? 
You are free to withdraw your participation at any time, and it will not affect your future 
care. If you withdraw your consent after your samples have been analysed it will be the 
responsibility of the research team to ensure that the samples are destroyed if you so wish. 
Who can I contact about the study? 
In the first instance any concerns or questions should be addressed to either your GP or 
hospital doctor. If you have further concerns you can contact: 
Professor R. A. Stockley 
Dr Simon Gompertz 
Dr Elizabeth Sapey 
Dr Alice Turner 
Dr Adam Usher      
Dr Anita Pye 
Address for correspondence: 
Dr Anita Pye 
Office 4, Lung Function & Sleep Dept 
Queen Elizabeth Hospital Birmingham 
Mindelsohn way 
Edgbaston 
Birmingham, B15 2WB 
Thank you for taking time to read this information leaflet 
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University Hospital Birmingham 
NHS Foundation Trust 
Queen Elizabeth Hospital Birmingham 
Edgbaston 
Birmingham 
B15 2WB 
CONSENT FORM 
Title: A study of clinical phenotypes, disease progression and epigenetics in patients 
with chronic obstructive pulmonary disease and its associated co-morbidities. 
I………………………………………………………………(Name in BLOCK CAPITALS) 
Have read the attached information concerning my participation in this study and have had the 
opportunity to discuss it and ask questions. All my questions have been answered in a satisfactory 
way. 
I voluntarily consent to take part in this study. 
I know that at any time, and without giving a reason, withdraw my participation in the study and 
that my future care and management will not be affected. 
I understand that I will have a copy of this Patient Information Leaflet and Written Consent to 
keep. 
I understand that relevant sections of my medical notes and data collected during the study may be 
looked at by individuals from regulatory authorities or from the NHS Trust, where it is relevant to 
my taking part in this research.  I give permission for these individuals to have access to my 
records. 
I hereby give permission for samples taken as part of this study to be stored for future use by the 
research team. 
I understand that data collected during the study will be stored on the database for use in future 
studies.  
I hereby give permission for my GP and hospital consultant to be informed about my 
participation in this research study. 
I hereby give my permission for my hospital number to be held on a COPD register       Yes 
held on a secure NHS computer and for the research team to contact me about  
future research projects           No 
……………………………………………………………………………………….. 
Patient’s signature   Date 
Name in BLOCK CAPITALS ……………………………….     
Responsible investigator 
I have explained the nature and purpose of this study for the person named above 
…………………………………………………………………………………………      
Responsible investigator/representative signature      Date 
Name in BLOCK CAPITALS ……………………………….  
Initials 
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Patient information leaflet 
Study code: RRK3404 
Title: A study of clinical phenotypes, disease progression and genetic 
susceptibility in patients with chronic obstructive pulmonary disease 
You have been asked to participate in a clinical study for research purposes. 
Before you decide to take part it is important that you understand why the 
study is being performed, what it involves, and the possible risks and benefits 
for you. Take your time reading the following information and discuss it with 
others if you wish. 
Introduction to the research & invitation to take part 
This study is being carried out by the research department in the Lung 
Investigation Unit at the Queen Elizabeth Hospital, which is part of University 
Hospitals Birmingham NHS Foundation Trust, and is led by Professor RA 
Stockley. Several hospitals in the West Midlands are working closely with 
Professor Stockley in order to help with the study. The department has a special 
interest in understanding and treating chronic lung disease, in particular chronic 
obstructive pulmonary disease, or COPD for short. You have been chosen because 
your hospital doctor has identified you as suffering from COPD and believes that 
you are suitable to take part in the study. 
What is the research about? 
The main purpose of the study is to find patterns of symptoms, breathing tests, 
blood and sputum tests that identify particular groups of patients with COPD. We 
also hope to establish the importance of environmental influences, such as chest 
infections, in the development of COPD and how it progresses over time. Other 
research suggests there may be genetic influences in COPD, which may affect 
particular groups of patients, or affect how their breathing tests change over time. 
We plan to study this in more detail to find out which genes are important in the 
types of COPD and its progression.  
What will I have to do? 
Please read this section carefully as it details the procedures that are specific to 
research and not part of usual clinical care 
If you agree to take part you will be seen by a research doctor at the time of your 
usual out-patient clinic appointment. They will explain more about the study and 
what it would mean for you. The study will take place over 5 years, and will 
involve seeing a research doctor after one of your out-patient appointments each 
year for at least 3 years. There will be no extra visits to the hospital other than 
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those for your usual out-patient appointments. If you would rather participate for 
only one visit, rather than several, please inform the research doctor. 
If you have brought a sample of sputum with you, you will be asked if some could 
be used for the research. If you have not brought any sputum with you, and 
usually cough it up every day, you will be given a container in which you may 
bring a sample on your next visit.  
A blood sample will be collected from you. This can be done at the same time as 
any other blood tests your hospital doctor has asked for. We will collect 4 small 
tubes of blood for the study, which is the equivalent of about 2 tablespoons.  
We will process the blood and sputum samples so that they can be stored safely in 
secure freezers at the University of Birmingham. For this study they will be used 
to examine markers relevant to COPD. They may also be valuable for future 
research in other areas, but will not be used for other studies without prior 
ethical approval.  
We will also extract your DNA from your blood, which will be stored in the same 
way. Your DNA will be used to look for genes that may influence the development 
of COPD. Your DNA will not be used for other studies. 
As well as collecting these samples we will also collect information about you by 
talking to you and by looking at your medical notes. This will include your date of 
birth, gender, height, weight, date you were diagnosed with COPD and whether 
you smoke now, or have done so in the past. We will also ask some questions 
about symptoms that people with COPD often experience, and ask you to fill in a 
questionnaire about the way COPD affects you. We will also look in your medical 
notes to see what medicines you take, the results of any breathing tests you have 
had done recently, and scans (if you have had one). All of this information will be 
recorded in written form only. 
All of the above procedures should take no more than half an hour on the first 
occasion, and be a little shorter on later visits. This will be in addition to seeing 
your usual hospital doctor. 
What are the benefits? 
You will have no personal benefit from the study. Your participation and 
donation of samples may benefit patients with COPD in the future by helping us 
to understand the disease better, and helping us to develop new treatments. 
What are the risks? 
We do not expect any harm to come to you as a result of providing samples or 
talking to the researchers. Sometimes blood tests can be uncomfortable, or leave 
bruising, but this will be temporary. 
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What are the alternatives? 
There are many ways of looking at blood and sputum samples, but relating them 
to breathing tests, symptoms and genes has not been done together before. It is 
therefore a new area of research, and there are no similar studies being done in 
the UK at present. 
What if I do not want to take part? 
The study is entirely voluntary and if you do not wish to participate it will not 
affect your future care. 
What happens to the information? 
If you decide to take part you will need to allow access to your medical records. 
They may be looked at by the research team, by the hospital research and 
development department and by regulatory authorities who check that the study 
is being carried out properly. By signing this form you are giving permission for 
this to be done. 
The information collected will be stored on a secure computer, but your name 
will not. This is known as linked anonymised data, meaning that only Professor 
Stockley will be able to link any of your information to your name. He will have 
sole access to a written record of your information, stored in a secure facility at 
University Hospitals Birmingham. All the data collected, samples you provide, 
and their results, including any information about your genes, will be coded with 
a number. The results of tests on your samples and about your genes will not be 
available to anyone outside of the research team and our collaborators. The link 
to your name will be destroyed after 15 years. Once the data is collected it will be 
the property of the research department. 
The results of the study may be published in a medical journal, but your identity 
will not be revealed. The results may be used in statistical tests, research and 
development of new treatments, diagnostic tests and medical aids. 
Who else is taking part? 
About 500 other patients with COPD will be asked to take part. 
What if something goes wrong? 
Since the study involves only simple tests that could form part of your routine 
care, we do not expect any harm to come to you. Whatever part of the study you 
choose or decide not to take part in will not affect your future care. If you are 
harmed by taking part in this research project there are no special compensation 
arrangements.  
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What happens at the end of the study? 
Throughout the study, and when it ends, your hospital doctor and general 
practitioner will continue to treat your chest problems. 
What happens if I have more questions? 
If you do not understand something in this leaflet, or have further questions you 
may ask the researcher now, or your hospital doctor. 
What happens now if I decide to take part? 
If you decide to take part you will be asked to read, sign and date the Written 
Consent Form attached to this sheet. By signing it you acknowledge that you have 
understood the aims of the research, and what you are being asked to do.  
In summary 
• The research aims to find out patterns of symptoms, breathing tests, blood
and sputum tests and scans in patients with COPD
• If you take part you will be asked to provide blood and sputum samples, and
answer questions about yourself and your chest problems at one out-patient
appointment per year for 3 years, or as many as you can manage
• All information will be stored in such a way that you cannot be identified by
anyone without Professor Stockley’s permission
Will my General Practitioner (GP) be informed? 
If you give your permission, your GP will be told about your participation in the 
study.  
What happens if I change my mind during the study? 
You are free to withdraw your participation at any time, and it will not affect your 
future care. If you withdraw your consent after your samples have been analysed 
it will be the responsibility of your hospital doctor to ensure that the samples are 
destroyed if you so wish. 
Who can I contact about the study? 
In the first instance any concerns or questions should be addressed to either your 
GP or hospital doctor. If you have further concerns you can contact 
Professor Robert Stockley      
Thank-you for reading this information leaflet 
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Written consent 
Study code: 
Title: A study of clinical phenotypes, disease progression and genetic 
susceptibility in patients with chronic obstructive pulmonary disease 
Enrolment number: 
I………………………………………………………………… (Name in BLOCK CAPITALS) 
Have read the attached information concerning my participation in this study 
and have had the opportunity to discuss it and ask questions. All my questions 
have been answered in a satisfactory way. 
I voluntarily consent to take part in this study. 
I know that at any time, and without giving a reason, withdraw my participation 
in the study and that my future care and management will not be affected. 
I understand that I will have a copy of this Patient Information Leaflet and 
Written Consent to keep. 
I hereby give my permission to authorise personnel from the research team to 
examine my medical records. 
I hereby give permission for samples taken as part of this study to be stored for 
future use by the research team. 
I understand that samples taken as part of this study will not be used in other 
studies without prior ethical approval. 
I hereby give permission for my GP and hospital consultant to be informed about 
my participation in this research study. 
………………………………………………………………………………………..      …………………… 
Patient’s signature               Date 
……………………………………………………………………………………….. 
Name in BLOCK CAPITALS 
Initials 
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Responsible investigator 
I have explained the nature and purpose of this study for the person named above 
…………………………………………………………………………………………      ……………………. 
Responsible investigator/representative signature                     Date 
………………………………………………………………………………………… 
Name in BLOCK CAPITALS 
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Subject initials: ………………. Enrolment No: ………………..
Title:  An open study to investigate the measurement and variability of inflammatory
cells, mediators and erythrocyte abnormalities in spontaneously produced sputum,
blood and urine from patients with COPD who present with acute exacerbations.
You are being asked to take part in a simple research study.  Before you decide to participate 
it is of importance that you understand why the study is performed, what it involves and 
possible benefits, risks and discomfort.  Take your time to read the following information and 
discuss it with your hospital doctor, if you wish. 
Introduction to the research and invitation to take part
This study is being carried out by the research department in the Lung Investigation Unit at
the Queen Elizabeth Hospital, which is part of University Hospitals Birmingham NHS
Foundation Trust and is led by Professor RA Stockley.
You have been chosen because you have been identified as suffering from COPD and
periodically you experience an increase in your symptoms of cough, sputum and
breathlessness (an exacerbation).
What is the research study about?
It is believed that patients with COPD have high levels of lung damage and higher levels of
certain body cells and substances that cause the lung damage compared with people without
COPD. These cells and substances can be detected in the sputum and blood of patients with
COPD. However less is known about how these cells and substances change over time when
the disease is stable or during an increase in your symptoms of cough, sputum production
and breathlessness (called an exacerbation). It is also unclear how these cells and
substances relate to your symptoms of cough, sputum production and breathlessness.
This is an exploratory research study to investigate how the cells and substances change in
sputum, blood and urine over an 8 week period in patients who present with an exacerbation
of COPD.
What will I have to do?
If you are not experiencing an exacerbation now, we will ask you to complete a symptom
diary, which asks about your daily symptoms. If your symptoms deteriorate for 2 or more
consecutive days, you should contact us and you will be seen by a member of the research
team. At this time, we will take a blood sample and collect your sputum and urine. If any
treatment is required, this will be prescribed by your usual health care worker, although we
may provide advice about the most appropriate treatment.
If you have just been admitted to hospital with an exacerbation, we will ask about your
symptoms, and take a blood sample from you today, with a sample of urine and a sample of
your sputum, if possible.
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Follow up visits will occur at day 7, 14 and 56, where blood, sputum and urine samples will be
collected again.
Who analyses the samples?
The samples will only be analysed by the Queen Elizabeth Hospital, Birmingham.  Test
results will be kept confidential in keeping with recent regulations.
What are the benefits?
You will have no personal benefit from the study, other than advice.  The participation and
donation of samples may provide benefit to future patients with COPD and related diseases
by helping doctors to understand the diseases better and by increasing the possibility of
developing new treatments.
What are the risks?
Nothing experimental will be done beyond the collection of samples, which is routine. The
risks from giving a sample of blood are a slight discomfort and the possibility of a bruise
developing where the blood was taken.
What are the alternatives?
The measurement of specific substances in sputum and blood samples to investigate
mechanisms in lung diseases is a new area of research.  There are no other alternatives to
this project which is unique to our department.
As smoking can worsen your condition, stopping smoking is one of the most important things
you can do to help your symptoms.  If you are currently smoking your doctor will talk to you
about the risks of continuing to smoke and the benefits of stopping.
What if I do not want to take part?
The study is entirely voluntary and if you do not wish to participate it will not affect your
present or future treatment and management.
What happens to the information?
If you consent to taking part in the study you need to allow us access to your medical records.
These may be inspected by the University Hospital Birmingham, the trust that is sponsoring
the study and may be inspected by regulatory authorities and/or the Independent Ethics
Committee to check that the study is being carried out correctly.  By signing the Written
Informed Consent Form you are giving permission for this to be done.
With your permission, we will contact both your General Practitioner and Hospital Consultant
and inform them that you are taking part in the study, and provide them with any results (such
as blood or sputum measurements) which may be helpful for your medical management.
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The information collected will be stored on a computer but your name will not.  All the data
collected and samples that you provide will be coded with a number, with only your doctor
having the link for this to your name.  The link will be destroyed after 15 years.
The results from the study may be published in a medical journal, but your identity will not be
revealed.
These data will be used:
 For statistical analysis.
 Understanding the nature of exacerbations.
Who else is taking part?
Approximately 250 people will be asked to take part in the study.
What if something goes wrong?
This is not a study with a new drug and all tests and collections have been used before in
routine clinical management of patients with COPD and do not cause any ill health.
We do not expect any harm to come to you and there are no special compensation
arrangements.
What happens at the end of the research study?
When you have finished taking part in this study, your doctors will continue to manage your
COPD in the usual way.
What if I have more questions or do not understand something?
If you do not understand any of the information in this leaflet or have any other questions
please feel free to ask your hospital Doctor at any time.
What happens now if I decide to take part?
If you decide to take part you will be asked to read and then sign and date the Written
Informed Consent Form attached to this information leaflet.  By signing the consent form you
acknowledge that you have understood the requirements for participating in the study.
What happens if I change my mind during the research study?
You are free to withdraw your participation in this study at any time.  If you withdraw your
future treatment and your level of care will not be affected.  If you change your mind about
participation the link between your name and number also enables samples that have not
been analysed to be traced and destroyed.  If you withdraw your consent after the samples
have been sent for analysis it will be the responsibility of the research team to ensure that the
samples are destroyed.
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Contact name and number: 
In the first instance if you have any concerns or questions you should contact:
Professor Stockley: 
Di Griffiths  
If you have any other concerns about the conduct of this study you can contact:
Dr Christopher Counsell, Research and Development Manager
Birmingham Clinical Research Office
Room 17, Education Centre, 1st Floor
Queen Elizabeth Hospital Birmingham
Birmingham, B15 2WB
Or
Patient Advice and Liaison Services
Queen Elizabeth Hospital Birmingham
Edgbaston
Birmingham, B15 2WB
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WRITTEN CONSENT
Subject initials: ………………. Enrolment No: ………………..
Title:  An open study to investigate the measurement and variability of inflammatory cells, mediators
and erythrocyte abnormalities in spontaneously produced sputum, blood and urine from patients
with COPD who present with acute exacerbations.
I,   ....................................................................................................
(Subject name, block letters) Initials
Have read the attached information concerning my participation in this study and
have had the possibility to discuss it and put questions.
All my questions have been answered in a satisfactory way and I give my consent
voluntarily to participate in this study.
I know that I can, at any time and without giving a reason, withdraw my participation
in the study and that my future care and management will not be affected.
I understand that I shall keep a copy of this Subject Information & Written Informed Consent.
I understand that relevant sections of my medical notes and data collected during the
study may be looked at by individuals from regulatory authorities or from the NHS trust
where it is relevant to my taking part in this research. I give permission for these individuals
to have access to my records.
I agree that my GP and other medically qualified people who may assist in my care during
the study may be informed of my participation in the study.
.................................................................………………………………….
Subject’s signature Date
..........................................................................….
Name, block letters
_____________________________________________________________
RESPONSIBLE INVESTIGATOR
I have explained the nature and purpose of the study for the person mentioned above.
......................................................................………………………………….
Responsible investigator/representative Date
signature
..........................................................................….
Name, block letters
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Subject initials: ………………. Enrolment No: ……………….. 
Title:  An open study to investigate the measurement and variability of inflammatory 
cells, mediators and erythrocyte abnormalities in spontaneously produced sputum, 
blood and urine from patients with COPD who present with acute exacerbations. 
You are being asked to take part in a simple research study.  Before you decide to participate 
it is of importance that you understand why the study is performed, what it involves and 
possible benefits, risks and discomfort.  Take your time to read the following information and 
discuss it with your hospital doctor, if you wish. 
Introduction to the research and invitation to take part 
This study is being carried out by the research department in the Lung Investigation Unit at 
the Queen Elizabeth Hospital, which is part of University Hospitals Birmingham NHS 
Foundation Trust and is led by Professor RA Stockley. 
You have been chosen because you have been identified as suffering from COPD and 
periodically you experience an increase in your symptoms of cough, sputum and 
breathlessness (an exacerbation).  
What is the research study about? 
It is believed that patients with COPD have high levels of lung damage and higher levels of 
certain body cells and substances that cause the lung damage compared with people without 
COPD. These cells and substances can be detected in the sputum and blood of patients with 
COPD. However less is known about how these cells and substances change over time when 
the disease is stable or during an increase in your symptoms of cough, sputum production 
and breathlessness (called an exacerbation). It is also unclear how these cells and 
substances relate to your symptoms of cough, sputum production and breathlessness. 
This is an exploratory research study to investigate how the cells and substances change in 
sputum, blood and urine over an 8 week period in patients who present with an exacerbation 
of COPD. 
What will I have to do? 
If you are not experiencing an exacerbation now, we will ask you to complete a symptom 
diary, which asks about your daily symptoms. If your symptoms deteriorate for 2 or more 
consecutive days, you should contact us and you will be seen by a member of the research 
team. At this time, we will take a blood sample and collect your sputum and urine. If any 
treatment is required, this will be prescribed by your usual health care worker, although we 
may provide advice about the most appropriate treatment. 
If you have just been admitted to hospital with an exacerbation, we will ask about your 
symptoms, and take a blood sample from you today, with a sample of urine and a sample of 
your sputum, if possible. 
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Follow up visits will occur at day 7, 14 and 56, where blood, sputum and urine samples will be 
collected again.  
Who analyses the samples? 
The samples will only be analysed by the Queen Elizabeth Hospital, Birmingham.  Test 
results will be kept confidential in keeping with recent regulations.  
What are the benefits? 
You will have no personal benefit from the study, other than advice.  The participation and 
donation of samples may provide benefit to future patients with COPD and related diseases 
by helping doctors to understand the diseases better and by increasing the possibility of 
developing new treatments. 
What are the risks? 
Nothing experimental will be done beyond the collection of samples, which is routine. The 
risks from giving a sample of blood are a slight discomfort and the possibility of a bruise 
developing where the blood was taken.    
What are the alternatives? 
The measurement of specific substances in sputum and blood samples to investigate 
mechanisms in lung diseases is a new area of research.  There are no other alternatives to 
this project which is unique to our department.   
As smoking can worsen your condition, stopping smoking is one of the most important things 
you can do to help your symptoms.  If you are currently smoking your doctor will talk to you 
about the risks of continuing to smoke and the benefits of stopping. 
What if I do not want to take part? 
The study is entirely voluntary and if you do not wish to participate it will not affect your 
present or future treatment and management. 
What happens to the information? 
If you consent to taking part in the study you need to allow us access to your medical records.  
These may be inspected by the University Hospital Birmingham, the trust that is sponsoring 
the study and may be inspected by regulatory authorities and/or the Independent Ethics 
Committee to check that the study is being carried out correctly.  By signing the Written 
Informed Consent Form you are giving permission for this to be done. 
With your permission, we will contact both your General Practitioner and Hospital Consultant 
and inform them that you are taking part in the study, and provide them with any results (such 
as blood or sputum measurements) which may be helpful for your medical management. 
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The information collected will be stored on a computer but your name will not.  All the data 
collected and samples that you provide will be coded with a number, with only your doctor 
having the link for this to your name.  The link will be destroyed after 15 years.  
The results from the study may be published in a medical journal, but your identity will not be 
revealed.   
These data will be used: 
 For statistical analysis.
 Understanding the nature of exacerbations.
Who else is taking part? 
Approximately 250 people will be asked to take part in the study. 
What if something goes wrong? 
This is not a study with a new drug and all tests and collections have been used before in 
routine clinical management of patients with COPD and do not cause any ill health. 
We do not expect any harm to come to you and there are no special compensation 
arrangements.  
What happens at the end of the research study? 
When you have finished taking part in this study, your doctors will continue to manage your 
COPD in the usual way.  
What if I have more questions or do not understand something? 
If you do not understand any of the information in this leaflet or have any other questions 
please feel free to ask your hospital Doctor at any time. 
What happens now if I decide to take part? 
If you decide to take part you will be asked to read and then sign and date the Written 
Informed Consent Form attached to this information leaflet.  By signing the consent form you 
acknowledge that you have understood the requirements for participating in the study. 
What happens if I change my mind during the research study? 
You are free to withdraw your participation in this study at any time.  If you withdraw your 
future treatment and your level of care will not be affected.  If you change your mind about 
participation the link between your name and number also enables samples that have not 
been analysed to be traced and destroyed.  If you withdraw your consent after the samples 
have been sent for analysis it will be the responsibility of the research team to ensure that the 
samples are destroyed. 
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Contact name and number:  
Dr Alice Turner: Telephone  
If you have any other concerns about the conduct of this study you can contact: 
Dr Christopher Counsell, Research and Development Manager 
Birmingham Clinical Research Office  
Room 17, Education Centre, 1st Floor 
Queen Elizabeth Hospital Birmingham 
Birmingham, B15 2WB 
 
Or  
Patient Advice and Liaison Services 
Queen Elizabeth Hospital Birmingham 
Edgbaston 
Birmingham, B15 2WB 
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Heartlands Hospital 
Bordesley Green 
Birmingham 
B9 5SS 
WRITTEN CONSENT 
Subject initials: ………………. Enrolment No: ……………….. 
Title:  An open study to investigate the measurement and variability of inflammatory cells, mediators 
and erythrocyte abnormalities in spontaneously produced sputum, blood and urine from patients 
with COPD who present with acute exacerbations. 
I,   .................................................................................................... 
(Subject name, block letters)  Initials 
Have read the attached information concerning my participation in this study and 
have had the possibility to discuss it and put questions.  
All my questions have been answered in a satisfactory way and I give my consent 
voluntarily to participate in this study.  
I know that I can, at any time and without giving a reason, withdraw my participation 
in the study and that my future care and management will not be affected.  
I understand that I shall keep a copy of this Subject Information & Written Informed Consent. 
I understand that relevant sections of my medical notes and data collected during the  
study may be looked at by individuals from regulatory authorities or from the NHS trust  
where it is relevant to my taking part in this research. I give permission for these individuals 
to have access to my records. 
I agree that my GP and other medically qualified people who may assist in my care during 
the study may be informed of my participation in the study. 
.................................................................…………………………………. 
Subject’s signature Date 
..........................................................................…. 
Name, block letters 
_____________________________________________________________ 
RESPONSIBLE INVESTIGATOR 
I have explained the nature and purpose of the study for the person mentioned above. 
......................................................................…………………………………. 
Responsible investigator/representative Date 
signature 
..........................................................................…. 
Name, block letters 
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Queen Elizabeth Hospital Birmingham 
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Patient information leaflet 
Study code: RRK3404 
Title: A study of clinical phenotypes, disease progression and genetic 
susceptibility in patients with chronic obstructive pulmonary disease, 
cystic fibrosis bronchiectasis and non-CF bronchiectasis 
You have been asked to participate in a clinical study for research purposes. 
Before you decide to take part it is important that you understand why the 
study is being performed, what it involves, and the possible risks and benefits 
for you. Take your time reading the following information and discuss it with 
others if you wish. 
Introduction to the research & invitation to take part 
This study is being carried out by the research department in the Lung Function 
& Sleep Department at the Queen Elizabeth Hospital, which is part of University 
Hospitals Birmingham NHS Foundation Trust, and is led by Professor RA 
Stockley. Several hospitals in the West Midlands are working closely with 
Professor Stockley in order to help with the study. The department has a special 
interest in understanding and treating chronic lung disease, in particular chronic 
obstructive pulmonary disease, or COPD for short, cystic fibrosis bronchiectasis 
and non-CF bronchiectasis. You have been chosen because your hospital doctor 
has identified you as suffering from one or more of these conditions and believes 
that you are suitable to take part in the study. 
What is the research about? 
The main purpose of the study is to find patterns of symptoms, breathing tests, 
blood and sputum tests that identify particular groups of patients with COPD, 
cystic fibrosis bronchiectasis and non-CF bronchiectasis. We also hope to 
establish the importance of environmental influences, such as chest infections, in 
the development of COPD, cystic fibrosis bronchiectasis and non-CF 
bronchiectasis and how it progresses over time. Other research suggests there 
may be genetic influences in COPD, cystic fibrosis bronchiectasis and non-CF 
bronchiectasis, which may affect particular groups of patients, or affect how their 
breathing tests change over time. We plan to study this in more detail to find out 
which genes are important in these conditions and their progression.  
What will I have to do? 
Please read this section carefully as it details the procedures that are specific to 
research and not part of usual clinical care 
If you agree to take part you will be seen by a member of the research team at the 
time of your usual out-patient clinic appointment. They will explain more about 
the study and what it would mean for you. The study will take place over 5 years,  
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and will involve seeing a member of the research team after one of your out-
patient appointments each year for at least 3 years. There will be no extra visits to 
the hospital other than those for your usual out-patient appointments. If you 
would rather participate for only one visit, rather than several, please inform the 
research team. 
If you have brought a sample of sputum with you, you will be asked if some could 
be used for the research. If you have not brought any sputum with you, and 
usually cough it up every day, you will be given a container in which you may 
bring a sample on your next visit.  
A blood sample will be collected from you. This can be done at the same time as 
any other blood tests your hospital doctor has asked for. We will collect 4 small 
tubes of blood for the study, which is the equivalent of about 2 tablespoons.  
We will process the blood and sputum samples so that they can be stored safely in 
secure freezers at the University of Birmingham. For this study they will be used 
to examine markers relevant to COPD, cystic fibrosis bronchiectasis and non-CF  
bronchiectasis. They may also be valuable for future research in other areas, but 
will not be used for other studies without prior ethical approval.  
We will also extract your DNA from your blood, which will be stored in the same 
way. Your DNA will be used to look for genes that may influence the development 
of COPD, cystic fibrosis bronchiectasis and non-CF bronchiectasis. Your DNA will 
not be used for other studies. 
As well as collecting these samples we will also collect information about you by 
talking to you and by looking at your medical notes. This will include your date of 
birth, gender, height, weight, date you were diagnosed and whether you smoke 
now, or have done so in the past. We will also ask some questions about 
symptoms that people with lung disease often experience, and ask you to fill in a 
questionnaire about the way your illness affects you. We will also look in your 
medical notes to see what medicines you take, the results of any breathing tests 
you have had done recently, and scans (if you have had one). All of this 
information will be recorded in written form only. 
All of the above procedures should take no more than half an hour on the first 
occasion, and be a little shorter on later visits. This will be in addition to seeing 
your usual hospital doctor. 
What are the benefits? 
You will have no personal benefit from the study. Your participation and 
donation of samples may benefit patients with COPD,  cystic fibrosis 
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bronchiectasis and non-CF  bronchiectasis in the future by helping us to 
understand the disease better, and helping us to develop new treatments. 
What are the risks? 
We do not expect any harm to come to you as a result of providing samples or 
talking to the researchers. Sometimes blood tests can be uncomfortable, or leave 
bruising, but this will be temporary. 
What are the alternatives? 
There are many ways of looking at blood and sputum samples, but relating them 
to breathing tests, symptoms and genes has not been done together before. It is 
therefore a new area of research, and there are no similar studies being done in 
the UK at present. 
What if I do not want to take part? 
The study is entirely voluntary and if you do not wish to participate it will not 
affect your future care. 
What happens to the information? 
If you decide to take part you will need to allow access to your medical records. 
They may be looked at by the research team, by the hospital research and 
development department and by regulatory authorities who check that the study 
is being carried out properly. By signing this form you are giving permission for 
this to be done. 
The information collected will be stored on a secure computer, but your name 
will not. This is known as linked anonymised data, meaning that only Professor 
Stockley will be able to link any of your information to your name. He will have 
sole access to a written record of your information, stored in a secure facility at 
University Hospitals Birmingham. All the data collected, samples you provide, 
and their results, including any information about your genes, will be coded with 
a number. The results of tests on your samples and about your genes will not be 
available to anyone outside of the research team and our collaborators. The link 
to your name will be destroyed after 15 years. Once the data is collected it will be 
the property of the research department. 
The results of the study may be published in a medical journal, but your identity 
will not be revealed. The results may be used in statistical tests, research and 
development of new treatments, diagnostic tests and medical aids. 
Who else is taking part? 
About 500 other patients with COPD, cystic fibrosis bronchiectasis and non-CF 
bronchiectasis will be asked to take part. 
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What if something goes wrong? 
Since the study involves only simple tests that could form part of your routine 
care, we do not expect any harm to come to you. Whatever part of the study you 
choose or decide not to take part in will not affect your future care. If you are 
harmed by taking part in this research project there are no special compensation 
arrangements.  
What happens at the end of the study? 
Throughout the study, and when it ends, your hospital doctor and general 
practitioner will continue to treat your chest problems. 
What happens if I have more questions? 
If you do not understand something in this leaflet, or have further questions you 
may ask the researcher now, or your hospital doctor. 
What happens now if I decide to take part? 
If you decide to take part you will be asked to read, sign and date the Written 
Consent Form attached to this sheet. By signing it you acknowledge that you have 
understood the aims of the research, and what you are being asked to do.  
In summary 
 The research aims to find out patterns of symptoms, breathing tests, blood
and sputum tests and scans in patients with COPD, cystic fibrosis
bronchiectasis and non-CF  bronchiectasis
 If you take part you will be asked to provide blood and sputum samples, and
answer questions about yourself and your chest problems at one out-patient
appointment per year for 3 years, or as many as you can manage
 All information will be stored in such a way that you cannot be identified by
anyone without Professor Stockley’s permission
Will my General Practitioner (GP) be informed? 
If you give your permission, your GP will be told about your participation in the 
study.  
What happens if I change my mind during the study? 
You are free to withdraw your participation at any time, and it will not affect your 
future care. If you withdraw your consent after your samples have been analysed 
it will be the responsibility of your hospital doctor to ensure that the samples are 
destroyed if you so wish. 
Who can I contact about the study? 
In the first instance any concerns or questions should be addressed to either your 
GP or hospital doctor. If you have further concerns you can contact 
Professor Robert Stockley      
Thank-you for reading this information leaflet
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University Hospital Birmingham 
    NHS Foundation Trust 
Queen Elizabeth Hospital Birmingham, B15 2WB 
Study code: RRK3404 Enrolment No: 
Title: A study of clinical phenotypes, disease progression and genetic susceptibility 
in patients with chronic obstructive pulmonary disease, cystic fibrosis 
bronchiectasis and non-CF bronchiectasis 
I………………………………………………………………… (Name in BLOCK CAPITALS) 
Have read the attached information concerning my participation in this study and have had 
the opportunity to discuss it and ask questions. All my questions have been answered in a 
satisfactory way. 
I voluntarily consent to take part in this study. 
I know that at any time, and without giving a reason, withdraw my participation in the study 
 and that my future care and management will not be affected. 
I understand that I will have a copy of this Patient Information Leaflet and Written Consent 
to keep. 
I understand that relevant sections of my medical notes and data collected during the study  
may be looked at by individuals from regulatory authorities or from the NHS Trust, where it 
is relevant to my taking part in this research.  I give permission for these individuals to have 
access to my records. 
I hereby give permission for samples taken as part of this study to be stored for future use 
by the research team. 
I understand that samples taken as part of this study will not be used in other studies 
without prior ethical approval. 
I hereby give permission for my GP and hospital consultant to be informed about my 
participation in this research study. 
………………………………………………………………………………………..      …………………… 
Patient’s signature   Date 
……………………………………………………………………………………….. 
Name in BLOCK CAPITALS 
Responsible investigator 
I have explained the nature and purpose of this study for the person named above 
…………………………………………………………………………………………      ……………………. 
Responsible investigator/representative signature   Date 
………………………………………………………………………………………… 
Name in BLOCK CAPITALS 
Initials 
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1.2 Severe A1ATD CT scanning protocol 
All subjects will be scanned within 4 hours after administration of a short-acting 
bronchodilator by spiral multi-slice CT of the chest in the supine position. Following 3 deep 
breaths the patient will be asked to take another deep breath and to hold it for the duration 
of the scan (full inspiration for approximately 10 seconds). This procedure can be repeated if 
applicable. No contrast medium will be injected.  
The scan will be taken from the diaphragm in the direction of the neck, to minimize 
inhalation artefacts in the images.  
Preferred scanning parameters will be 140 kVp, 40 mA, and 10 second scanning time, pitch 
1.5 (4 times 5mm collimation), with reconstructed slice thickness of 5mm and 1mm.  Field of 
view 500mm. 
Image reconstruction algorithms will be performed according to a standardized protocol of 
each CT scanner, using a smooth filter (defined by the type of the CT scanner). 
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1.3 Potentially pathogenic organism (PPM) classification 
(205). 
 
PPMs Non PPMS 
Haemophilus influenza Streptococcus viridans 
Haemophilus parainfluenzae Neisseria species 
Streptococcus pneumoniae Candida species 
Moraxella Catarrhalis Corynebacterium species  
Pseudomonas Enterococcus species 
Staphylococcus aureus Coagulase negative staphylococcus aureus 
Enterobactacteriaceae 
• Escherichia coli 
• Proteus mirabilis 
• Klebsiella pneumonia 
• Serratia marcescens 
• Enterobacter cloacae 
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1.4 Lung function parameters recorded 
 
Lung function parameter Unit Abbreviation 
Forced expiratory volume in 1 second L FEV1 
Forced expiratory volume in 1 second % predicted % FEV1 
Forced vital capacity L FVC 
Forced vital capacity % predicted % FVC 
Forced expiratory volume in 1 second/ forced vital capacity ratio  FEV1/FVC 
Total lung capacity L TLC 
Residual Volume L RV 
Transfer factor of lung for carbon monoxide (or ‘gas transfer’) mmol/min/kPa TLCO 
Gas transfer corrected for volume mmol/min/kPa/L KCO 
 
1.5 Lung function recommended normal regression 
equations 
Variable Men Women 
FEV1 = 4.30H - 0.029A - 2.49 = 3.95H - 0.025A - 2.60 
FVC = 5.76H - 0.026A - 4.34 = 4.43H - 0.026A - 2.89 
TLC = 7.99H - 7.08 = 6.60H - 5.79 
RV = 1.31H - 0.022A - 1.23 = 1.81H + 0.16A - 2.00 
TLCO = 11.11H - 0.066A - 6.03 = 8.18H - 0.049A - 2.74 
KCO = - 0.013A + 2.2 = - 0.007A + 2.07 
 
H = Height (in metres), A = Age (years). FEV1: Forced expiratory volume in 1 second, Forced 
vital capacity, TLC: Total lung capacity, RV: Residual volume, TLCO: Transfer factor of the lung 
for carbon monoxide, KCO: gas transfer corrected for volume. 
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1.6 The FACED bronchiectasis severity score (209) 
Maximum score = 7. FEV1 = Forced Expiratory Volume in 1 second. mMRC= Modified Medical 
Research Council score 
 
FACED  Points 
FEV1 % predicted  
≥ 50% 0 
< 50% 2 
Age  
<70 0 
≥70 2 
Chronic colonisation with pseudomonas  
No 0 
Yes 1 
Extent of bronchiectasis (number of lobes)  
1-2 0 
>2 1 
Dyspnoea (mMRC score)  
0 - 2 0 
3 - 4 1 
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